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INTRODUCTION
function of hemoglobin•	
Blood cells can be classified in two groups: red blood cells or erythrocytes, that 
transport O2 and CO2 bound to hemoglobin and white blood cells or leukocytes which combat 
infections and in some cases phagocytose and digest debris (1). In addition blood contains a large 
number of platelets that participate in the process of blood clotting. Remarkably all these cells are 
ultimately generated from a common stem cell in the bone marrow (1, 99, 165-167). A schematic 
representation of the main lineage commitment steps in hematopoesis is depicted in Figure 1 (after(18)). 
Figure 1.Schematic representation of hematopoiesis. A number of transcription factors involved in hematopoiesis are indicated 
(after (18)).
Hemoglobin is a tetramer composed of four globin peptide chains, two α-like and 
two β-like, with each globin chain binding one heme molecule (1). Oxygen binds to the iron 
ion complexed with the heme molecule. The globin chains prevent this process from becoming 
irreversible by folding and creating a protein pocket which prevents two heme molecules from 
coming together and the iron ion from being oxidized (11).The α-hemoglobin chain consists 
of 141 amino acids and is found in fetal hemoglobin and in normal adult hemoglobin A. The 
β-globin chain consist of 146 amino acids and is found in normal adult hemoglobin A (1). 
globin gene structure•	
All animals that use hemoglobin for oxygen transport have different hemoglobin 
species expressed in early and later developmental stages (144, 145) . The major hemoglobin in 
human fetal life is HbF (α2γ2), and the major hemoglobin in adult life is HbA (α2β2). Adult hemoglobin 
A2 (α2δ2) is a minor hemoglobin expressed at less than 2% of the total hemoglobin (6, 145). 
In man, two gene clusters direct the synthesis of hemoglobin chains: (1) the α-globin 
locus containing the embryonic ζ globin gene and the two adult α1 and α2 globin genes and (2) the 
β-globin locus, which consists of the ε-Gγ-Aγ-δ-β globin genes arranged in the order in which they are 
expressed during development (Figure 2A) (144, 145). The β-like globin genes extend over 50 kb on 
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chromosome 11 and evolutionarily arose from a single ancestral globin gene as a result of successive 
duplication events. The evolution of γ-globin genes is most likely related to the increased oxygen 
affinity of HbF over HbA, which facilitate oxygen delivery to the fetus in the placental circulation (153).
The mouse model has been extensively used to study the regulation of the human 
globin gene expression primarily through the use of transgenic animals (144, 145, 149). The 
regulation of human globin genes in transgenic mouse models can be assessed using the endogenous 
mouse globin genes as reference. This species has no distinct fetal stage of erythropoiesis and 
hence no γ-globin genes. The mouse β-globin locus consists of the εy-βh1-βmin-βmaj globin genes 
(Figure 2B) (reviewed in (6, 144, 145)), and erythroid development involves a single switch from 
embryonic to adult globin chains. In mice the embryonic to adult switch takes place at around 11.5 
days of gestation, with the emryonic εy gene being orthologous to the human ε-globin gene and the 
βh1 gene orthologous to the human γ gene (Figure 3B). In contrast to man the fetal liver stage of 
erythropoiesis in mouse produces α globin and β major and β minor, but no embryonic globin chains 
(reviewed in (67, 145)). It is thus considered an adult stage for globin chain synthesis in erythropoiesis. 
Erythropoiesis in man (Fig 3A) begins in the yolk sac but at about five weeks of 
gestation the site of hematopoiesis changes from the yolk sac to the fetal liver, which remains the 
main site of erythopoiesis until about the twentieth week of gestation. Subsequently, the site of 
hematopoiesis shifts to the spleen and the bone marrow (around the thirtieth week of gestation) 
and by the time of birth, the bone marrow is the main hematopoietic organ ((145) and references 
therein). The shifting sites of erythropoiesis coincide with changes in the hemoglobin composition 
of the red cells and also in other morphological and biochemical characteristics. Expression of 
ε-globin is restricted to the yolk sac, whereas the γ and β globins are restricted to erythroblasts of 
liver origin (145). During the second (γ to β globin) switch, which occurs gradually around birth, 
the adult stage δ and β globin genes are activated, whereas γ globin is suppressed to very low 
levels (1%-2%) (78, 145). All normal adults produce a small quantity (~1%) of fetal hemoglobin, 
which appears to be confined to a small population of red cells which are called F cells (125, 172). 
When the 70kb human β locus was analyzed in transgenic mice, the expression 
pattern was shown to be similar to the pattern observed in humans (149) (Figure 3C). The ε-globin 
gene showed a similar expression pattern to the mouse εy gene, but the level of expression 
was much lower than that of εy or of γ-globin genes. Importantly, it was observed that the 
γ-globin genes were expressed in high levels throughout the embryonic yolk sac stage, with 
significant levels of γ-globin expression remaining in the early fetal liver stage. Expression of 
γ-globin is switched off at day 16 of development in the fetal liver. These observations suggest 
that the human γ-globin genes detect a distinct fetal stage in the mouse fetal liver, which is not 
ε Gγ Aγ δ β
1234567
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LCR
globin locusB. Mouse 
A. Human β- globin locus
Figure 2. A) Scheme of human 
β-globin locus B) scheme of mouse 
β-globin locus
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detected by any of the endogenous mouse globin genes. This difference between the human 
and mouse fetal globin genes could be accounted for by changes in the transcription factor 
environment that can be detected by the human γ-globin regu;atory elements but not by those 
of the mouse embryonic globin genes. The same set of experiments showed that expression of 
human β globin gene follows that of βmaj almost completely (149). The developmental pattern 
of expression of the human β-globin locus introduced in transgenic mice as a 130kb YAC was 
similar to the one observed with the 70kb transgene and is shown in Figure 3C (15, 57, 149, 154).
Hemoglobinopathies •	
0
20
40
60
80
100
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1693 6 adult
Post-conception months
Birth
ε
γ β
δ
A. Human globin switching
%
to
ta
l g
lo
bi
n
%
to
ta
l g
lo
bi
n
B. Murine globin switching
%
to
ta
l g
lo
bi
n
0
20
40
60
80
100
0 3 6 9 12 15 18 21 24 27 30
βh1
β
εy
Birth
8 10 12 4 16 1 1 3 5 7
Age daysGestation days
%
to
ta
l g
lo
bi
n
0
20
40
60
80
100
120
0 5 7 10 11 13 14 15 18 20 24 25 30
Birth
8 10 2 14 16 18 1 3 5 7
Age daysGestation days
ε
Aγ β
C. Regulation of human globin YAC in transgenic mice
%
to
ta
l g
lo
bi
n
%
to
ta
l g
lo
bi
n
Figure 3. A) Human globin expression levels measured 
throughout development. Squares represent β globin 
expression levels, triangles γ globin expression levels 
and dots ε globin expression levels. B) mouse globin 
gene expression during development: circles- εy 
globin expression levels, squares βh1 expression 
levels, triangles β major globin expression levels. 
C) Expression levels of human globin genes in the 
blood of transgenic mice. Circles, human ε- globin; 
triangles, human Aγ globin; squares, human β globin 
(after (133)).  
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 Thalassaemias, which are the commonest monogenic diseases in man, result from 
over 200 different mutations in the human α- and β- globin genes. Thalassaemia is an autosomal 
recessively inherited group of disorders (31),  associated with a wide spectrum of symptoms, 
ranging from intrauterine death to very mild, symptom-free anemia (163, 164). Thalassaemias are 
classified according to the particular globin chain which is ineffectively produced, as α, β (these 
two are by far the most important), δβ, and γδβ thalassaemias. The most important and probably the 
most intensively studied hemoglobinopathies are sickle cell anemia and hemoglobin E thalassaemia 
(disease usually found in people of Southeast Asian ancestry, especially in Cambodia, Laos and 
Thailand, it is believed to be the most common hemoglobinopathy in the world) (163). Importantly, 
treatment with regular blood transfusions and adequate chelation therapy has improved prognosis 
for the severe forms of thalassaemia. Table 1 shows the thalassaemias typology (after (145)) 
Many insights into the regulation of hemoglobin switching have been obtained 
by the study of mutations that increase fetal hemoglobin production during adult life. 
These mutations are clinically relevant, because increased synthesis of HbF in individuals 
that have co-inherited  sickle cell anemia or β thalassemia reduces disease severity (145). 
All normal adults produce a small quantity (~1%) of fetal hemoglobin, 
which appears to be confined to a small population of red cells which are called F cells (125, 
172). Hereditary persistence of fetal hemoglobin (HPFH) characterizes a condition where 
production of variable levels at (>1%) of HbF persists into childhood and adult life (125). In 
molecular terms, there are deletion HPFHs, characterized by deletions in the 3’ of the human 
β globin locus resulting in the total absence of the δ and β globin genes, and non-deletion 
HPFHs caused by mutations affecting the promoters of the  Gγ or Aγ genes (145). Some of 
these mutations are listed in Table 1 (based on (145) and references therein). Importantly, 
mutations that increase HbF levels have been found to ameliorate the effects of β-thalassemia 
and sickle cell disease, when co-inherited (145). Thus, studying the HPFH-associated mutations 
can be potentially useful for the development of therapeutic approaches to treat thalassemias. 
A number of different agents to treat thalassemic patients have been already tested 
in clinical trials for their efficiency in reactivating or augmenting fetal globin production in the 
adult stage. Hydroxyurea, an S-phase-specific agent that inhibits ribonucleotide reductase and 
activated guanylyl cyclase (raising the levels of cGMP) has been shown to increase HbF even 
in pediatric patients. However, hydroxyurea has many other side effects, including increased red 
cell size, presumably by altering cellular hydration and reducing the white cell count which may 
also play a role in reducing the number of painful crises (123, 125). There have also been several 
studies to assess the effect of recombinant erythropoietin (Epo) (a cytokine produced by the 
kidney that regulates red blood cell production), either alone or in combination with hydroxuurea 
in treating thalassaemias, as there is  indirect evidence that rapid erythroid expansion may favor 
HbF production (109, 110, 123). The administration of butyrate fatty acid compounds has also 
been associated with varying responses in increasing HbF levels. Continuous butyrate infusions 
administered to patients induced γ-globin expression, F cells, F reticulocytes and HbF but the 
effects declined with the prolonged administration. As butyrate is also known to cause growth 
arrest in G1 phase of the cell cycle, a pulse regimen was successfully tested to avoid its anti-
proliferative effects (3, 4). Butyrate is known to inhibit histone deacetylases (HDACs) and thus 
may work by interfering with repressive chromatin associated complexes binding to the γ-globin 
promoter and thus de-repressing the γ-globin expression (24, 35, 132). Finally, 5-azacytidine and 
its derivatives are agents that result in DNA hypomethylation and have been shown to induce 
HbF production in patients with sickle cell disease and thalassaemia (38-40, 49, 68). However, 
concern about its potential carcinogenic effects (the same concern as for hydroxyurea) halted its 
development as a therapeutic agent in patients with hemoglobin disorders (49). Nevertheless, the 
use of agents that affect histone acetylation (butyrate) and DNA methylation in inducing HbF 
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suggest an epigenetic basis in the silencing of γ globin expression in the adult which can be reversed. 
Regulation of globin genes•	
The expression of the human and mouse β-like globin genes, is controlled by the 
complex interaction between:
cisA. -acting sequences : the locus control region (LCR) and downstream regulatory 
sequences
trans-actingB.  factors: transcription factors and chromatin remodeling and 
modifying cofactors and complexes
Cis-regulation of globin genes•	
The LCR  consists of five erythroid specific DNaseI hypersensitive sites (HS1-5) 
located from 8 to 22 kbp 5’to the ε- globin gene (see also Figure 2A) (61, 158, 159). The functional 
core of each HS is approximately 250 nucleotides long and consists of several binding sites for various 
transcription factors (such as GATA-1, EKLF, NF-E2) (reviewed in (17, 67)). There is evidence that 
distinct HS sites contribute specific functions, e.g. HS5 acts as an insulator (developmental-specific 
chromatin border) (161) and HS3 as a critical activator of the entire gene locus (117, 119, 130).  The 
order of the genes relative to the LCR is conserved in mammals, so the genes which are active early 
in development are closer to the LCR than genes which are activated later (41, 63, 66, 131, 134). 
Deletion of the LCR in humans causes β-thalassaemia (144) with no globin 
expression and no evidence of an open chromatin domain organization in the locus (83, 144). 
In transgenic mice bearing the globin gene locus without an LCR, expression levels are severely 
affected but temporal globin expression or switching does not appear to be affected (147). The 
position of globin genes with respect to the LCR is crucial for their activation as shown for the 
ε-globin gene, which when relocated to the 3’end of the locus becomes transcriptionally silent at 
all developmental stages (136, 139, 140, 154). Moreover when the β-globin gene was placed in a 
proximal position to the LCR it becomes transcribed at all developmental stages (15, 28, 41, 64). 
Various models explaining how the LCR activates downstream globin genes have 
been previously proposed: a looping (60), a tracking (13), a facilitated tracking (13), and a linking 
(14) model. Presently most of the experimental evidence available supports a looping model  (41, 
59, 128, 130, 156, 171). 
According to this model, the LCR and the distal 5’ and 3’ hypersensitive regions 
are thought to interact together to form a developmentally stable three dimensional core called 
the Active Chromatin Hub (ACH) (36, 42, 128, 156). This represents the spatial clustering of 
regulatory elements that appear to concentrate transcription factors and chromatin remodelers at 
one site. The globin genes undergo developmental switches in their interaction with the ACH, 
correlating with the switch in their transcriptional activity. The intervening chromatin that domains 
that contain the inactive genes loops out of the ACH at any given developmental stage (36). 
Several experimental approaches provided evidence for a competitive mechanism 
as the basis of the γ to β globin gene switching. It was shown that the LCR interacts with only one 
globin gene promoter at a time “flip-flopping” between two or more promoters depending on the 
developmental stage (171). The competition is explained by the preferential interaction between 
the LCR and the γ globin genes (presumably mediated by stage specific transcription factors) 
which outcompete the β globin gene during the embryonic/fetal stage of development. A gene 
is likely to achieve competitive dominance when it interacts more frequently and more strongly 
with the LCR than other competing genes (41, 60). Thus, it seems necessary to evolve promoter-
mediated silencing for the proximal genes, which is what is observed for the ε and γ globin genes. 
When the γ globin gene is silenced at the adult stage, the LCR preferentially interacts with the β 
gene (10, 41, 45, 59). 
ε- globin gene silencing. Experiments in transgenic mice showed the LCR- 
dependent yolk sac erythropoiesis-restricted expression of the ε-globin gene. This led to the 
16
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concept of autonomous silencing, whereby all the elements responsible for turning off ε gene 
expression in the fetal/adult stage are contained within the canonical gene or adjacent sequences 
(136). Further experimental investigations identified sequences that participate in silencing, 
in both the proximal and distal ε-globin gene promoter (53, 103, 135, 155). Thus, mutation 
of the GATA-1, YY1 or Sp1 sites upstream of the ε promoter abolished ε-globin silencing 
(135), raising the possibility that globin gene silencing is the result of the combinatorial 
action of several transcriptional factors participating in the formation of a silencing complex. 
γ-globin gene silencing. Figure 4 shows the transcription factor binding sites that 
have been mapped in the γ globin promoter (after (145)). The identification of DR1 (direct repeat 
1) sites in the γ globin but also in the ε globin gene promoters led to the suggestion that nuclear 
receptors such as COUP-TFII or TR2 and TR4 could be implicated in globin gene silencing 
(53, 150). Further studies in transgenic mice have localized a silencing element in the -378 to 
-730 region upstream of the γ promoter (146).  It has been suggested that this sequence contains 
elements that contribute to the autonomous silencing of the γ gene (144). This hypothesis was 
strengthened by the further identification of a GATA-1 site mutation in -378 to -730 sequences 
that resulted in HPFH (75, 144). Mutational studies using human γ gene hybrid promoters suggest 
that the CACCC box is the main proximal motif that participates in γ globin silencing (102). 
Several transcription factors have been implicated in globin gene silencing. For 
-235 -215-200 -175 -145
CAC
-115
CAAT
-85
CAAT
-30
ATAA
stb 1
GATA GATA
GATA FKLF
oct1
cEBP?
CP1
COUPTF?
CP1
CDP
cEBP? SSP
-370
StuI
Sp1DRED
SSP
Gglobin
Figure 4. Scheme of transcription factor binding sites on the γ globin gene promoter (145)
example, Mbd2 was recently reported to mediate γ-globin silencing, as Mbd2 knock-out mice 
continue expression of γ-globin in adulthood.  Mbd2 does not however bind directly to the promoter 
(137). Other transcription factors that are part of complexes and are implicated in γ globin silencing 
are discussed further in this chapter. A number of studies have demonstrated that nuclear receptors 
also have a profound impact on the development of hematopoietic cells, e.g., RXR and TR/c-erb-A 
effectively regulate erythroid cell growth and differentiation (7, 8). Also the v-erbA oncoprotein an 
oncogenic version of TR/c-erbA, arrests differentiation of erythroblasts and cooperates with v-erbB 
in producing fatal erythroleukemia in chickens (183, 184).  Additionally, activation of both GR 
and ER is required for the efficient induction and self-renewal of erythroid progenitor cells (9, 148, 
170). Interestingly, introduction of dominant-negative RAR in bone marrow cells immortalized a 
lymphohematopoietic progenitor, which can be induced to differentiate into lymphoid, myeloid, 
and erythroid lineages (85, 157). 
Chromatin modification marks have been shown to characterize the chromatin of 
active and silenced globin genes. Histone hyperacetylation has been associated with the opening of 
the chromatin structure and activation of genes including genes in the β-globin locus (54, 81, 130). 
Histone hyperacetylation at the LCR and  β-globin promoter has been associated with the formation 
of the Active Chromatin Hub (βACH) in the adult stage (54, 156). Histone acetyltrasferases (HATs) 
together with the chromatin remodeling SWI/SNF complexes have been shown to be active at 
the murine and human β-globin locus in facilitating transcriptional activation (2, 121, 122). In 
addition, the specific inhibition of HDACs was shown to selectively increase acetylation at a 
hypoacetylated promoter in fetal liver cells, suggesting that active deacetylation contributes to the 
silencing of the β- locus promoters, particularly γ globin (16, 25, 174). These observations also 
suggest that γ-globin is epigenetically regulated and that its suppression is reversible. ChIP studies 
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also show that methylation of histone 3 lysine K79 (H3-K79me), at the active murine β globin 
gene in adult erythroid cells is dependent on the presence of p45/NF-E2 (74). Moreover, recent 
experiments have shown that methylation of histone H3 at lysine 4 (H3-K4me4) is mediated by 
the MLL complex, and that H3 acetylation at lysine 9 (H3-K9ac) marks the active β major globin 
gene. These modifications are in dynamic equilibrium with repressive the H3-K9me3 mark (37).  
Several protein complexes have been reported to bind to the promoters of the globin 
genes in the β-locus, here we briefly discuss some of them and we concentrate on one, namely, the 
DRED complex.  
 p22NF-E4 has been recently shown to be part of the stage selector protein (SSP) 
complex and to have a role in globin switching (188, 189).  Enforced expression of human p22NF-
E4 increases γ-globin expression in K562 cells, whereas over-expression of p22NF-E4 in transgenic 
mice carrying the human β- globin locus YAC results in a delayed human γ – to β- globin switch 
(189). In addition, NF-E4 interacts with and is a target of the co-activator PCAF acetyltrasferase. 
Acetylation prolongs the half-life of NF-E4 and reduces interaction with HDAC1 maximizing the 
activating ability of NF-E4 at the γ globin promoter (188). 
The PYR chromatin remodeling complex was isolated from MEL cells and shown 
to be present only in adult hematopoietic cells. It binds to a 250 bp polypyrymidine (PYR)-rich 
DNA sequence 1kb upstream of the human δ-globin gene (120). Deletion of the δ-globin gene 
promoter fragment, which includes the PYR binding sequence results in a delay of γ- to β- switch 
in transgenic mice (45, 121). A transcription factor –Ikaros- has been recently identified as the 
DNA binding subunit of PYR complex (122). Interestingly, Ikaros knock out mice that are also 
transgenic for the human β-globin locus YAC show delayed human γ- to β- globin switching (108). 
The PYR complex can have an activating or repressive function, as it contains subunits of the 
SWI/SNF complex and subunits of the NuRD complex (including HDACs) (122). A simplified 
scheme of human globin gene switching is depicted in Figure 5. 
The CAC box and the CCAAT box are conserved motifs found in the globin 
promoters. The distal CCAAT box in γ-globin promoter contains an approximate direct repeat 
(DR1) TGACCAATAGCC. Importantly, the CAAT box regions of the ε and ζ genes as well 
as murine εy and βh1 also contain a DR-1 type sequence (53). Hereditary persistence of fetal 
hemoglobin (HPFH) has been associated with deletions/mutations in distinct plates in the γ- globin 
promoter (like e.g. the -117 Greek HPFH (32) ). It was noted that of the sixteen different mutations 
identified in the Gγ and Aγ promoters that are associated with HPFH six are located within DR1 
elements. These observations suggested an essential role for the DR1 elements in both ε- and γ- 
globin gene silencing in definitive erythroid cells (53, 153, 155). 
EKLF was the first candidate protein thought to be responsible for the stage- specific 
repression of ε-globin, which binds to CACCC element in ε-globin promoter (initially it was 
identified to bind CACCC element of and activate the β-globin gene promoter (116)). However 
analysis of transgenic EKLF knock-out mice containing a mutation introducing an EKLF binding 
site in the ε-globin gene promoter did not reveal any changes in ε- globin expression (155). It was 
subsequently suggested that there must be a definitive erythroid stage specific repressor which 
binds to Direct Repeats in the ε-globin gene promoter, and this entity was named DRED (DIRECT 
REPEAT ERYTHROID DEFINITIVE). The γ-globin gene promoter also contains a single DR1 
sequence, which was also speculated to have a repressive function. So far no DR1 elements have 
been identified in the adult β-globin promoter (150, 154, 155). 
An alternative model for globin switching presented in Lee et al (93), suggested 
that CCTTG elements, located very close to the DR elements, would play a key role in the γ- 
globin silencing. Comparison of transgenic mice bearing a mutDR1 YAC, a mutCCTTG YAC, 
and the wild-type human β-globin locus YAC revealed a 10 fold increase in Aγ- globin mRNA 
levels in adult spleen when DR1 was disrupted. Disruption of the CCTTG motif caused only 
18
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slight elevation of Aγ-globin mRNA and only in fetal liver cells. Together those observations 
supported the hypothesis that DR motifs are important regulators of globin gene switching and 
that the elements in the Aγ promoter contribute significantly to the mechanism controlling globin 
switching (126). 
DRED (Direct Repeat Erythroid Definitive), a 540 kDa protein complex, has been 
isolated from MEL cells and was shown to bind to direct repeats present in the ε- and γ-globin 
promoters. Importantly, DRED binding is reduced 3-fold when a point mutation that gives rise to 
HPFH is present in the γ-globin promoter at position -117. DNA-affinity purification of the DRED 
complex revealed the presence of five proteins: CDP, USF-1, LBP-1a, and the orphan nuclear 
receptors TR2 and TR4. DRED DNA binding activity was confirmed by EMSA only for TR2 and 
TR4 (150). This complex is further described in Chapter 4. 
TR2 and TR4- nuclear orphan receptors
Cloning the TR2/TR4 genes and their regulation and expression •	
The human testicular orphan nuclear receptors TR2 and TR4 were isolated from 
human prostate and testis cDNA libraries using an oligonucleotide probe homologous to the DNA 
binding domain (DBD) of the steroid hormone receptor (SR) (21). There are three TR2 isoforms 
that arise as the result of alternative splicing. The TR2 gene was mapped to human chromosome 12 
at band q22, whereas the TR4 gene was mapped to human chromosome 3 at band q24,3 but their 
cDNA is highly homologous (105, 180). 
TR2/TR4 genes have been identified in many species: mouse, rat, human, Drosophila, 
sea urchin and amphibian (76). SmTR2/TR4 a Schistosoma mansoni worm homologue of the TR2/
TR4 group of nuclear receptors is a 1,943 amino acid protein, the largest nuclear receptor reported 
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Figure 5. Simplified model of human 
globin gene switching from embryonic 
via fetal to adult stage, as indicated 
by the vertical arrows. The LCR has 
a preference for acting on the closest 
ε globin promoter at the embryonic 
stage. In the fetal stage DRED and other 
transcription factor complexes silence ε 
globin which no longer competes for the 
LCR with the γ globin gene. In this way 
γ globin expression can be activated. 
In the adult stage, the DRED, PYR, 
SSE and possibly other transcription 
factor complexes silence γ globin and 
block interactions with the LCR. The β 
globin promoter can be now activated 
by the LCR. In addition, EKLF has been 
indicated as it has been described to play 
role in β globin activation (after (6))
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to date and it binds to the DR3 consensus hormone response element (70).
TR2 has a higher abundance in the mouse and rat reproductive organs, while TR4 is 
highly expressed in brain and male reproductive organs. Both TR2 and TR4 are highly expressed in 
the proliferation-active population of most developing organs, whereas expression is dramatically 
reduced in the more differentiated cell types (150, 160). In contrast to TR2, which is widely 
expressed throughout animal development (and can be detected as early as day 9 post coitum), TR4 
has been detected with distinct abundance in specific brain regions (21). At embryonic days 14.5 
and 19.5 high expression of TR4 was found in the central nervous system with lower expression 
detected throughout the embryo (160). 
Several factors have been found to regulate TR2 and TR4 expression. For example 
the Ciliary Neurotrophic Factor α (CNTFRα) can increase TR2 and TR4 expression and TR2 then 
induces CNTFRα transcription through binding to a DR element within the CNTFR gene (85). 
In addition, all-trans retinoic acid (RA) stimulates cellular proliferation in 3T3-L1 preadipocytes 
by activating TR2 through an IR0-type RA response element in the TR2 promoter (62, 181). In 
contrast, irradiation and over-expression of p53 can repress transcription and translation of TR2 
gene in human MCF-7 cells (106). 
TR2/TR4 protein structure •	
 The cDNA sequence analysis shows that the human TR4 protein consists of 615 
aa with a calculated MW of 67.3kDa. The TR2 cDNA encodes for a 603 aa polypeptide, and a 
calculated MW of 67kDa (76). The TR2 and TR4 receptors share high homology in their N-terminal 
domains and in the proximal box (P-box) of the DNA binding domain but differ in the length of 
their ligand binding domains (LBD) (see Figure 6). These similarities suggest that TR2 and TR4 
may act on the same hormone response element (HRE) (72, 106, 182). 
Both TR2 and TR4 have been reported to be posttranslationally phosphorylated, 
and SUMO-ylated. TR4 activity can be modulated by MAPK-mediated phosphorylation. 
Hyperphosphorylation of the N-terminal activation domain (AF-1) renders TR4 a repressor, whereas 
hypophosphorylation of this domain makes it an activator. The TR4 opposing transcriptional 
activities as an activator or repressor are mediated through the specific recruitment of the P/CAF 
coactivator or the RIP140 corepressor by hypophosphorylated and hyperphosphorylated forms of 
the protein, respectively (71).
 In vivo metabolic labeling showed that the LBD of TR2 could be phosphorylated by 
protein kinase C (PKC). Phosphorylation increased the stability and nuclear accumulation of TR2. 
(79). Further experiments have shown multiple serines in the DBD of TR2 to be phosphorylated. 
PKC mediated phosphorylation of the DBD facilitates DNA binding by TR2 and the recruitment 
of the P/CAF coactivator. Thus, TR2 serves as an activator in the phosphorylated state (in contrast 
to TR4 which when phosphorylated has repressive function) (80). A more recent report has shown 
LBD
1 108 179 231 603
LBD
81.2% 62.4%
1
134 201 254 615
Human TR2
Human TR4
DBD
DBDZF ZF
ZFZF
Figure 6. TR2 and TR4 orphan nuclear receptors. The homology between their DBD and LBD domains in % is indicated 
(97)
that Lys238 located in the LBD of TR2 can be SUMO-ylated resulting in the replacement of 
coregulators recruited to the Oct4 promoter (129). More specifically non- SUMO-ylated TR2 is 
localized to the promyelocytic leukemia (PML) bodies and activates Oct4. In contrast, SUMO-
ylated TR2 seems to be released from PML bodies to act as an Oct4 repressor. SUMOylation of 
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TR2 induces an exchange of coregulators: corepressor RIP140 replaces coactivator P/CAF which 
switches TR2 from and activator to a repressor (129). 
TR2/TR4 as transcriptional regulators•	
TR2 and TR4 bind to the AGGTCA repeat motifs spaced by 0-6 nucleotides (direct repeats: 
DR0- DR6) in  hormone response elements (HREs) with different affinity: DR1>DR2: DR5, DR4, 
DR6> DR3 (107). TR2 and TR4 may also compete for binding to target sites with other nuclear 
receptors such as RAR, RXR, vitD receptor, and TRα1 (72).
There have been several examples in literature showing that TR2 and TR4 can 
act as a repressors or activators (97) depending on the HRE that they bind to and also on their 
post-translational modification (discussed above). TR4 was shown to increase expression from 
the proximal promoter of the human oxitocin gene (by binding to DR4 element in the promoter) 
(162) and luteinising hormone (by binding to DR0 element) (186) activity. On the other hand, 
TR4 can repress the 21-OHase gene (by binding to monomeric AGGTCA element) (91). Rabbit 
TR4 was shown to act as a repressor in the estrogen- receptor mediated signaling pathway (65, 
76). Finally, TR4 can bind  bipartite repeats of many target genes including SV40 (88), the ciliary 
neurothrophic factor receptor gene (179), a DR4 of the thyroid hormone target genes (94) and a 
DR3 of the vitamin D3 target genes (96), the Bcl2 promoter (82), the promoter of the peroxisome 
proliferators- activated receptor α (PPARα) target genes (69, 175, 187).
TR2 has a modulatory effect on several signaling pathways involving retinoic 
acid (107), thyroid hormone (23) and ciliary neurothrophic factor (178), erythropoietin gene (92) 
aldolase gene (22), histamine receptor gene (90, 107) and simian virus 40 (89), in the human 
RARβ gene (27).TR2 was also shown to induce the expression of HPV-16 gene  (by binding DR4 
element)(34). 
Both TR2 and TR4 can suppress retinoic acid induced transactivation of human 
HaCaT keratinocytes. They can suppress RA- mediated but not vitamin D mediated transcriptional 
activity in these cells (95).
TR2 and TR4 knock-out phenotypes•	
TR2 knock out mice revealed no apparent developmental or pathological 
abnormalities (141). By contrast, TR4 null mice were born at lower than Mendelian ratios, with a 
significantly lower proportion of female knockout mice compared to male knockouts. These mice 
display reduced postnatal growth with TR4 null dams exhibiting defects in maternal behavior in 
that they do not build nests or collect pups to a single location, or crouch over pups, or nurse their 
offspring. An additional phenotype observed among TR4 null mice is the accumulation of fluid 
surrounding the eye (33). Closer investigation of TR4 null mice revealed reduced myelination 
which was particularly obvious in the forebrains and in early developmental stages (185). The 
cerebellum was also significantly reduced in size (26). Mouse embryonic fibroblast (MEF) cells 
prepared from TR4 null mice are more susceptible to UV-irradiation mediated apoptosis compared 
to the TR4- wild-type littermates (82). 
Double TR2 and TR4 knock out mice die before 7.5 day post coitum (C. Chang, 
unpublished and (152)). 
Known protein interactions•	
It was previously demonstrated that, TR2 and TR4 can either act as homodimers or 
heterodimers, however they preferentially heterodimerize as coexpression of these two receptors 
exerts a much stronger repressive activity on a DR5 containing reporter compared to expressing 
either receptor alone. In developing testis, TR2 and TR4 are coexpressed in the same testicular cell 
populations and exhibit a parallel pattern of expression during development (107).
 TR2 and TR4 have been shown to heterodimerise with other nuclear receptors 
(98). The androgen receptor can interact with TR4 and function as repressor to down-regulate 
the TR4 target genes by preventing TR4 binding to its target genes. The heterodimerization of 
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AR and TR4 also allows TR4 to repress AR target gene expression demonstrating a bidirectional 
suppression of their target genes (98). 
Receptor Interacting Protein 140 (RIP140) was shown to interact with TR2 using 
yeast two-hybrid system using the LBD of TR2 as bait. This interaction was further confirmed 
by immunolocalization experiments in COS cells (87). The RIP-interacting domain of TR2 maps 
to the C-terminal 10- to 20-amino-acid sequence of TR2, but the C terminus of TR2 alone is not 
sufficient for this interaction (87). RIP140 was also shown to interact with several other nuclear 
receptors (including ERα and AR) (5, 19, 20, 73). In addition Luciferase assays in COS cells 
showed that RIP140 potentiates the trans repression via a TR2  IR7 (inverted repeat) regulatory 
element (87). It has also been previously shown that TR2 co-immunoprecipitates with HDACs 3 
and 4. Dissection of TR2 domains showed that the DNA binding domain (DBD) was responsible 
for the interaction with HDACs 3 and 4 (27, 55, 56). 
 TR4 associated protein TRA16 is the first reported specific co-repressor of TR4, 
isolated by screening a human testis library by yeast two-hybrid using full length TR4 as the 
bait. This interaction was also further confirmed by immunofluorescence (177). TRA16 is a novel 
protein of 139 aa, with a total molecular weight of 16 kDa. TRA16 strongly interacts with TR4 
(176). Luciferase reporter assays in COS cells showed that TRA16 can repress TR4-mediated 
activation in a dose dependent manner (177). It was further suggested that TRA16 may confer 
its co-repressor function by interrupting the binding of TR4 to its target DNA sequence (177). 
Another yeast two-hybrid system, using the hinge-LBD domain of TR4 as a bait, identified TIP27 
as a co-repressor (118). This interaction was confirmed by in vitro and in vivo pull-down assays 
(118). Luciferase reporter assays showed that TIP27 repressed TR4-mediated transactivation on a 
DR1-Luc reporter construct but that this repression was not mediated byTR4 binding to the DR1 
element. The exact mechanism  of TIP27 function is still unknown (118). 
TR2 and TR4 in hematopoiesis•	
TR4 is highly expressed in hematopoietic cells. In fact, TR4 mRNA is very abundant 
in primary cultures of chicken bone marrow cells. Ectopic expression of TR4 in bone marrow cells 
resulted in an effective outgrowth in the myeloid compartment. Interestingly, although erythroid 
cells showed prominent expression of TR4 in all species analyzed, an outgrowth of erythroid 
progenitor cells was not observed. In addition, if introduced into established erythroid progenitors, 
TR4 had only a marginal growth promoting activity (84).
TR2 and TR4 have been shown to be the core DNA binding activity of the 
DRED complex. EMSA experiments, measuring the Ki for the DR1 elements in β-like globin 
gene promoters, showed that TR2 and TR4 bind different DRs with different affinities in the 
following order: human ε distal > ε proximal> γ; mouse εγ distal> βh1> εγ proximal. Data from 
these experiments also indicate that the affinity of the ε globin distal DR1 element for the TR2 
homodimer is lower than that for the TR4 homodimer or TR2/TR4 heterodimer, whose affinities 
are very similar (151). 
In transgenic mice bearing a dominant negative dnTR4 mutant that does not bind 
DNA  and a human β-globin locus YAC, the human ε-globin gene was activated in both primitive 
and definitive erythroid cells (126, 151). In contrast the human fetal γ-globin gene was only slightly 
affected during primitive erythropoiesis in the yolk sac, but was induced in the fetal liver (definitive 
erythropoiesis) stage. These data suggest that TR2/TR4 comprise a stage-specific, gene-selective 
repressor of the human embryonic and fetal globin genes. 
In addition, recent publications have shown that forced expression of TR2 and TR4 
under the control of the GATA-1–HRD in mice caused a reduction of murine εy transcription in a 
dose dependent manner (150). 
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Aims of the thesis
Despite the many attempts, so far there has been no general agreement in the field 
regarding the nature of  the mechanisms governing β-globin switching (51, 52, 111, 138). Many 
transcriptional regulators have been suggested to be key factors in this process (12, 46, 53, 113, 
114, 116, 143, 155, 173, 188, 189) and have become targets for pharmaceutical development 
(24, 29, 30, 35, 38, 50, 58, 77, 86, 100, 101, 104, 112, 123, 124, 132, 142, 169, 190). In addition, 
the experimental and clinical observations support the idea that the chromatin structure of the 
globin gene promoters, particularly of the embryonic ε-globin and the fetal γ-globin genes, is an 
important parameter in developmental globin gene switching (36, 43, 44, 47, 48, 67, 108, 115, 127, 
128, 130, 146, 156, 168). 
DRED is a recently identified complex (150) that has been implicated in embryonic 
ε-and fetal γ-globin gene silencing in adult (126, 150, 151). The core DRED component is the 
orphan nuclear receptor heterodimer TR2/TR4 which has been shown to bind to DR1 elements in 
the ε and γ globin gene promoters (126, 150, 151), however  the mechanism of their function in 
erythroid cells is not well  understood. 
The aim of this work was to purify TR2/TR4 interacting partners in erythroid cells, to 
gain more insight into how TR2/TR4 can silence (and also possibly to activate) the different globin 
genes in a temporal and spatial regulatory manner. To this end we used an in vivo biotinylation 
tagging technique which, as we further demonstrate, proves to be a very powerful tool for efficient 
protein complexes purification. It can also be very efficiently used for the mapping of transcription 
factor binding sites in vivo by chromatin immunoprecipitation (ChIP) experiments.
Table 1. Types of mutations in non- deletion HPFH, after (145) and the  references therein.
Type and ethnic group Mutation
Gγ HPFH
Japanese Gγ- 114  C to T
Australian Gγ -114 C to G
Black/Sardinian Gγ-175 T to C
Tunisian Gγ-200 +C
Black Gγ-202 C to G
Aγ HPFH
Georgian Aγ-114 C to T
Black Aγ-114 to -120 deleted
Greek Aγ-117 G to A
Cretan Aγ-158 C to T
Black Aγ-175 T to C
Brazilian Aγ-195 C to G
Chinese/Italian Aγ-196 C to T
British Aγ-198 T to C
Georgian Aγ-202 C to T
Table 2. Thallassaemias (based on (145) )
( δβ)º  thalassemia βº thalassemia (deletions that remove the β 
globin promoter)
Japanese Turkish/Bulgarian
Spanish African American
Indian Croatian
Turkish Thai
Macedonian/Turkish Czech
Black Turkish
Eastern European Asian Indian
Laotian Australian
Thai Dutch
Mediterranean/Sicilian Southeast Asian
Hb Lepore Filipino
(Aγδβ)º thalassemia Italian
Cantonese Deletions removing sequences of the LCR
Malaysian (1) and (2) Dutch
Chinese Anglo-Saxon
Yuannanese English
Thai Hispanic
German (εγδβ)º thalassemia
Belgian Mexican
Italian Canadian
Turkish Irish
American black Dutch
Indian
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Abstract
Efficient tagging methodologies are an integral aspect of protein complex characterization 
by proteomic approaches. Due to biotin’s very high affinity for avidin and streptavidin, 
biotinylation tagging offers an attractive approach for the efficient purification of protein 
complexes. The very high affinity of the biotin/(strept)avidin system also offers the 
potential for the single-step capture of lower abundance protein complexes, such as 
transcription factor complexes. The identification of short peptide tags that are efficiently 
biotinylated by the bacterial BirA biotin ligase, led to an approach for the single-step 
purification of transcription factor complexes by specific in vivo biotinylation tagging. 
A short sequence tag fused N-terminally to the transcription factor of interest is very 
efficiently biotinylated by BirA co-expressed in the same cells, as was demonstrated 
by the tagging of the essential hematopoietic transcription factor GATA-1. The direct 
binding to streptavidin of biotinylated GATA-1 in nuclear extracts resulted in the single-
step capture of the tagged factor and associated proteins, which were eluted and 
identified by mass spectrometry. This led to the characterization of several distinct 
GATA-1 complexes with other transcription factors and chromatin remodeling co-
factors, which are involved in activation and repression of gene targets. Thus, BirA-
mediated tagging is an efficient approach for the direct capture and characterization 
of transcription factor complexes.
Key words: biotinylation tagging; BirA; transcription factors; chromatin; mass spectrometry; 
size fractionation; GATA-1
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1. Introduction
 Completion of the sequencing of an ever-increasing number of genomes has led to a shift 
of focus towards the characterization of the protein complement of cells, i.e. the proteome. A key 
aspect of proteomic analysis is the development of simple methodologies for the efficient isolation 
of protein complexes for peptide analysis and identification by powerful mass spectrometric 
approaches. This is particularly challenging for the analysis of nuclear proteins involved in 
transcriptional regulation such as transcription factors and their chromatin associated co-factors 
due to their relatively lower abundance, the different parallel functions that they execute (e.g. 
activation and repression involving different partners) and the often transient nature of their 
interactions. Transcription factor purification approaches involving several pre-purification steps 
are laborious and costly and most likely result in the isolation of only the most abundant of the 
protein complexes formed by the factor. We describe here the application of in vivo biotinylation 
tagging as a simple approach for the efficient direct purification of transcription factor complexes 
from crude nuclear extracts (1). 
Biotin is a naturally occurring cofactor essential for certain metabolic enzymes such as 
carboxylases. Specific protein-biotin ligases are responsible for covalently attaching biotin to 
these enzymes. The key to using biotinylation lies in the fact that biotinylated substrates can be 
bound very tightly by the naturally occurring proteins avidin and streptavidin (Kd = 10
-15), a fact 
that has been widely exploited in many affinity-based biochemical applications. In addition, in 
vivo biotinylation tagging offers a number of advantages for protein purification purposes. Firstly, 
there are few naturally biotinylated proteins (mostly cytoplasmic and mitochondrial) ensuring that 
non-specific background binding remains low. Secondly, the very high affinity of (strept)avidin for 
biotin allows high stringencies to be employed during purification without fear of losing binding 
of the tagged protein.
The biotinylation tagging approach described here is based on previous work on the 
screening of a combinatorial synthetic peptide library for efficient biotinylation by the bacterial 
BirA biotin ligase (2). This led to the identification of a number of short sequence tags that can be 
very efficiently biotinylated in vitro (2, 3). Such tags were subsequently utilized for the efficient 
in vivo biotinylation of tagged proteins in bacterial cells through the co-expression of BirA (4, 5). 
We have applied this approach in mammalian cells and demonstrated its efficiency in specifically 
biotinylating nuclear proteins in cultured cells and transgenic mice through the co-expression 
of the BirA biotin ligase together with the tagged protein (Figure 1A) (1). Our work is focused 
primarily on the biotinylation tagging of hematopoietic transcription factors in erythroid cells. 
Most of our work to date has been carried out with GATA-1, a critical transcription factor for 
erythroid cell differentiation. We have been able to very efficiently biotinylate GATA-1 in cultured 
mouse erythroleukemic cells (Figure 1B and C; (1)) leading to the isolation and characterization of 
GATA-1 protein complexes by direct binding of nuclear extracts to streptavidin beads. Using this 
approach we identified a number of GATA-1 complexes, containing other essential hematopoietic 
transcription factors (FOG-1, Gfi-1b and TAL-1) and chromatin remodeling and modification 
complexes (MeCP1 and ACF/WCRF). These complexes were implicated in the transcriptional 
activation and repression of different subsets of target genes (6). Thus, biotinylation tagging 
has proven to be a very efficient method for the single-step purification and characterization 
of transcription factor complexes. It should also be noted that we have no evidence so far that 
biotinylation tagging adversely affects the physiological properties of the tagged protein (1).
In this chapter we describe protocols for the binding of nuclear extracts expressing a specific 
biotin-tagged protein to streptavidin beads and the preparation of the eluted material for analysis 
by mass spectrometry. We do not provide protocols for the stable transfection of cultured cells as 
these will vary depending on the cell line/type used in each case. We routinely prepare large scale 
nuclear extracts from a few liters of cultured cells, we test for the presence of the biotin tagged 
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Figure 1: (A) Scheme for the specific biotinylation of tagged GATA-1 by BirA biotin ligase in mouse erythroleukemic 
(MEL) cells. The sequence of the 23aa peptide tag fused to the N-terminus of GATA-1 is shown. The asterisk indicates 
the lysine residue that becomes specifically biotinylated by BirA. Speckled boxes indicate the positions of the two 
GATA-1 Zinc-fingers. (B) Biotinylation of tagged GATA-1 in MEL cells. Left panel: Western blot with an anti-
GATA-1antibody to detect endogenous and tagged GATA-1 proteins. Right panel: Western blot of the same extracts 
with streptavidin-HRP conjugate to detect biotinylated GATA-1. Biotinylated GATA-1 (asterisk) is clearly visible in 
the right panel only in the lane of the double transfected cells. (C) Efficiency of GATA-1 biotinylation and binding 
to streptavidin beads. Left panel: Western blot using anti-GATA-1 antibody to detect binding of tagged GATA-1 to 
streptavidin beads Input and unbound material are shown in lanes 1 and 3. Right panel: the same filter stripped and 
re-probed with streptavidin-HRP to detect the binding of biotinylated GATA-1 to streptavidin beads (lane 5). Lane 6 
shows that very little tagged GATA-1 remains unbound by streptavidin. In: Input (nuclear extract); El: Eluted material; 
Un: Unbound material. Reproduced with permission from (1). Copyright (2003) National Academy of Sciences, 
USA.
protein in high molecular weight complex(es) by gel filtration using a Superose 6 column and then 
carry out the binding of the tagged factor to streptavidin paramagnetic beads. 
We normally check the efficiency of the biotin tagging and the binding to streptavidin beads 
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by testing the nuclear extract (input), the bound material (eluate) and the flowthrough (unbound) by 
Western blotting using first an antibody against the tagged protein followed, by streptavidin-HRP 
14 16 18 20 22 24 26 28 30 32 34 36 38
Tagged
GATA-1
Endog.
GATA-1
Fraction #
V0 670kDa 70kDa
Figure 2: Superose 6 fractionation profiles of nuclear extracts from MEL cells expressing biotin-tagged GATA-1 detected by 
Western blotting. The tagged GATA-1 protein is migrating with a slower mobility to that of the endogenous GATA-1 due to the 
extra tag sequences fused to it. The elution of the molecular weight markers is indicated at the top. V0: void volume.
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Figure 3: TEV protease cleavage of bioGATA-2 bound to streptavidin beads. Panel (A): sequence and translation of the shorter 
biotinylation tag and the TEV protease cleavage site. Panels (B) and (C): Lane 1: nuclear extract from MEL cells expressing 
tagged GATA-2 (there is no endogenous GATA-2 expressed in MEL cells). Lane 2: biotinylated GATA-2 (bioGATA-2) bound to 
the beads. Lane 3: TEV protease cleavage of bound GATA-2. (A) Detection with anti-GATA-2 antibody. (B) Detection of the blot 
shown in panel A with streptavidin-HRP. TEV-cleavage of bioGATA-2 results in a downshift in size of the protein and loss of the 
biotin-tag (compare lanes 2 and 3 in panels A and B, respectively). Remaining uncleaved bioGATA-2 is indicated with an asterisk 
in panel B.
conjugate on the same blot. In this way the fraction of the tagged protein that becomes biotinylated 
in vivo and subsequently captured by the streptavidin beads can be determined. As shown in 
Figure 1, for GATA-1 the biotinylation efficiency and capture by the beads is nearly 100%. The 
proteins eluted from the beads are fractionated by SDS-PAGE, the gel is stained and photographed 
(Figure 4). The gel lane with the fractionated proteins is excised and cut into small pieces (or gel 
plugs) along its entire length. The gel plugs are then processed for protein identification by mass 
spectrometry. The following sections describe in detail all of these techniques. We also provide 
an overview of the background binding in experiments using nuclear extracts and the specific 
enrichment observed when purifying biotin tagged transcription factors (Figure 4). Lastly, we 
provide protocols for the size fractionation of nuclear extracts using a preparative Superose 6 
column and for the cleavage of proteins bound to streptavidin beads using TEV protease (Figure 
3). Both approaches are presented with the aim of reducing the background in protein purification 
by biotinylation tagging. Given the increase in the potential applications of biotinylation tagging 
for protein purification, the description of such protocols may prove a useful resource.
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2. Materials
2.1 Cell culture
Dulbecco’s Modified Eagle’s Medium (DMEM) (Cambrex Bio Science, Belgium), 1. 
supplemented with 10 % Fetal Bovine Serum (FBS, Hyclone, Belgium).
2. Penicillin (used at 100u/ml final concentration) and streptomycin (used at 100µg/ml final 
concentration), stored at –20oC (100x stock from Cambrex Bio Science, Belgium).
100% Dimethylsulfoxide (DMSO, Merck, Germany), used at 2% final concentration.3. 
Neomycin (Gibco-BRL, UK), stock prepared as 100mg/ml in phosphate buffered saline 4. 
(PBS, see below), filter-sterilized, aliquoted, stored at –20oC and used at 400µg/ml final 
concentration.
Puromycin (Sigma, St. Louis, MO), 1000x stock aliquoted and stored as above and added 5. 
to 1µg/ml final concentration.
2.2 Nuclear extract preparation
1. Dulbecco’s Phosphate Buffered Saline (PBS, Cambrex Bio Science, Belgium)
Protease inhibitors: Complete (Roche, Germany). Use 1 tablet for 50ml of solution2. 
Cell resuspension buffer: 2.23.  M sucrose in 10 mM HEPES-KOH, pH 7.9, 25 mM KCl, 
0.15 mM Spermine, 0.5 mM Spermidine, 1 mM EDTA (with protease inhibitors added as 
above).
Standard household blender with rotating blades for homogenizing cells. 4. 
Nuclear lysis buffer: 10 mM HEPES, pH 7.9, 100 mM KCl, 35.  mM MgCl2, 0.1 mM EDTA, 
20% glycerol (with protease inhibitors added as above).
Coomassie Plus Assay reagent (Pierce, IL).6. 
Protein standards:  dilutions of 0, 100, 200, 300, 400 and 500 7. µg/ml of chicken egg albumin 
(Sigma-Aldrich, MO) in ddH2O prepared from a 20 mg/ml stock solution. 10 µl of each 
standard diluted in 1 ml (final volume) of ddH2O is used for obtaining a standard curve.
Spectrophotometer: Ultraspec II (LKB Biochrom), cuvettes (Sterna, Germany).8. 
Conductivity meter: Philips PW 9526.9. 
Standards for determining salt concentration: 100, 200 300, 400 mM KCl diluted in ddH10. 2O 
from a 1M KCl stock solution. 10 µl of each standard are diluted in 1 ml (final volume) of 
ddH2O for obtaining a standard curve.
2.3 Size fractionation by Superose 6 gel filtration
Superose 6 analytical grade column:1.  HR 10/30 with a total bed volume of 24 ml. Preparative 
grade column: XK 50/600 with a bed height of 30.3 cm, total bed volume of 589 mL, both 
purchased form Amersham Biosciences (UK). Range of separation of 5,000 to 5,000,000 
Da. 20% ethanol is used as preservative. The column is connected to an AKTA FLPC 
system (Amersham Biosciences).
Gel filtration calibration kit: dextran blue and high molecular weight standards (Amersham 2. 
Biosciences, UK).
Column running buffer: 20mM HEPES, 0.5mM EGTA, 1mM MgCl3. 
2,
 200mM KCl, 10% 
glycerol. All buffers used for gel filtration column should be filtered prior to use.
100% Trichloroacetic acid (TCA, Sigma-Aldrich, MO).4. 
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2.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Pre-cast NuPAGE 4-12% Bis-Tris gel (Invitrogen, UK).1. 
Gel electrophoresis buffer: 1 X MOPS buffer diluted from 20 X stock solution and NuPAGE 2. 
antioxidant (both from Invitrogen, UK).
Sample loading buffer, final concentration: 62.5 mM Tris-HCl pH 6.8, 25% glycerol (v/v 3. 
from 100% stock, Sigma-Aldrich, St. Louis, MO), 2% SDS (v/v from 20% stock in ddH2O), 
0.01% bromophenol bl (w/v, Sigma-Aldrich, St. Louis, MO), 5 % β-mercaptoethanol (v/v, 
100% stock, Merck, Germany). Can be prepared as a 4X stock solution.
Broad range pre-stained SDS-PAGE molecular weight standards (BioRad, Hercules, CA).4. 
SimplyBlue Safestain gel staining solution (Invitrogen, UK).5. 
2.5 Western blotting
ProTran1.  nitrocellulose membrane (Schleicher & Schuell, Germany).
Gel-blotting paper (Schleicher & Schuell, Germany).2. 
Blotting buffer: 25 mM Tris (made directly from the solid), 192 mM Glycine (made directly 3. 
from the solid), 20% methanol.
Tris-Buffered Saline (TBS): 10 mM Tris-HCl, pH 7.4, 150 mM NaCl. Can be prepared as 4. 
a 10X stock and stored at room temperature.
Blocking buffer: 5% Bovine Serum Albumin (BSA, Roche, Germany) in 1X TBS, prepared 5. 
fresh.
Washing buffer 1x TBS adjusted to 0.5M NaCl (using a 5M NaCl stock solution), 0.3% 6. 
Triton X-100 (Sigma-Aldrich, MO).
Primary and secondary antibody dilution: in blocking buffer with 0.2% NP-40.7. 
Secondary antibodies: anti-rabbit (1/50000 dilution), anti-mouse (1/15000 dilution) from 8. 
Amersham Biosciences (UK), anti-rat (1/3000 dilution) and anti goat (1/4000 dilution) 
from DakoCytomation (Denmark). All antibodies are purchased as horseradish peroxidase 
(HRP) conjugates.
Enhanced Chemiluminescence (ECL) kit (Amersham Biosciences, UK).9. 
Bio-Max MR film (Kodak, Rochester, NY).10. 
2.6 Streptavidin binding
1. Streptavidin paramagnetic beads (Dynabeads M280, Dynal, Sweden).
Chicken Egg Albumin (Sigma-Aldrich, MO).2. 
Binding buffer: 1X TBS, 0.3% 0.3% NP-40 (Nonidet-40, Sigma-Aldrich, MO). 3. 
HENG buffer: 10 mM HEPES-KOH, pH 9, 1.5 mM MgCl4. 2, 0.25 mM EDTA, 20 % glycerol, 
1mM PMSF (phenyl methyl sulfonyl fluoride, prepared as a 100x stock in ethanol and 
stored at –20oC). 
Wash buffer: HENG buffer with 250 mM KCl and 0.3% NP-40.5. 
Elution buffer: 1X sample loading buffer.6. 
Magnets: Dynal MPC-1 and MPC-S magnets, for large and small volumes respectively 7. 
(Dynal, Sweden).
2.7 TEV protease cleavage
Nuclear extract dilution buffer: 20mM Tris-HCl pH7.5, 0.45% NP-40.1. 
Tobacco Etch Virus (TEV) protease (AcTEV Protease, Invitrogen, Scotland).2. 
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2.8 Sample preparation for mass spectrometry
Trypsin, sequencing grade (Roche,1.  Germany). 10x stock made by dissolving lyophilized 
powder in 1mM HCl to 100ng/µl final concentration. 
50mM Ammonium bicarbonate (Sigma-Aldrich, MO). Dissolved in ddH2. 2O and filter 
sterilized.
100% Acetonitrile (Sigma-Aldrich, MO).3. 
100% Formic acid (Sigma-Aldrich, MO).4. 
Gel slice destaining solution: 25mM ammonium bicarbonate in 50% acetonitrile prepared by mixing equal 5. 
volumes of the stock solutions given above.
50mM iodoacetamide (Sigma-Aldrich, MO) prepared in 50mM ammonium bicarbonate.6. 
6.5mM DTT (dithiothreitol, (Sigma-Aldrich, MO) prepared in 50mM ammonium bicarbonate.7. 
3. Methods
3.1 Cell culture
Mouse Erythroleukemia (MEL) cells are Friend virus transformed erythroid progenitors 1. 
arrested at the proerythroblast stage of differentiation (7). MEL cells are cultured in DMEM 
supplemented with 10% FBS at 37°C and 5% CO2. Cells are grown to a maximum of 2x10
6 
cells/ml and routinely split to a density of 5x104 cells/ml. Cells appear to be semi-adherent 
and rounded with a smooth surface (see Note 1). 
For induction, cells are diluted to 5x102. 5 cells/ml and cultured in DMEM with 2% DMSO 
(v/v) for at least 3 days. Cells become smaller but remain round and when pelleted appear 
pink/red due to hemoglobinization. 
3.2 Nuclear extract preparation
Cells are harvested in 1 liter centrifuge bottles by centrifugation at 640 x 1. g for 40 min at 4°C 
in a Beckman J4 centrifuge and washed once with 100 ml of ice-cold PBS. Resuspended 
cells are transferred into 50ml Falcon tubes and re-pelleted in an Eppendorf 5810R benchtop 
centrifuge at 2540 x g for 10 min at 4oC. The supernatant is discarded.
The cell pellet is gently resuspended by pipetting up and down in 200 ml of cell resuspension 2. 
buffer with protease inhibitors added. Cells are equilibrated to the new osmotic conditions 
for 20 min on ice.
Cells are3.  lysed in a blender using a single 30 second pulse at setting 3 (see Note 2). Excessive 
foaming should be avoided. 
Lysis efficiency is checked under the microscope by staining a 10 μl aliquot with an equal 4. 
volume of Unna stain (Methylgreen-Pyronin). Nuclei appear blue whereas intact cells 
appear with a blue nucleus surrounded by a non-stained cytoplasm. Optimal lysis should 
result in more than 90% of the nuclei appearing free of cytoplasm. 
Nuclei are pelleted by ultracentrifugation at 141,000 x 5. g using the SW28 rotor for 2 h at 
4°C. A clean white pellet corresponding to the nuclei should be visible at the bottom of the 
tube. The top layer (cellular debris/cytoplasm) is discarded.
Nuclei are resuspended in 15 ml of nuclear lysis buffer and proteins are extracted by the 6. 
drop wise addition of a 3.3M KCl solution with gentle agitation on ice, until the final 
concentration is ~350-400mM (see Note 3). Nuclear lysis and protein extraction are 
allowed to proceed by incubating on ice for 20 min. Two phases should be visible: one is 
clear and represents the soluble nuclear extract fraction whereas the other phase appears 
viscous and represents the insoluble fraction of mostly chromatin fragments. 
Insoluble material is removed by ultracentrifugation at7.  300,000 x g using the SW50.1 
rotor for 1 h at 4°C. The supernatant (soluble nuclear extract, approximately 17-18ml) is 
aliquoted in 1-5ml aliquots. 
A small aliquot is used to measure protein concentration using the Bradford method. First, 8. 
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a standard curve is obtained by adding 200µl of Bradford reagent to 800 μl of each of the 
chicken egg albumin standards, incubating for 5 min at room temperature and measuring the 
absorbance at 595nm in a spectrophotometer. The absorbance of dilutions of the aliquot of 
the nuclear extract are measured in the same way. The concentration of the nuclear extract 
is determined using the standard curve, taking the dilution of the sample into account. 
The salt concentration of the solution is determined by measuring the conductance of the 9. 
sample with a conductivity meter. First, a calibration curve of conductance is obtained 
using the KCl dilutions as standards. The conductivity of a diluted aliquot of the nuclear 
extract is then measured and its approximate salt concentration is estimated using the 
calibration curve.
Nuclear extracts are snap frozen in liquid nitrogen and stored at –70°C (10. see Note 4).
3.3 Analytical Superose 6 gel filtration (see Note 5)
An aliquot of nuclear extract is thawed on ice and centrifuged for 5 min at full speed using 1. 
a microcentrifuge at 4°C. The volume of extract loaded on the column should not exceed 
1% of the column volume.
The pump and the column are equilibrated with column running buffer. The running 2. 
program is set up as follows: 100 μl/min flow rate; sample volume loop 200µl; fraction 
volume 500 μl; elution length 1 column volume of running buffer; alarm pressure set at 0.5 
MPa (see Notes 6 and 7). After each run the column is washed with 2 column volumes of 
running buffer.
The calibration standards are run through the column to establish the elution volume of 3. 
protein complexes and of free protein monomers (see Notes 8-10).
Collected fractions are concentrated by trichloroacetic acid precipitation (TCA), as follows: 4. 
125 μl of cold 100 % TCA are added to each 500 µl fraction, mixed well and incubated on 
ice for 30 min.
Proteins are pelleted by centrifugation at full speed in a microcentrifuge at 45. 0C for 20 
min.
The supernatants are discarded and the pellets washed with at least 5006. µl 1% ice cold TCA 
(in ddH2O) and re-centrifuged as above.
The supernatants are discarded again and the pellets are washed with ice-cold acetone and 7. 
re-centrifuged as above.
The pellets are air dried (on ice) and re-suspended in 50 μl of sample loading buffer (8. see 
Note 11). The fractionation patterns of specific proteins are determined by SDS-PAGE and 
Western blotting, as described below. An example of a GATA-1 Superose 6 fractionation 
profile of nuclear extracts from MEL cells expressing biotin-tagged GATA-1, is shown 
in Figure 2. From this, it is clear that both endogenous and tagged GATA-1 elute in high 
molecular weight (>670kDa) fractions. The fractionation profile of tagged GATA-1 follows 
that of the endogenous GATA-1 protein.
3.4 Preparative gel filtration by Superose 6
Steps 1 and 3 are as above.1. 
Running program: 4ml/min flow rate; sample volume loop 5ml; fraction volume 10ml; 2. 
elution length 1.5 column volumes; alarm pressure set at 0.65Mpa (see Note 12).
Fractions are collected in 15 ml Falcon tubes and used for precipitation (see below) or for 3. 
binding to streptavidin beads (section 3.6).
Proteins are precipitated with 20% TCA (2.5 ml of 100 % TCA are added to every 10ml 4. 
fraction) and kept on ice for 1h. The tubes are centrifuged in an Eppendorf 5810R benchtop 
centrifuge at maximum speed (2540 x g) for 20 min at 4°C. The pellet is subsequently washed 
with ice-cold 1% TCA (in ddH2O). At this step the pellet can be carefully resuspended and 
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transferred into microfuge tubes. The samples are re-pelleted by spinning as above, or in 
a microfuge for 20 min, full speed at 4ºC. The pellets are washed with ice-cold acetone, 
centrifuged again as above and air dried on ice. The protein pellets are finally resuspended 
in 50µl of sample loading buffer and denatured by boiling before loading on an SDS-PAGE 
gel (section 3.8). 
3.5 Binding to streptavidin beads
5-10mg of nuclear extract is thawed on ice and diluted to 150mM KCl final concentration 1. 
by the dropwise addition of ice-cold HENG with gentle shaking (see Note 13). NP-40 is 
adjusted to a 0.3% final concentration.
We routinely use 200 μl of resuspended streptavidin beads per 5mg of nuclear extract. The 2. 
beads are blocked with 200ng/ml chicken egg albumin (CEA) in a 1ml final volume (made 
up with HENG buffer), for 1 hour at room temperature on a rotating platform.
The beads are immobilized using a magnetic rack and the blocking solution is removed. 3. 
The beads are then resuspended in the diluted nuclear extract and incubated on a rotating 
platform 4°C for 2 hours to overnight. 
The beads are immobilized on ice using the magnetic rack. The supernatant, corresponding 4. 
to the unbound fraction or flowthrough, is collected and saved.
The beads are washed in 1 ml of washing buffer as follows: 2 quick rinses followed by 3 5. 
washes, 10 min each at room temperature on a rotating platform.
After the last wash, the beads are resuspended in 50 μl of sample buffer. Bound proteins are 6. 
eluted by boiling the beads for 5 min.
The eluted material is fractionated by SDS-PAGE and processed for analysis by mass 7. 
spectrometry as described below.
3.6 Binding of preparative Superose 6 fractions to streptavidin beads
After determining the fractionation profile of the protein(s) of interest by SDS-PAGE and 1. 
Western blotting (as below), the peak fractions are pooled in a suitable sterile container 
(we conveniently use a sterilized glass measuring cylinder). All work is carried out on ice 
or in the cold room.
KCl and NP-40 concentrations are adjusted to 150mM and 0.3%, respectively (as above) 2. 
with gentle mixing.
The diluted fractions are divided equally into separate 50ml Falcon tubes, so that tubes are 3. 
not more than ¾ full, and resuspended streptavidin M280 beads (equilibrated and blocked 
as above) are added followed by overnight incubation at 4oC on a rotating platform. We use 
approximately 10µl of streptavidin M280 beads for every 10ml fraction.
The beads are immobilized using the Dynal MPC-1 magnet and the supernatant 4. 
corresponding to the unbound fraction is removed and saved. The immobilized beads from 
each tube are resuspended in washing buffer and pooled by transferring to a microfuge 
tube.
The beads are washed 4-5 times at room temperature in 1ml washing buffer for 5-10 min 5. 
each.
The bound proteins are eluted by boiling the beads in sample buffer (506. µl of sample buffer 
per 20µl of immobilized beads). The eluted material is fractionated by SDS-PAGE and 
processed for analysis by mass spectrometry as described below.
3.7 TEV protease cleavage
With the aim of reducing the non-specific background observed in streptavidin binding experiments, 
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we developed a modified version of the biotin tag for the N-terminal tagging of fusion proteins. 
This tag consists of a shorter (14aa) amino acid sequence than the one previously used but which is 
also very efficiently biotinylated by the BirA biotin ligase (3). The biotin tag sequence is followed 
by a 7aa cleavage site for the highly specific TEV-protease (Tobacco Etch Virus protease) (Figure 
3A). In this way, the biotinylated protein and associated complexes can be specifically released 
from the streptavidin beads by cleaving off with the TEV protease (Figure 3B and C).
Immediately after the washing steps (step 5, section 3.5) the streptavidin paramagnetic 1. 
beads are resuspended in 1xTBS/0.3% NP-40 buffer (95µl of buffer for every 50µl of 
resuspended beads used in the outset of the experiment). 
5-10% (v/v) of TEV-protease is added to the resuspended beads followed by incubation for 2. 
1-3h at 16oC with shaking (see Note 14).
The supernatant can be collected (it should contain the cleaved protein) and, if necessary, 3. 
can be concentrated by TCA precipitation, as above.
The efficiency of protease cleavage can be monitored by testing an aliquot of the supernatant 4. 
by SDS-PAGE and Western blotting (Figure 3B and C). The material that remains bound to 
the beads after TEV protease cleavage can be eluted by boiling in sample buffer and tested 
by SDS-PAGE. Successful cleavage results in the loss of the biotin-tag (as visualized by 
Streptavidin-HRP, Figure 3C) accompanied by a downshift in the size of the tagged protein 
thus resulting in faster migration by SDS-PAGE (as visualized by the tagged protein-
specific antibody, Figure 3B).
3.8 SDS-PAGE
We preferably use NuPAGE pre-cast gels since they give clear and reproducible results in terms 
of resolution and sharpness of the protein bands. This if of particular importance if the gel is to be 
processed for mass spectrometry. There is also the added advantage of using gradient precast gels 
(e.g. 4-12%) for resolving proteins in a wide range of molecular weights. We use the Invitrogen 
electrophoresis system for running the NuPAGE gels.
Pre-cast gels are removed from the plastic envelope and rinsed in ddH1. 2O. The sticker near 
the bottom of the gel and the comb are removed carefully. 
800 ml of 1X MOPS electrophoresis buffer are prepared.2. 
The gel is placed in the electrophoresis system (Invitrogen). The outside chamber is filled 3. 
with 600 ml of 1X MOPS. 
500 μl of antioxidant are added to the remaining 200 ml of the 1X MOPS buffer, mixed and 4. 
used to fill the inner chamber. 
The wells of the gel are rinsed twice with the running buffer.5. 
The samples in sample loading buffer are boiled for 5 min to denature the proteins and 6. 
loaded directly onto the gel. 5-10 µg of nuclear extract are loaded per lane.
The gel is electrophoresed at 200V constant voltage for 60-75 min.7. 
3.9 Western blotting
Samples that have been separated by SDS-PAGE are electrophoretically transferred onto 
nitrocellulose membrane by “wet blotting”. For protein transfer we use the Trans-Blot electrophoretic 
transfer cell (Bio-Rad, CA).
Four gel-blotting papers are cut to the size of the gel. A “sandwich” is set up consisting of 1. 
a sponge, 2 pieces of blotting paper, the gel, the membrane, another 2 pieces of blotting 
paper and a sponge (see Note 15). The membrane is pre-wetted in water followed by 
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transfer buffer.
The “sandwich” is placed in the transfer tank containing transfer buffer pre-chilled at 42. 0C, 
such that the membrane is between the gel and the anode. 
Blotting is carried out under constant amperage at 390 mA for 70 min in the cold room (3. see 
Note 16).
At the end of the transfer, the “sandwich” is disassembled and the membrane is rinsed in 4. 
1x TBS / 0.05% NP-40 (see Note 17).
The membrane is blocked at room temperature in freshly prepared blocking buffer for 1 5. 
hour on a rocking platform.
The blocking buffer is discarded, replaced by the primary antibody (in this case anti-6. 
GATA-1 N6 antibody diluted 1:5000) in blocking buffer / 0.2 % NP-40 and incubated 
overnight at 4°C on a rotating wheel.
The primary antibody is removed and the membrane washed three times with 50 ml of 7. 
washing buffer, 15 min each wash at room temperature (see Note 18).
A freshly prepared secondary antibody (in this case anti-rat diluted 1:3000 in blocking 8. 
buffer) is added to the membrane and incubated for one hour at room temperature on a 
rocking platform.
The secondary antibody is discarded and the membrane is washed as in step 8, followed by 9. 
one wash for 5 min in 1xTBS/0.05% NP-40.
The membrane is lifted out of the wash buffer and excess liquid is removed by touching it 10. 
on a clean tissue and placed in a clean tray such as a plastic weigh boat. 
3 ml of ECL solution (per filter) is prepared according to the manufacturer’s instructions 11. 
and immediately added to the membrane and shaken gently for 1 min to ensure an even 
coverage of the membrane by the liquid.
Excess liquid is again removed by touching the membrane on a clean tissue. The membrane 12. 
is wrapped in cling wrap and exposed to film in an autoradiography cassette in a dark room, 
as soon as possible.
3.10 Preparation of samples for mass spectrometry (see Note 19)
The procedures described below are for the analysis by liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) using a Q-Tof Ultima API mass spectrometer. The treatment of samples 
may vary depending on the type of analysis and the instrument used. It is best to consult with the 
mass spectrometry facility where the analysis is to be carried out for the processing of samples.
Following electrophoresis by SDS-PAGE the gel is stained overnight with Colloidal Blue, 1. 
according to the manufacturer’s instructions.
The gel is destained in several changes of ddH2. 2O until the background (i.e. the non-protein 
containing part of the gel) is completely destained. This usually takes several hours (i.e. 
more than 12 hours).
The destained gel is photographed to provide a record of the purification experiment.3. 
20-25 microfuge tubes are rinsed in 60% acetonitrile.4. 
The entire lane is cut out lengthwise and divided into5.  at least 20 gel slices. Each gel slice 
is placed in a separate tube.
Each gel slice is destained in 100 μl of destaining solution (25mM ammonium bicarbonate in 6. 
50% acetonitrile) for 20-30min. This step is repeated until the gel slice becomes completely 
destained (usually 3-4 times). Alternatively, gel slices can be destained overnight at 4oC.
Each gel slice is dehydrated in 100 μl of 100% acetonitrile for 5-10min at room temperature. 7. 
The plug become hard and white at this step.
The gel slices are reduced8.  with freshly prepared 6.5mM DTT solution for 45-60min at 
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37oC.
The solution is discarded and proteins in the gel slices are alkylated by adding 1009. µl of 54 
mM iodoacetamide solution and incubating for 60min at room temperature in the dark.
The solution is discarded and the gel slices are washed in 10010. µl of gel slice destaining 
solution for 15 min at room temperature. This step is repeated once more.
The washing solution is discarded and the gel slices are dried in 100 μl of 100% acetonitrile for 11. 
10min. The solution is again discarded and the gel slices are dried at room temperature.
Proteins are in-gel digested in 1512. µl of 10 ng/μl modified trypsin at (diluted from the 100x 
stock in 50 mM ammonium bicarbonate) for 30 min on ice (see Note 20). 15 μl of 50 
mM ammonium bicarbonate are added to the samples followed by overnight incubation at 
37°C.
Samples are equilibrated to room temperature. 3013. µl of 2% acetonitrile in 0.1% formic acid 
are added to the samples and incubated at room temperature for 15 min. The samples are 
then vortexed briefly and sonicated for 1 minute. 
The supernatants are collected in separate tubes and the remaining gel slices are treated 14. 
with 30µl of 50% acetonitrile in 0.1% formic acid and incubated as above. Samples are 
again vortexed and sonicated as above and the supernatants are collected and pooled with 
the corresponding supernatants from step 14.
The samples are vacuum dried in a vacuum centrifuge for 45-60 minutes until they are 15. 
dry.
The eluted peptides are now ready for analysis by mass spectrometry.16. 
Figure 4A shows an example of a preparative binding of nuclear extracts from MEL cells expressing 
biotinylated GATA-1 (lane 3) and control extracts from cells expressing the BirA biotin ligase 
only (lane 5). The control binding experiment shows that background consists of a few strongly 
stained bands against a backdrop of more faintly staining bands. Analysis by mass spectrometry 
identified the strongly staining bands as corresponding to naturally biotinylated proteins such as 
carboxylases (1). The bulk of the remaining background proteins corresponded to abundant nuclear 
proteins such as splicing factors, proteins involved in ribosome biogenesis etc. (Figure 4B). The 
low background binding (<1% of the total) of transcription factors and chromatin remodeling and 
modification proteins is of note (Figure 4B). By contrast, analysis of the GATA-1 purification gel 
slice shows a large increase in the binding of transcription factors and chromatin remodeling and 
modification proteins, thus indicating specific co-purification with biotin-tagged GATA-1 (Figure 
4C) (6). 
A number of these interactions have been validated by independent immunoprecipitation 
experiments using nuclear extracts from non-transfected MEL cells and shown to include essential 
hematopoietic transcription factors such as FOG-1, TAL-1 and Gfi-1b in addition to chromatin 
remodeling complexes such as MeCP1 and WCRF/ACF (6). In addition, the analysis of the GATA-1 
binding experiment identified abundant chromatin associated proteins, such as topoisomerases, as 
background due to their indirect co-purification with GATA-1 by virtue of their association with 
chromatin. Thus, we have defined background in these experiments as consisting primarily of 
naturally biotinylated proteins, abundant nuclear proteins associated with RNA metabolism and 
ribosome biogenesis and abundant chromatin associated proteins that are indirectly co-purified 
with chromatin-bound transcription factors.
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Future prospects
We have shown that biotinylation tagging is highly efficient in cultured cells (Figure 
1) and transgenic mice (1) and we have used this approach to identify a number of different 
complexes formed by the essential hematopoietic transcription factor GATA-1 (6). Due to its 
efficiency and ease of application, biotinylation tagging offers the prospect of rapidly expanding 
the characterization of transcription factor complexes. For example, the biotinylation tagging 
of the hematopoietic transcription factor partners of GATA-1 and the characterization of their 
protein complexes will lead to the rapid elucidation of the distinct and overlapping transcriptional 
networks these factors regulate in hematopoiesis. Similarly, the biotinylation tagging of chromatin 
co-factors will lead to a better understanding of their interactions with tissue-specific transcription 
factors and the molecular basis of their functions (i.e. chromatin remodeling and modification 
in activation and repression). Furthermore, efforts in reducing the background along the lines 
described here (i.e. a pre-purification steps such as gel filtration or the use of protease cleavage) 
will help in further expanding the utility of biotinylation tagging, for example in preserving the 
native properties of complexes or in determining stoichiometries. The utility of biotinylation 
tagging will be further increased through the development of additional tools such as the recent 
derivation of a transgenic mouse strain that expresses BirA ubiquitously in all tissues (8), or the 
construction of a codon-optimized version of BirA for the efficient expression in mammalian cells 
(9). The recent description of the biotinylation of cell surface proteins (10) should also serve to 
expand the utility of this approach. Lastly, it should be noted that in vivo biotinylation tagging 
can also be employed (e.g. instead of antibodies) in all other applications involving an affinity 
purification or detection step, such as immunofluorescence (1), immunoprecipitations (1, 11) and 
chromatin immnoprecipitation (ChIP) assays (1, 12).
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Figure 4: (A) Colloidal Blue-stained gel of a binding experiment of crude nuclear extracts to streptavidin beads. Lane 1: Marker 
(M). Lane 2: input nuclear extract from tagged GATA-1/BirA double transfected cells. Lane 3: proteins eluted after binding to 
streptavidin beads. Lane 4: input nuclear extract from BirA transfected cells. Lane 5: proteins eluted after binding to streptavidin 
beads. Arrow in lane 3 indicates protein band containing biotinylated GATA-1, as determined by mass spectrometry. (B) Classification 
according to Gene Ontology criteria of proteins identified by mass spectrometry from the control experiment using extracts from 
cells expressing BirA (around 500 peptide sequences were identified). This represents the background binding. (C) Classification 
according to Gene Ontology criteria of proteins identified by mass spectrometry using extracts from cells expressing biotin tagged 
GATA-1 (more than 1000 peptide sequences were identified). A significant increase in the identification of chromatin remodelling 
proteins and transcription factors is clearly notable compared to the control experiment shown in (B). Fig. 4A reproduced with 
permission from (1). Copyright (2003) National Academy of Sciences, USA.
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5. Notes
We routinely screen 12-20 stable transfected MEL cell clones by SDS-PAGE in order to 1. 
select a clone that expresses the tagged protein at no more than 50% of the expression level 
of the endogenous protein. This is in order to ensure that the physiological interactions and 
functions of the protein of interest are not disturbed as a result of the overexpression of the 
tagged protein.
The specific lysis conditions will depend on the make of blender employed. It is 2. 
recommended that conditions are optimized for cell density, length of lysis time and speed 
setting of the blender.
The final salt concentration is critical for the extraction of nuclear proteins. 3. 
We routinely obtain around 100 mg of nuclear extract from 4 liters of MEL cell culture at 4. 
a density of 2x106 cells/ml.
There are a large variety of column matrices commercially available for gel filtration, with 5. 
each matrix having different optimal separation ranges and physicochemical properties 
(e.g. ability to withstand high pressure in the column). Thus, the choice of matrix will 
depend on the desired range of fractionation and the liquid chromatography operating 
system available to the user (e.g. FPLC or HPLC).
Users must also refer to the manufacturer’s instructions and training for use of the column 6. 
and the FPLC apparatus.
The resolution efficiency of new columns, expressed as the number of theoretical plates 7. 
per meter of column under normal running conditions, should be tested first. This can be 
done by injecting a sample of acetone (5mg/mL) in ddH2O water. Indicative efficiency for 
the analytical grade column is 11100 theoretical plates/m.
While loading the extract, care must be taken that no air bubbles enter the loop. Air bubbles 8. 
as well as cell debris can damage the column bed.
Once a new column is installed, the void (V9. 0) volume is determined by the peak of elution 
of dextran blue. In order to further calibrate the column, a mixture of at least two proteins of 
known molecular weight should also be injected. Recommended standards: bovine serum 
albumin (67kDa), thyroglobulin (669kDa), aldolase (158kDa).
If there is any suspicion that the column bed has been damaged, it is best to run the 10. 
calibration standards again.
If the blue color of the sample loading buffer turns yellow, it is due to the protein sample 11. 
being acidic which will also affect migration of the sample during SDS-PAGE. A few 
microliters of Tris-HCl pH9.0 are usually sufficient to neutralize the sample.
To avoid pressure build up the run can be started at a flow rate of 1ml/min. It is also better 12. 
to inject the sample with the lower flow rate.
The concentration of 150mM KCl is critical for the efficient binding of biotinylated proteins 13. 
to streptavidin beads. We have found that even modest increases in salt concentration 
severely affect binding efficiency.
Protease cleavage also works well with shorter incubation times (5-30min) and a broader 14. 
temperature range (4-37oC).
Avoid handling membrane directly, use gloves and forceps.15. 
Under these transfer conditions, the temperature of the buffer can rise significantly and 16. 
frothing may occur. This does not affect the transfer.
The gel can be stained after blotting in order to visualize residual proteins as a test for the 17. 
efficiency of transfer as well as an indication of the amount of protein loaded per lane.
The primary antibody can be stored and re-used. Sodium azide is added to the antibody 18. 
solution to a 0.02% final concentration and stored at 40C (sodium azide stock: 10% w/v in 
ddH2O. Caution: sodium azide is highly toxic.
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In order to reduce the risk of contaminating the samples for mass spectrometry, particularly 19. 
with keratins, work is carried out in a hood wearing double gloves, a lab coat and always 
using sterile plasticware.
The volume of trypsin solution added will depend on the size of the gel slice. The volumes 20. 
given above are for appr. 4x2mm gel slices. At this stage, gel slices should swell and little 
solution should remain visible.
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Abstract
GATA-1 is essential for the generation of the erythroid, megakaryocytic, eosinophilic 
and mast cell lineages. It acts as an activator and repressor of different target genes, e.g. in 
erythroid cells it represses cell proliferation and early hematopoietic genes while activating 
erythroid genes, yet it is not clear how both of these functions are mediated. Using a biotinylation 
tagging/proteomics approach in erythroid cells we describe distinct GATA-1 interactions with 
the essential hematopoietic factor Gfi-1b, the repressive MeCP1 complex and the chromatin 
remodeling ACF/WCRF complex, in addition to the known GATA-1/FOG-1 and GATA-1/
TAL-1 complexes. Importantly, we show that FOG-1 mediates GATA-1 interactions with the 
MeCP1 complex, thus providing an explanation for the overlapping functions of these two 
factors in erythropoiesis. We also show that subsets of GATA-1 gene targets are bound in 
vivo by distinct complexes, thus linking specific GATA-1 partners to distinct aspects of its 
functions. Based on these findings we suggest a model for the different roles of GATA-1 in 
erythroid differentiation. 
Keywords: chromatin/GATA-1/hematopoiesis/repression/transcription factors
Subject category: Chromatin and transcription
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Introduction
Hematopoiesis has served as a model for cellular commitment and differentiation.  Hematopoietic 
stem cells (HSCs) commit to a number of divergent yet narrowly defined lineages, each giving 
rise to a specific type of blood cell. Lineage commitment involves the upregulation of a particular 
transcription program with the concomitant suppression of “multipotentiality” and transcriptional 
programs specifying alternative lineages (Orkin, 2000). 
GATA-1 is a key regulator of the differentiation of the erythroid, megakaryocytic, eosinophilic 
and mast cell lineages and is the founding member of the GATA family of zinc-finger factors 
implicated in the development and differentiation of several cell types . Efforts to understand 
GATA-1 functions have identified a number of protein interactions with transcription factors, 
such as TAL-1 (and its associated proteins Ldb1, LMO2 and E2A), EKLF, PU.1 and Sp1 
(reviewed by Cantor, 2002). GATA-1 is also reported to interact with chromatin remodeling/
modification proteins, including the CBP/p300 histone acetyltransferases and the SWI/SNF 
chromatin remodeling complex (Blobel et al., 1998; Kadam and Emerson, 2003). Prominent 
amongst the GATA-1 interacting partners is FOG-1, originally identified in a yeast two-hybrid 
screen (Tsang et al., 1997). A direct interaction between the two factors is required for erythroid 
differentiation (Crispino et al., 1999) and the GATA-1 and FOG-1 knockout phenotypes are very 
similar (Tsang et al., 1998). 
GATA-1 functions as both an activator and a repressor. The GATA-1/FOG-1 complex has been 
shown to repress some genes, such as GATA-2, and activate others, such as β-globin or the 
EKLF gene (Anguita et al., 2004; Letting et al., 2004; Pal et al., 2004). GATA-1 has also been 
linked to the repression of genes with cell proliferation functions, e.g. myc and myb (Rylski 
et al., 2003), though its protein partners are unknown. The multimeric GATA-1/TAL-1/Ldb1/
E2A/LMO2 complex binds to closely spaced GATA and E-box binding motifs and has been 
associated with the activation of erythroid genes, such as glycophorin A and the α-globin locus 
(Anguita et al., 2004; Lahlil et al., 2004). The duality of GATA-1 as an activator and repressor has 
been reinforced by the recent microarray analysis of terminal erythroid differentiation following 
induction of GATA-1 expression (Welch et al., 2004). Despite all this information, important 
questions remain as to how can GATA-1 accommodate all these functions and interactions at 
the same time in erythroid cells? In addressing this, we have undertaken a biotinylation tagging-
proteomics approach to characterize GATA-1 complexes from erythroid cells (de Boer et al., 
2003). We show that GATA-1 forms distinct complexes with hematopoietic transcription factors 
and chromatin remodeling and modification complexes. Our findings provide an explanation 
for a number of previous observations regarding GATA-1 functions and protein interactions. 
In addition, we provide evidence for distinct GATA-1 complexes performing specific functions 
in erythroid cells, thus providing a new framework for future work on GATA-1 and its parallel 
functions in erythroid differentiation.
Results
Identification of GATA-1 complexes from erythroid cells by biotinylation tagging 
and mass spectrometry
GATA-1 was tagged by fusing of a small (23aa) peptide sequence to its N-terminus. This 
tag is efficiently biotinylated by the bacterial BirA biotin ligase which is co-expressed in stably 
transfected mouse erythroleukemic (MEL) cells, allowing a single step purification of biotinylated 
GATA-1 using streptavidin beads under mild conditions (de Boer et al., 2003). Proteins co-
purified with GATA-1 from MEL cells chemically induced to undergo terminal differentiation, 
were identified by mass spectrometry, classified according to Gene Ontology terms or by BLAST 
searches and compared to the background (Suppl. Table 1). Additional experiments employed 
more stringent conditions and different nuclear extract preparations from induced MEL cells. We 
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Figure 1: Confirmation by streptavidin pull-downs (A-C) and immunoprecipitations (D-G) of proteins identified co-purifying with 
GATA-1. (A) Streptavidin pull-downs of transcription factors. Biotinylated GATA-1 (top panel) is detected by streptavidin-HRP 
and is absent from the BirA only transfected cells. (B) Pull-downs of the MeCP1 complex. (C) Pull-downs of ISWI-containing 
complexes. SB: streptavidin-bound. (D) Immunoprecipitations (IP) using antibodies against GATA-1, TAL-1, FOG-1 (lanes 2, 3 
and 4, respectively) and nucleophosmin as negative control (lane 5). (E) IP of the MeCP1 complex by antibodies against GATA-1 
and MTA2 (lanes 2 and 3) and nucleophosmin (lane 4). (F) GATA-1, can be specifically IP’d by an antibody against MTA2 (G) IP 
of the ACF/WCRF complex by GATA-1 antibodies. Nuclear extract equivalent to 5% used in each pull-down or IP was loaded as 
control for input material. IP: immunoprecipitating antibody. Arrows show the detecting.
rejected proteins that appeared in the background binding experiments (de Boer et al., 2003), or 
proteins that belonged to a subnuclear compartment from which GATA-1 is excluded, e.g. the 
nucleolus (Elefanty et al., 1996). Streptavidin pull-downs of nuclear extracts under more stringent 
conditions (Fig. 1A-C) and immunoprecipitations of induced non-transfected MEL nuclear extracts 
provided further validation (Fig. 1D-G). The identities of proteins confirmed in this way as co-
purifying with GATA-1 are shown in Table 1. 
Finding FOG-1, TAL-1 and Ldb1 co-purifying with GATA-1 (Tsang et al., 1997; Wadman et 
al., 1997) validated our approach. The Gfi-1b hematopoietic transcription factor was also 
identified under moderate stringency conditions and verified by immunoprecipitation (Fig. 1D, 
lane 2) demonstrating an interaction between the two factors. This is in line with the similarities 
observed in the Gfi-1b and GATA-1 knockout phenotypes which result in differentiation arrest of 
the erythroid and megakaryocytic lineages (Pevny et al., 1995; Saleque et al., 2002). Chromatin 
remodeling and modification proteins also co-eluted with GATA-1 (Table 1) including the entire 
MeCP1 complex (Fig. 1). MeCP1 consists of the methyl-DNA binding protein MBD2 (Feng and 
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Zhang, 2001), p66/p68 (Feng et al., 2002) and the multi-subunit Mi-2/NuRD complex containing 
the nucleosome stimulated Mi-2β ATPase, the histone deacetylases HDAC1 and HDAC2 and 
other subunits of unknown function . The Mi2/NuRD and MeCP1 complexes are associated with 
epigenetic mechanisms of repression during development (Ahringer, 2000), potentially linking the 
GATA-1 repressive functions to the MeCP1 complex.
The SNF2h and ACF1 members of mammalian ISWI chromatin remodeling complexes also 
co-purified with GATA-1 (Table 1, Fig. 1C, G). SNF2h, a homolog of the Drosophila protein ISWI, 
is the “signature” ATPase of this class of complexes and participates in three distinct complexes 
in human cells: RSF, hACF/WCRF, hCHRAC (reviewed in (Corona and Tamkun, 2004)). We did 
not detect by mass spectrometry or immunoprecipitation (not shown) the additional p15 and p17 
protein partners present in the hCHRAC complex hence GATA-1 appears to interact with SNF2h/
ACF1 in the context of the ACF/WCRF complex (Bochar et al., 2000). ISWI/SNF2h-containing 
chromatin remodeling complexes have been associated with gene activation and repression 
(reviewed by (Corona and Tamkun, 2004). The interaction between SNF2h and GATA-1 may 
help explain the observation that knocking down SNF2h expression in primary hematopoietic 
progenitor cells blocked erythroid differentiation (Stopka and Skoultchi, 2003).
Further validation for the GATA-1 interactions was provided by reverse immunoprecipitations 
using antibodies against TAL-1, FOG-1 (Fig. 1D) or MTA2 (Fig. 1E). TAL-1 antibodies specifically 
immunoprecipitated GATA-1 and Ldb1 (Fig. 1D), as previously observed (Osada et al., 1995; 
Visvader et al., 1997). LMO2 or E2A were not detected co-purifying with GATA-1 from induced 
MEL cells, but it cannot be excluded that their absence is due to the very low abundance of the 
GATA-1/TAL-1/Ldb1/E2A/LMO2 complex (Table 1), in agreement with previous reports of a 
very small fraction of LMO2 being immunoprecipitated by GATA-1 antibodies (Osada et al., 
1995). Interestingly, FOG-1 antibodies immunoprecipitated GATA-1 but not TAL-1, Ldb1, or Gfi-
1b (Fig. 1D, lane 4). The converse was also true using TAL-1 antibodies (Fig. 1D, lane 3). Thus, 
GATA-1 interactions with TAL-1, FOG-1 and Gfi-1b are non-overlapping and must thus occur 
in distinct complexes. GATA-1 was also immunoprecipitated by MTA2 antibodies (Fig. 1F). By 
contrast, the Sin3A co-repressor, which interacts with HDACs but not in the MeCP1 complex, 
was not immunoprecipitated by GATA-1 or MTA2 antibodies (Fig. 1E) further supporting the 
specificity of the GATA-1 interactions with MeCP1. The participation of GATA-1 in multiple 
protein interactions is supported by size fractionation experiments of nuclear extracts, which showed 
that GATA-1 fractionates with a broad profile overlapping the profiles of the partners identified 
here (Suppl. Fig. 1), also providing evidence for interactions occurring in distinct complexes (for 
example, fractionation peaks of MeCP1 versus SNF2h/ACF1).  
Other abundant chromatin-associated proteins also co-purified with GATA-1 (Table 1), 
including topoisomerases and Ku autoantigen or ADP ribosyltransferase (PARP). We tested the 
association of these proteins with DNA and GATA-1 by treating nuclear extracts with DNase I. In 
contrast to MTA2, there were no topoisomerase I or PARP co-purifying with GATA-1 after DNase 
I treatment. (Suppl. Fig. 2). Though it remains formally possible that interactions of GATA-1 
with topoisomerase I or PARP are relevant and require DNA, on the basis of our DNase I results 
and on previous evidence by other groups describing topoisomerases as a common contaminant 
(Eberharter et al., 2001), we did not pursue these further. 
GATA-1 forms several distinct complexes 
To directly confirm the distinct GATA-1 interactions and to assess how the GATA-1 
partners may be partitioned in the GATA-1 complexes, we carried out sequential immunodepletion 
experiments. First, we used an antibody against one of the GATA-1 partners, i.e. FOG-1, TAL-1 
or MTA2 in order to immunodeplete from a nuclear extract the fraction of GATA-1 that is in 
complex with this factor (Fig. 2A). The remaining GATA-1 in the supernatant was subsequently 
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immunoprecipitated with a GATA-1 antibody and both immunoprecipitates were tested for the 
presence or absence of GATA-1 and interacting proteins (Fig. 2A). 
We first established that antibodies against GATA-1, TAL-1, FOG-1 and MTA2 were efficient 
in immunodepleting most of these proteins from nuclear extracts (Fig. 2B). As expected, FOG-1 
antibodies immunoprecipitated a fraction of GATA-1 (Fig. 2C, lane 2). Surprisingly, MTA2 was also 
specifically immunoprecipitated by FOG-1 antibodies (Fig. 2C, lane 2), suggesting an interaction 
between FOG-1 and the MeCP1 complex. This was confirmed by the reverse immunoprecipitation 
of FOG-1 by an MTA2 antibody (Fig. 2E). There was no immunoprecipitation of TAL-1, Gfi-1b or 
ACF1 by FOG-1 antibodies (Fig. 2C, lane 2). Importantly, MTA2 could no longer be detected in 
the subsequent immunoprecipitation of the supernatant with GATA-1 antibodies, (Fig. 2C, lane 3). 
Thus the fraction of GATA-1 that is in complex with MTA2 (and MeCP1) was depleted in the first 
step by the FOG-1 antibodies, leading us to conclude that FOG-1 and GATA-1 interact together in 
the same complex with MeCP1. Further confirmation was provided by the immunoprecipitation of 
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sequential immunoprecipitations (IP). (A) 
Experimental procedure. (B) Efficiency 
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FOG-1 immunodepletion, FOG-1 IP (lane 
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MeCP1-associated histone deacetylase (HDAC) activity by GATA-1 and FOG-1 antibodies (Suppl. 
Fig. 3). Following the FOG-1 immunodepletion, GATA-1 antibodies could still immunoprecipitate 
TAL-1, Gfi-1b and ACF1 (Fig. 3C, lane 3). This confirms that GATA-1 participates in a complex 
with FOG-1 and MeCP1 that is distinct from those with TAL-1, Gfi-1b or ACF/WCRF. Using 
TAL-1 antibodies in the first immunodepletion step, a small fraction of GATA-1, but no MTA2 or 
ACF1 was immunoprecipitated (Fig. 2D, lane 2). 
We also carried out an MTA2 immunodepletion to determine whether the entire fraction 
of GATA-1 interacting with FOG-1 does so in the context of the MeCP1 complex. Following 
the immunodepletion of MTA2 (Fig. 2B), an appreciable amount of FOG-1 was subsequently 
immunoprecipitated by GATA-1 antibodies (Fig. 2E, lane 3). Thus, GATA-1 also interacts with 
FOG-1 independently of the MeCP1 complex. Interestingly, the MTA2 antibody specifically 
immunoprecipitated the slower migrating of the two bands detected by the FOG-1 antibody, 
suggesting differential interaction with one of the two FOG-1 isoforms, while GATA-1 can interact 
with both FOG-1 isoforms (Fig. 2E, lane 3). Taken together, these experiments show that GATA-1 
forms at least five complexes: first with FOG-1 and MeCP1, second with FOG-1 alone, third with 
TAL-1 (and Ldb1 since it can be almost completely immunodepleted by TAL-1 antibodies [not 
shown]), fourth with Gfi-1b and fifth with ACF/WCRF. 
The GATA-1 zinc fingers mediate differential protein interactions 
GATA-1 contains two evolutionarily conserved, closely spaced zinc finger domains. The 
C-terminal zinc finger (C-ZnF) is essential for DNA binding whereas the N-terminal zinc finger 
(N-ZnF) is primarily involved in protein-protein interactions, for example with FOG-1, which 
contribute to the specificity and stability of DNA binding by the C-ZnF (review by (Blobel and 
Weiss, 2001). Significantly, the C-ZnF is essential for all in vivo GATA-1 functions, whereas 
the N-ZnF is required for definitive, but not primitive, erythropoiesis erythropoiesis (Shimizu et 
al., 2001). We addressed how the GATA-1 zinc fingers mediated its multiple protein interactions 
by expressing in MEL cells biotin-tagged mutants lacking the N-ZnF or the C-ZnF followed by 
streptavidin pull-downs (Fig. 3A-C). As described (Tsang et al., 1998), GATA-1 interaction with 
Figure 3: (A-C): 
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FOG-1 requires the N-ZnF. Interactions of the MeCP1 members MTA2, Mbd2 and HDAC 1 also 
occur through the N-ZnF of GATA-1 (Fig. 3A). Interestingly, interactions of GATA-1 with TAL-1 
require both zinc fingers (Fig. 3B), whereas interactions with SNF2h or Gfi-1b require only the 
C-ZnF (Fig. 3C). , We tested by immunoprecipitation using Gfi-1b antibodies whether Gfi-1b 
and SNF2h were in complex but found no evidence of such an interaction (not shown). Thus 
the multiple, distinct interactions of GATA-1 are differentially mediated through its zinc finger 
domains.
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FOG-1 mediates interactions of GATA-1 with the MeCP1 complex in repressing 
transcription
 We next tested whether FOG-1 mediates interactions between GATA-1 and the MeCP1 
complex. . GATA-1 was transiently expressed in HeLa cells (which express endogenous MeCP1, 
but not GATA-1 or FOG-1) with or without FOG-1, followed by immunoprecipitation using 
FOG-1 or MTA2 antibodies (Fig. 4A-B). We find that the interaction of GATA-1 with MTA2 
occurs only in the presence of FOG-1 (Fig. 4B), whereas FOG-1 interacts with MTA2 regardless 
of the presence or absence of GATA-1 (Fig. 4B, upper panel). Expression of the GATA-1 zinc-
finger deletion mutants (Fig. 4B, lower panel) confirmed these observations. We conclude that 
interaction of GATA-1 with the MeCP1 complex requires interaction with FOG-1, which thus 
serves as the bridging factor.
We next tested whether the well known GATA-1 and FOG-1 mediated repression is due 
to the recruitment of the MeCP1 complex to a GATA-dependent promoter. To this end, we used 
a reporter plasmid containing the rabbit β-globin minimal promoter (pOVEC-1, (Westin et al., 
1987), carrying four copies of an optimal GATA-1 binding sequence, or four copies of a mutated 
Figure 4: (A-B): FOG-1 bridges GATA-1 and MeCP1 . Nuclear extracts from HeLa cells transfected with the FOG-1 and 
GATA-1 combinations indicated, were immunoprecipitated with FOG-1  (panel A) or MTA2 antibodies (panel B) and 
detected with FOG-1 and GATA-1 antibodies. dZn-N and dZn-C: GATA-1 N- and C-terminal zinc-finger deletion mutants. 
Arrows: cross-reacting IgG. Asterisk (panel B): GATA-1 signal. (C) Real-Time PCR transcription assays in transfected HeLa 
cells. GATA-1 activates transcription of pG-OVEC, whereas co-transfection of FOG-1 represses to basal levels. (D) Specific 
recruitment of Mi-2β by co-transfected GATA-1 and FOG-1 by ChIP assays in HeLa cells. Mi-2β recruitment to the repressed 
gene requires GATA-1 binding to the promoter. 
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sequence that abolish GATA-1 binding (Whyatt et al., 1993). The GATA-binding promoter was 
activated more than six-fold by co-transfection of GATA-1 alone (Fig. 4C). As expected, co-
transfection of FOG-1 and GATA-1 repressed activation of the GATA-dependent promoter (Fig. 
4C). Chromatin immunoprecipitations (ChIP) showed that repression by GATA-1 and FOG-1 was 
due to the specific recruitment of the MeCP1 complex. Binding of Mi-2β to the repressed gene was 
specifically enriched in GATA-1 and FOG-1 transfected cells (Fig. 4D), but not in cells transfected 
with GATA-1 only. The promoter bearing the mutated GATA binding sites does not bind MeCP1, 
even in the presence of FOG-1 (Fig. 4D). Thus, FOG-1/MeCP1 repression is mediated through 
GATA-1 binding at its cognate binding sites.
GATA-1, FOG-1, MeCP1 and Gfi-1b are bound to repressed genes in vivo
The results above suggest that GATA-1/FOG-1 interactions can tether MeCP1 to repressed 
GATA-1 target sequences in vivo. We therefore employed ChIP assays using the GATA-2 locus, 
which is repressed by GATA-1 in a FOG-1 dependent manner (Grass et al., 2003; Pal et al., 2004). 
As seen before, the -2.8kb region upstream of the GATA-2 promoter was enriched for GATA-1 and 
FOG-1 binding (Fig. 5A). The same sequence was also enriched for Mbd2 binding (Fig. 5A), with 
similar results obtained with an antibody against Mi-2β (Suppl. Fig. 4A). No binding of TAL-1 or 
Gfi-1b was observed in the GATA-2 sequences. Interestingly, the –3.4kb, but not the –4.2kb and 
–2.2kb flanking sequence used as negative controls for GATA-1 binding, was enriched for FOG-1 
and Mbd2 binding (Fig. 5A and Suppl. Fig. 4A) suggesting that the FOG-1/MeCP1 binding at 
-3.4kb may reflect a very localized spreading of these proteins over a few nucleosomes to sequences 
upstream of the -2.8kb element, or that they were accidentally crosslinked to neighboring DNA. 
The latter possibility would suggest that the FOG-1/MeCP1 complex is closer to the upstream 
sequences around the GATA binding sites (see also below). We found no evidence that the binding 
of the GATA-1/FOG-1/MeCP1 complex to the –2.8kb region was mediated by DNA methylation 
(Suppl. Fig. 5), however this does not exclude the possibility of highly localized methylation to 
specific CpG residues elsewhere in the GATA-2 locus. Thus, considering that GATA-1 binding 
is essential for GATA-2 repression (Pal et al., 2004), our findings strongly suggest that GATA-1, 
FOG-1 and MeCP1 form the repressive complex responsible for GATA-2 silencing (see below). 
Ectopic expression of FOG-1 in eosinophilic cells results in the downregulation of 
eosinophilic GATA-1 target genes and the reprogramming of these cells towards an earlier, less 
differentiated cell type which may represent a common progenitor for the erythroid/megakaryocytic 
and eosinophilic lineages (Querfurth et al., 2000). We thus reasoned that eosinophilic GATA-1 
target genes, like the major basic protein (MBP) (Du et al., 2002), which is inactive in erythroid 
cells (Welch et al., 2004), may be suppressed by the GATA-1/FOG-1/MeCP1 complex. We tested 
this hypothesis by ChIP in induced MEL cells using as control chromatin from mouse eosinophils 
where MBP is expressed (Guyot et al., 2004). As expected, the promoter of the MBP gene was 
bound by GATA-1 in eosinophils (Fig. 5B). Importantly, GATA-1 was also bound to the inactive 
MBP promoter in induced MEL cells (Fig. 5C).  FOG-1 and Mbd2 were also bound to the MBP 
promoter in MEL cells but not in eosinophils (Fig. 5C), consistent with the prediction above. 
Similar results were also obtained with an antibody against Mi-2β (Suppl. Fig. 4B). Again, no 
TAL-1 of Gfi-1b binding was detected in the MBP promoter (Fig. 5C). Strikingly, in MEL cells 
we again found binding of the FOG-1 and MeCP1 complex, but not of GATA-1, to the +0.6kb 
sequence located close to the MBP promoter but not to other sequences located further upstream 
(-1.8kb) or downstream (+1.2kb) of the promoter (Fig. 5C and Suppl. Fig. 4B). This observation 
is similar to that seen at the GATA-2 –2.8kb element. 
We next tested the myc and myb genes which are down-regulated with MEL differentiation 
(Chen and Bender, 2001; Lachman and Skoultchi, 1984) and references therein). Repression of 
the myc and myb genes has been linked to the proliferation arrest that accompanies terminal 
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Figure 5: Binding of GATA-1 
repressive and activating complexes 
to target genes by ChIP assays 
in induced MEL cells. Binding 
patterns of GATA-1, FOG-1, Mbd2, 
TAL-1 and Gfi-1b to the –2.8kb 
element of the GATA-2 locus (A), 
the MBP promoter in eosinophils 
(B) and in MEL cells (C), the myb 
(D) and  myc (E) promoters and 
at the EKLF upstream enhancer 
(F). Relative enrichment has been 
normalized to input and corrected for 
background binding of species- and 
isotype-matched immunoglobulins. 
Antibodies: GATA-1, N6 (Santa 
Cruz); FOG-1 as in Tsang et al. 
(1997); Mbd2 S923 (Ng et al., 1999); 
TAL-1 as in Porcher et al. (1996); 
Gfi-1b, D19 (Santa Cruz).
erythroid differentiation. The myc gene has also been shown to be a GATA-1 target gene in G1E 
cells (Rylski et al., 2003; Welch et al., 2004). We found GATA-1 binding to both promoters in 
induced MEL cells but we could not detect binding of FOG-1 or Mbd2 to the same sequences 
(Fig. 5D and E). By contrast, Gfi-1b (absent from all other genes tested) was found binding to both 
promoters (Fig. 5D and E), suggesting a role for the GATA-1/Gfi-1b complex in the repression of 
genes associated with cell proliferation. This may explain the observations of rapidly proliferating 
Gfi-1b -/-immature erythroid precursors in colony assays (Saleque et al., 2002) and of Gfi-1b 
overexpression inducing proliferation arrest and differentiation in erythroid progenitors (Garcon 
et al., 2005).
 Finally, we also tested the EKLF gene as an example of a gene that is activated during 
erythropoiesis. The EKLF enhancer sequence contains a GATA-E-box motif (Anderson et al., 
1998) which is bound in vivo by GATA-1 independently of FOG-1 (Letting et al., 2004). Strong 
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GATA-1 binding and a clear enrichment for TAL-1 binding was indeed detected at the EKLF 
enhancer (Fig. 5F), thus providing a clear demonstration for the alternative (activating) GATA-1 
complex with TAL-1 binding to a target gene in vivo. This may be related to the low level of 
HDAC activity associated with the TAL-1 immunoprecipitate (Suppl. Fig. 3A). No significant 
binding of FOG-1, Mbd2 or Gfi-1b could be detected in the EKLF enhancer sequences (Fig. 5F). 
Our analysis of the GATA-1/ACF/WCRF complex by ChIP, or any other, assays has been 
hindered by the quality of ACF/WCRF reagents available to us, hence it is presently not known 
whether the GATA-1 and ACF/WCRF complex binds to active or repressed genes. 
GATA-1 represses GATA-2 expression through the recruitment of FOG-1 and MeCP1
In order to confirm that GATA-2 repression during erythroid differentiation is specifically due 
to GATA-1 recruiting FOG-1 and the MeCP1 complex, we took advantage of the GATA-1 null 
G1E proerythroblastic cell line. These cells are derived from in vitro differentiated GATA-1 null 
ES cells and can undergo terminal differentiation only upon restoration of GATA-1 expression 
(Weiss et al., 1997). We used two G1E cell lines. The first one expresses wild type GATA-1 fused 
to an estrogen receptor (ER) ligand binding domain (GATA-1-ER) which can mediate terminal 
erythroid differentiation upon induction by estradiol (Tsang et al., 1997). The second cell line 
expresses ER fused to a mutant GATA-1 form bearing a single V205M amino acid substitution 
in the GATA-1 N-terminal zinc finger. Whilst not affecting GATA-1 DNA binding, this mutant 
abrogates interaction with FOG-1 and fails to rescue differentiation of G1E cells (Crispino et al., 
1999; Nichols et al., 2000). We first determined that repression of the GATA-2 gene in G1E cells 
was absolutely dependent on GATA-1 being capable of interacting with FOG-1 (Fig. 6A). We next 
tested by ChIP whether interaction of GATA-1 with FOG-1 binding at -2.8kb was responsible for 
the recruitment of MeCP1 to this sequence and to the neighboring –3.4kb sequence  (Fig. 5A). 
As control, we also tested the more distal –4.2kb sequence which did not show binding for any of 
these factors (Fig. 5A). In agreement with the MEL data, GATA-1, FOG-1 and Mi-2β were bound 
to the –2.8kb and to the –3.4kb sequence (for FOG-1 and Mi-2β) in differentiated GATA-1-ER 
cells (24 hours after induction with estradiol), albeit at lower levels compared to MEL cells (Fig. 
6B, left panels). By contrast, in the GATA-1(V205M)-ER expressing cells GATA-1 was bound  to 
the –2.8kb sequence, but no binding of FOG-1 and Mi-2β to the –2.8kb or –3.4kb sequences was 
detected (Fig. 6B right panels). We conclude that FOG-1 and the MeCP1 complex are specifically 
recruited by GATA-1 to the GATA-2 locus and are responsible for GATA-2 repression in terminal 
erythroid differentiation. 
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Discussion
We describe here the characterization of GATA-1 complexes from erythroid cells by in 
vivo biotinylation tagging and purification by streptavidin beads. This work has led to a number 
of important findings. First, we identified novel GATA-1 partners, including the essential 
hematopoietic factor Gfi-1b and the chromatin remodeling and modification complexes MeCP1 
and ACF/WCRF, in addition to the known GATA-1 interacting factors FOG-1, TAL-1 and Ldb1. 
Second, we showed that GATA-1 forms several distinct complexes with FOG-1, with FOG-1 and 
MeCP1, with TAL-1/Ldb1, with Gfi-1b and with the ACF/WCRF complex. Third, we found that 
the most abundant of the GATA-1 complexes are those with FOG-1 and with FOG-1 and MeCP1, 
with FOG-1 serving as the bridging factor between GATA-1 and the MeCP1 complex. Fourth, 
we showed that the distinct interactions of GATA-1 with its protein partners are differentially 
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Figure 6: Silencing of GATA-2 
requires recruitment of FOG-1 
and MeCP1 by GATA-1. (A) The 
V205M GATA-1 mutation fails to 
repress GATA-2. GATA-2 mRNA 
was measured by Real-Time PCR 
in G1E GATA-1-ER and G1E 
GATA-1(V205M)-ER cells before 
(0 hours) and after 24 hours of 
estradiol induction. Expression 
at  0 hour was normalized 
against GAPDH expression 
and set as 1. (B) ChIP to show 
binding of GATA-1, Mi-2β and 
FOG-1 in G1E GATA-1-ER 
(left panels) and in G1E GATA-
1(V205M)-ER (right panels) at 
time 0 and 24 hours of estradiol 
induction.  Relative enrichment 
has been normalized to input 
and corrected for background 
binding of species- and isotype-
matched immunoglobulins. Data 
represent an of two independent 
IPs and three PCRs with duplicate 
samples. Antibodies used were as 
in the legend of Figure 5, except 
Mi-2β  antibody (Fujita et al., 
2003).
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mediated through the two GATA-1 zinc finger domains. Fifth, we show that the known GATA-1 
and FOG-1 mediated repression is due to the recruitment of the MeCP1 complex to the repressed 
gene(s). Sixth, we present evidence for the in vivo binding of the repressive GATA-1/FOG-1/
MeCP1 complex to silenced hematopoietic genes in erythroid cells and of the activating GATA-1/
TAL-1 complex to erythroid specific genes. Significantly, we also showed binding of the GATA-1/
Gfi-1b complex to genes associated with cell proliferation functions, which become repressed 
with erythroid differentiation. Finally, our work demonstrates the utility of biotinylation tagging 
as an efficient approach for the rapid isolation and identification by mass spectrometry of multiple 
protein complexes.
Biotinylation tagging and protein complex purification
From our previous work (de Boer et al., 2003) and the work described here, we show that 
background using biotinylation tagging consists of naturally biotinylated proteins, of abundant 
nuclear proteins such as splicing factors binding nonspecifically to the beads (de Boer et al., 2003) 
and, potentially, of abundant chromatin-associated proteins, such as topoisomerase I, which are 
indirectly pulled-down with the tagged transcription factor (Suppl. Table 1). We have validated 
a number of the remaining proteins as being true GATA-1 partners, some of which represent 
low abundance or weaker GATA-1 interactions, e.g. with TAL-1/Ldb1, Gfi-1b and ACF/WCRF. 
Importantly, purification required a single capture step. 
We cannot be certain that we identified all GATA-1 complexes in differentiated MEL cells. 
Indeed, some of the size-fractionation profiles (Suppl. Fig. 1) suggest that there may be additional 
protein partners that were not identified perhaps due to their very low abundance or instability. 
This may be the case for the multimeric GATA-1/TAL-1/Ldb1/E2A/LMO2 complex. Sveral lines 
of evidence have suggested the presence of this complex in erythroid cells binding to distinct E-box 
and GATA motifs spatially arranged 9 to 12 nucleotides apart (review by (Lecuyer and Hoang, 
2004). Many erythroid genes identified to-date contain such motifs, including GATA-1 itself, 
EKLF, glycophorin A and 4.2 protein (Lecuyer and Hoang, 2004). Evidence for the multimeric 
GATA-1/TAL-1 complex binding to erythroid genes in vivo, such as α globin and glycophorin A, 
has been provided recently by ChIP assays (Anguita et al., 2004; Lahlil et al., 2004). Nevertheless, 
we did not find any co-purification of E2A or LMO2 with GATA-1 from induced MEL cells. 
The complementary isolation by biotinylation tagging of protein partners, such as TAL-1, will be 
informative in that respect and may also reveal additional protein partners.
Novel GATA-1 protein partners
We describe here, for the first time, an interaction of GATA-1 with the essential hematopoietic 
transcription factor Gfi-1b. This factor contains six C-terminal C2H2 zinc fingers, which bind a 
defined DNA consensus sequence, and an N-terminal SNAG domain associated with repression 
(Doan et al., 2004; Duan and Horwitz, 2003). The Gfi-1b knockout is remarkably similar to that 
of GATA-1, i.e. it shows embryonic lethality E15 due to the developmental arrest of erythroid and 
megakaryocytic differentiation in the fetal liver (Saleque et al., 2002). Our data that GATA-1 and 
Gfi-1b (but not FOG-1 or MeCP1) are bound to the myb and to the myc promoters provide a basis 
for the similarities in the two knockouts (Pevny et al., 1995; Saleque et al., 2002). These data may 
also be related to the proliferation defects observed in GATA-1 overexpressing mice (Whyatt et al., 
2000). It is important to note that although there are also similarities between the FOG-1 and Gfi-
1b knockout phenotypes, we did not find FOG-1 and Gfi-1b to directly interact in induced MEL 
cells (Fig. 2). Possibly, the two factors regulate common gene targets through distinct complexes 
and binding sites. Alternatively, the functions of GATA-1 with FOG-1 or Gfi-1b could be separate, 
e.g. differentiation (FOG-1) versus proliferation arrest (Gfi-1b), with each function being essential 
for erythropoiesis.
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We also describe, for the first time, interactions of GATA-1 with the MeCP1 and ACF/
WCRF complexes, linking GATA-1 to repressive functions (with MeCP1) and chromatin structure. 
Previous evidence linking GATA-1 to chromatin structure involved interactions with the histone 
acetyltransferases (HATs) CBP and p300 (Blobel et al., 1998) and in vitro experiments where 
GATA-1 co-operated with the SWI/SNF remodeling complex in transcriptional activation (Kadam 
and Emerson, 2003). However, we did not observe these interactions in our GATA-1 purification 
from induced MEL cells or in immunoprecipitations (data not shown). 
Our observations on the interactions of GATA-1 (and FOG-1) with the MeCP1 complex 
add to previous reports linking MeCP1 (and the closely related NuRD complex) to transcription 
factors in hematopoiesis (Hutchins et al., 2002; Kim et al., 1999; O’Neill et al., 2000). The 
conditional knockout of Mi-2β in thymocytes revealed a requirement in different stages of T cell 
maturation (Williams et al., 2004). In addition, the characterization of the MTA3 member of NuRD 
in B lymphocytes showed an interaction with BCL-6, a key repressor of the mature plasma cell 
transcription program (Fujita et al., 2004). It was thus suggested that MTA3 and the NuRD complex 
play a role in the maintenance of a population of less differentiated, “poised” B lymphocytes (Fujita 
et al., 2004). In contrast to these data, our data in erythroid cells suggest that the MeCP1 complex 
works with tissue-specific transcription factors to effect terminal differentiation by shutting down 
transcription programs associated with early multipotential (“poised”) states.
GATA-1 and FOG-1 interactions
Considerable evidence has linked GATA-1 functions to FOG-1 (reviewed by (Blobel and 
Weiss, 2001; Cantor and Orkin, 2002). A single amino acid change in the N-terminal zinc finger 
of GATA-1 which abolishes interaction with FOG-1 (Crispino et al., 1999), resulted in lethality in 
mice due to severe anemia (Chang et al., 2002) and is associated with dyserythropoietic anemia in 
patients (Nichols et al., 2000). Our work suggests that the overlapping functions of GATA-1 and 
FOG-1 in erythropoiesis occur in the context of two distinct complexes, a GATA-1/FOG-1/MeCP1 
complex and a GATA-1/FOG-1 complex. Clearly, the association of GATA-1 and FOG-1 with the 
MeCP1 complex provides the molecular basis for the well-documented repressive properties of 
GATA-1 and FOG-1 interactions (Crispino et al., 1999; Fox et al., 1999; Letting et al., 2004; Pal 
et al., 2004). Only the slower migrating isoform of FOG-1 (Fig. 3) interacts with the GATA-1/
MeCP1 complex, providing a potential mechanism for the selective formation of the GATA-1/
FOG-1/MeCP1 complex.
We suggest that the separate GATA-1/FOG-1 complex without MeCP1 links GATA-1 with 
FOG-1 to transcriptional activation. For example, disruption of GATA-1 and FOG-1 interactions 
down-regulates erythroid genes such as α and β globin, Band 3, DC11 and HD2 genes (Crispino 
et al., 1999; Letting et al., 2004). ChIP assays have also shown GATA-1 and FOG-1 to be bound 
in vivo to active genes such as the α globin locus and the GATA-1 gene itself (Anguita et al., 
2004; Pal et al., 2004). Significantly, in the α globin locus the GATA-1/FOG-1 complex occupies 
sites distinct from those occupied by the GATA-1/TAL-1/Ldb1 complex (Anguita et al., 2004), in 
agreement with our findings of distinct GATA-1 complexes.
Our finding that FOG-1 bridges GATA-1 to the repressive MeCP1 complex partly explains 
the common features of the GATA-1 and FOG-1 knockouts and the phenotypes caused by the single 
amino acid change in the N-terminal zinc finger of GATA-1 in mice and patients. In the GATA-1 
knockout FOG-1/MeCP1 cannot be tethered to target genes, whereas in the FOG-1 knockout, the 
interaction between GATA-1 and the MeCP1 complex cannot take place. In patients, the lack of 
interaction between GATA-1 and FOG-1 would also fail to tether the MeCP1 complex to some of 
their target genes.  
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GATA-1 complexes and erythropoiesis
An important aspect in hematopoietic development to a particular lineage is the suppression 
of alternative “primed” lineage transcription programs and of genes that maintain multipotentiality, 
while upregulating genes associated with the differentiated cell type (Enver et al., 1998; Orkin, 
2000). In addition erythroid terminal differentiation is accompanied by cell cycle arrest. GATA-1 
has been implicated in the regulation of most of these aspects (Blobel and Weiss, 2001). In fact, 
a recent microarray analysis of GATA-1 dependent erythroid terminal maturation revealed an 
early wave of repression of genes like GATA-2, myc and myb, followed by the upregulation of 
erythroid specific genes (Welch et al., 2004). Here we identified two GATA-1 repressive complexes 
acting on distinct sets of genes. Thus we suggest that the GATA-1/Gfi-1b complex acts early and 
suppresses genes involved in cell proliferation, e.g. myc and myb, while the GATA-1/FOG-1/
MeCP1 complex also acts early to suppress genes required to maintain the “primed” multipotential 
state, e.g GATA-2 and alternative hematopoietic lineage genes, e.g. MBP (Fig. 7). In contrast, the 
GATA-1/FOG-1 and the GATA-1/TAL-1/Ldb1 complexes would play a major role in the later 
upregulation of erythroid genes (Fig. 7). The role of the GATA-1/ACF/WCRF complex remains 
to be established. Thus, GATA-1 provides specific early versus late differentiation functions in 
the context of distinct complexes (Fig. 7). The model of different GATA-1 complexes executing 
specific tasks in different stages of erythroid differentiation suggests a dynamic aspect in the 
GATA-1 complex interactions during differentiation and also raises the prospect of dissecting the 
contribution of distinct GATA-1 interactions in erythropoiesis (i.e. essential versus dispensable) 
by selectively manipulating a specific GATA-1 complex at a time.
ACF1
TAL-1
Ldb1
LATE
EARLY
GATA-1
FOG-1
Activation
Erythroid genes
SNF2h
Activation?
Repression?
Gfi-1b
FOG-1 + MeCP1
Repression
alternative lineages,
lineage priming
Repression
Cell proliferation
genes
Figure 7: Model for the distinct GATA-1 complexes and their role in erythropoiesis. Broken arrow indicates unknown function 
and timing. See text for explanation.
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Materials and Methods
Constructs, nuclear extract preparation, streptavidin binding, mass spectrometry and 
immunoblot analysis. Tagged constructs and procedures involving MEL cells, biotinylated 
proteins and mass spectrometry were previously described (de Boer et al., 2003). The GATA-1 
zinc finger deletions have been described (Whyatt et al., 1993). G1E cells and induction were 
described (Tsang et al., 1997; Weiss et al., 1997).
Superose 6 gel filtration. Size fractionation of protein complexes was done on an AKTA FPLC 
apparatus with a Superose 6 10/30 column (Amersham Biosciences, Piscataway NJ). Fractions 
were precipitated with 100% trichloroacetic acid and analyzed by Western immunoblotting, as 
described (de Boer et al., 2003). Molecular size standards were thyroglobulin (670kDA) and 
albumin (66kDa) (Amersham Biosciences, Piscataway NJ).
Immunoprecipitations. Nuclear extracts were ple-cleared at 4°C using Protein G sepharose beads 
and affinity-purified IgG (rat [Santa Cruz, CA, sc-2026], rabbit [Santa Cruz, sc-2027], goat [Santa 
Cruz, sc-2028]) in HENG150 buffer. GATA-1 and TAL-1 antibodies were crosslinked to beads 
using dimethyl pimelimidate. Immunoprecipitations were performed in HENG150 / 0.3% NP-40 
buffer overnight at 4°C using protein-G Sepharose beads. Washes were done at room temperature 
in HENG250 / 0.3% NP-40 buffer. Bound material was eluted by boiling in 1x Laemmli buffer. 
HeLa transient transfection and transcription assays. GATA-1 and FOG-1 cDNAs cloned 
in pCDNA 3.1 (Invitrogen, Carlsbad CA) were transiently transfected using 2µg DNA and 
Lipofectamine 2000 (Invitrogen, Carlsbad CA). Cells were harvested after 24 hours and nuclear 
extracts were used for immunoprecipitations as above. pEGFP-N1 (Invitrogen, Carlsbad CA) 
was  included as transfection efficiency control. Transcription was assayed by Real-Time PCR 
with primers for exon 2 of the pOVEC reporter plasmid. ChIP assays were done as below using 
GATA-1 and Mi-2β antibodies. The endogenous human GAPDH gene was used as control.
ChIP assays. Preparation of crosslinked chromatin (2x107 induced MEL cells treated with 0.4% 
formaldehyde for 10 minutes at room temperature), sonication to 300-800 base pair fragments 
and immunoprecipitations were as described in the Upstate protocol (www.upstate.com). Anti-
GATA-1 protein-DNA immunocomplexes were immunoprecipitated in an additional step with 
an AffiniPure rabbit anti-rat antibody (Jackson ImmunoResearch Laboratories, West Grove, PA). 
Eosinophilic chromatin was prepared as previously described (Guyot et al., 2004). At least two 
independent chromatin immunoprecipitations were carried out per experiment. Antibodies used : 
GATA-1, N6 (Santa Cruz); Mbd2, S923 sheep polyclonal (Ng et al., 1999) and rabbit polyclonal 
anti Mbd2/3 antibody (Upstate 07-199); FOG-1 rabbit polyclonal (Tsang et al., 1997); TAL-1 
rabbit polyclonal (Porcher et al., 1996); Gfi-1b D19 goat polyclonal (Santa Cruz sc-8559).
Real time PCR. Quantitative RealTime PCR (Opticon I, MJ Research) was done using SYBR 
Green I. PCR primers were designed by Primer Express 2.0 (PE Applied Biosystems). The qPCR 
Core Kit (Eurogentec, Belgium) was used with 400 nM of each primer under the following cycling 
conditions: 950C for 10 minutes, 40 cycles of 30 seconds at 950C, 60 seconds at 600C, 15 seconds 
at 750C.  Enrichment for a specific DNA sequence was calculated using the comparative CT method 
(Litt et al., 2001). PCR primer sequences are provided in Supplementary Materials and Antibodies. 
See Supplementary Information.
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Supplementary Figure 1: Size-fractionation profiles by Superose 6 column of GATA-1 (panel A), members of the MeCP1 and 
ACF/WCRF complexes (panel B) and transcription factors (panel C). Molecular mass markers are indicated on the top. V0: void 
volume. N.E.: input nuclear extract. 
GATA-1 displays a broad fractionation profile with several peaks. The profile of tagged GATA-1 closely follows that 
of endogenous GATA-1, is stable in salt concentrations up to 1M and is not dependent on the presence of DNA (data not shown). 
Members of the MeCP1 complex showed overlapping peaks around fractions 20-22 (e.g. MTA2, RbAp46/48, Mbd2/3) in contrast 
to Sin3A which peaked around fractions 18-20. SNF2h and ACF1 peaked around fractions 26-28 and are distinctly different from 
those of the MeCP1 complex. p17 elutes in fractions 34-36, further suggesting that GATA-1 interactions with SNF2h and ACF1 
occur in the context of the ACF/WCRF complex. These observations also suggest that GATA-1 interactions with MeCP1 and ACF/
WCRF occur in distinct complexes. Fractionation profiles of transcription factors FOG-1, Ldb1, TAL-1 and Gfi-1b are largely 
coincident within the higher molecular weight fractions 16-28, though peaks vary between them. For most of these factors little or 
no protein is detected in the free protein fractions (i.e. fractions 32-38), in contrast to Sp1 which elutes as free protein.
and its partner LMO2 act as negative regulators of erythroid differentiation. Proc Natl Acad Sci U S A, 94, 
13707-13712.
Wadman, I.A., Osada, H., Grutz, G.G., Agulnick, A.D., Westphal, H., Forster, A. and Rabbitts, T.H. (1997) The 
LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which 
includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. Embo J, 16, 3145-3157.
Weiss, M.J., Yu, C. and Orkin, S.H. (1997) Erythroid-cell-specific properties of transcription factor GATA-1 
revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol, 17, 1642-1651.
Welch, J.J., Watts, J.A., Vakoc, C.R., Yao, Y., Wang, H., Hardison, R.C., Blobel, G.A., Chodosh, L.A. and Weiss, 
M.J. (2004) Global regulation of erythroid gene expression by transcription factor GATA-1. Blood, 104, 
3136-3147.
Westin, G., Gerster, T., Muller, M.M., Schaffner, G. and Schaffner, W. (1987) OVEC, a versatile system to study 
transcription in mammalian cells and cell-free extracts. Nucleic Acids Res, 15, 6787-6798.
Whyatt, D., Lindeboom, F., Karis, A., Ferreira, R., Milot, E., Hendriks, R., de Bruijn, M., Langeveld, A., Gribnau, 
J., Grosveld, F. and Philipsen, S. (2000) An intrinsic but cell-nonautonomous defect in GATA-1-
overexpressing mouse erythroid cells. Nature, 406, 519-524.
Whyatt, D.J., deBoer, E. and Grosveld, F. (1993) The two zinc finger-like domains of GATA-1 have different DNA 
binding specificities. Embo J, 12, 4993-5005.
Williams, C.J., Naito, T., Arco, P.G., Seavitt, J.R., Cashman, S.M., De Souza, B., Qi, X., Keables, P., Von Andrian, 
U.H. and Georgopoulos, K. (2004) The chromatin remodeler Mi-2beta is required for CD4 expression and 
T cell development. Immunity, 20, 719-733.
Supplementary Figures
73
GATA-1 forms distinct activating and repressive complexes in erythroid cells
Supplementary Figure 3: Histone deacetylase (HDAC) assays. (A) HDAC activity associated with proteins immunoprecipitated 
by the indicated antibodies. Protein G beads and rat and goat immunoglobulins (IgG) were used as background controls. Three 
different nuclear extracts were used in the GATA-1 immunoprecipitations (extract 1: non-transfected MEL cells; extracts 2 and 
3: biotinylated GATA-1). (B) HDAC activity immunoprecipitated by HDAC2, FOG-1 and GATA-1antibodies is sensitive to the 
Class I HDAC inhibitors TSA and OSI-2040. (C) Antibodies against the Mi2/NuRD-associated protein MTA2 deplete a consid-
erable part of the HDAC activity associated with FOG-1 and GATA-1 immunoprecipitates. Immunoglobulins (IgG) were used 
as background control.
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DNase I Supplementary Figure 2: DNase I treatment of nuclear extracts shows the 
indirect co-purification of abundant chromatin associated proteins with 
GATA-1. Nuclear extracts from MEL cells treated or not treated with DNAse 
I were immunoprecipitated with GATA-1 antibodies. Co-immunoprecipitation 
of abundant chromatin associated proteins such as topoisomerase I orPARP, 
identified by mass spectroscopy as co-purifying with GATA-1, was lost upon 
DNAse I treatment. By contrast, co-immunoprecipitation of MTA2, a member 
of the MeCP1 complex co-purified with GATA-1, was unaffected by DNase I 
treatment thus showing a direct interaction with GATA-1.
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Supplementary Figure 5: DNA methylation assay by restriction enzyme digestion at the –2.8kb element of the GATA-2 locus. 
Genomic DNA (5-10g) from non-induced (left panel) and induced (right panel) MEL cells was first digested with Eco RI, 
which releases a 3.9kb fragment, followed by digestion with Eag I (methylation sensitive, indicated by asterisk), or Xmn I as 
control for complete digestion of the genomic DNA samples. Eag I maps close to the GATA-1 binding sites in the –2.8kb element 
of the GATA-2 locus and within the PCR fragment (grey box, not to scale) amplified in the ChIP assays shown in Figures 5 and 
6. Digested DNA was blotted and probed with a 1.2kb Apa I fragment (solid line) which detects 1kb and 2.1kb fragments on the 
Eag I digests and 1.7kb and 2.2kb fragments on the Xmn I digests. For both digests, the larger fragments are weaker due to their 
limited overlap with the probe. It can be seen that Eag I digests completely in DNA of both induced and non-induced MEL cells, 
thus suggesting that its recognition site is not affected by DNA methylation.
Supplementary Figure 4: ChIP assay to show 
GATA-1, Mbd2 and Mi-2 β binding to the 
GATA-1 (panel A) and MBP (panel B) loci in 
induced MEL cells. It is clear that the binding 
pattern observed for GATA-1 and Mbd2 in 
these gene loci in Figure 5A and 5C is repro-
duced by the binding pattern of Mi-2β. Mi-2β 
antibody: as in (Fujita et al., 2003).
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GO Biological process GO Cell. 
component
Total no. of 
peptides
Remarks
chromatin modeling/
modification 
transcriptional regulation
nucleus 289 ATPase-dependent chromatin remodeling, HDACs
Unknown 158 putative transcription factors, RNA binding 
proteins, nucleolar
proteins, receptors etc.
mRNA processing nucleus 139 splicing factors
DNA topological change nucleus 130 topoisomerases
transcription regulation, 
DNA dependent
nucleus 105 Transcription factors
Metabolism mitochondrion 54 carboxylases
protein biosynthesis cytosol 53 ribosomal proteins
ribosome biogenesis nucleolus 37 apoptotic chromatin condensation inducer in the 
nucleus
DNA repair nucleus 28 XRCC1, Ku autoantigen
nucleolus biogenesis nucleus 24
cell proliferation nucleus 23 Ki-67
DNA replication nucleus 23 ORC
chromatin assembly nucleus 21 histones
Cytoskeleton 18 tubulin
structural molecule nucleus 11 NuMA1
protein targeting nucleus 7
Apoptosis nucleus 4 CDC5
protein chaperone nucleus 4
cell cycle nucleus 3 RCC1
signal transduction 2 GTP binding protein 3
Total # of peptides: >1100
Gel slices: ~45
MW range: 15-324kDa
Supplementary Table I:  Classification by Gene Ontology (GO) criteria of proteins identified by mass spectrometry as co-purifying 
with GATA-1
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PRoTein idenTiTy numbeR of PePTides AddiTionAl PuRificATions
MeCP1 complex
Mi-2 82 +
HDAC 1 10 +
HDAC 2 17 +
MTA1 47 +
MTA2 10 +
MTA3 4 -
Mbd2 14 +
Mbd3 9 +
p66 11 +
RbAp46 10 +
RbAp48 8 +
ACF/WCRF complex
SNF2h 21 +
ACF1 4 -
Transcription factors
FOG-1 (Hem.) 47 +
TAL-1 (Hem.) 2 +
Gfi-1b (Hem.) 1 -
Ldb1 (Ubiq.) 1 +
DNA repair
Rfc5 10 +
XRCC1 3 -
Ku70 9 +
PARP 10 +
DNA ligase III-β 1 -
DNA Topological change
DNA Topo I 34 +
DNA Topo II α 64 +
DNA Topo II β 32 -
Table I: Proteins specifically co-purifying with biotin tagged GATA-1 as compared to the control purification (de Boer et al., 
2003). A number of these proteins have been validated by immunoprecipitations and other assays (see text).  Hem: hematopoietic 
transcription factors. Ubiq: ubiquitous transcription factors
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Materials and Methods
ChIP PCR primer sequences:
EKLF upstream enhancer forward PCR primer: 5’-CTGGCCCCCCTACCTGAT-3’
EKLF upstream enhancer reverse PCR primer: 5’-GGCTCCCTTTCAGGCATTATC-3’
EKLF -1.35kb forward PCR primer: 5’-TGCTCCCCACTATGATAATGGA-3’
EKLF -1.35kb reverse PCR primer: 5’-GCCACAACCAAAGAAGACATTTT-3’
MBP -1.2kb forward PCR primer: 5’-GGGTCTAATTCCGAGGGTGAGT-3’ 
MBP -1.2kb reverse PCR primer: 5’-GGCCTGGAAATCACTGAGCTA-3’
MBP promoter forward PCR primer: 5’-CCGCCAAGGTGTCTATAAATGC-3’
MBP promoter reverse PCR primer: 5’-TGGGTCTTGTCAAGTTTGCAAA-3’
MBP +0.6kb forward PCR primer: 5’-GAAGTAGAGGCAGGATAATCAGGAA-3’
MBP +0.6kb reverse PCR primer: 5’-AGGATGAACCAGGGCTAATGC-3’
MBP +1.8kb forward PCR primer: 5’-TGTGACAGACGTGGACCTTCA-3’ 
MBP +1.8kb reverse PCR primer: 5’-TGCATCCAGAGTCACCCATAAG-3’
GATA2 -4.2kb region forward PCR primer: 5’-GAATTTCCTGCCGGTCCAT-3’
GATA2 -4.2kb region reverse PCR primer: 5’-GACGCGTTGGCTTTGTGTG-3’
GATA-2 -3.4kb forward PCR primer: 5’-TCCATCCAGCAGCTTTAGGAA-3’
GATA-2 -3.4kb region reverse PCR primer: 5’-GGGTTCGAAGCCACTCCAA-3’
GATA-2 -2.8kb region forward PCR primer: 5’-CCGGGCAGATAACGATTGG-3’
GATA-2 -2.8kb region reverse PCR primer: 5’-TTCATCTCGGCCGGCTAAT-3’
GATA-2 -2.2kb region forward PCR primer: 5’-AGGACCCCCTGCTTCTTGTTTC-3’
GATA-2 -2.2kb region reverse PCR primer: 5’-GGCAGTATGAGGCCCAGAATCTT-3’
Myb promoter forward PCR primer: 5’-GGGCGCCAGATTTGG-3’
Myb promoter reverse PCR primer: 5’-GGAGGAAACAGGTTGATATTAAAGT-3’
Myb -0.8kb forward PCR primer: 5’-GTAGGTTTGTCCAGCAAGTGTTTG-3’
Myb -0.8kb reverse PCR primer: 5’-AGGTGCCTACCACGCACTTCT-3’
Myc promoter forward PCR primer: 5’-CCAGACATCGTTTTTCCTGCATA-3’
Myc promoter reverse PCR primer: 5-‘CCGCTCAGTGTGTGGAGTGATA-3’
Myc -0.7kb forward PCR primer: 5’-ACACACACATACGAAGGCA-3’
Myc -0.7kb reverse PCR primer: 5’-ACCGTTAACCCCTTCCTCCC-3’
pOVEC exon 2 forward PCR primer: 5’-TCACCTGGACAACCTCAAAGG-3’
pOVEC exon 2 reverse PCR primer: 5’-CAGGATCCACGTGCAGCTT-3’
GAPDH forward PCR primer: 5’-TGAAGGGGAAGCTCAGTCG-3’
GAPDH reverse PCR primer: 5’-TCCACCACCCTGTTGCTGTA-3’
PCR primers for RNA analysis in G1E cells
GATA-2 mRNA primers:
Exon III forward PCR primer: 5’-ACTATGGCAGCAGTCTCTTCCATC-3’
Exon V reverse PCR primer: 5’-AAGGTGGTGGTTGTCGTCTGAC-3’
DNase I treatment of nuclear extracts
Nuclear extracts (50µg) were diluted to 150 mM KCl with HENG buffer and 5 % glycerol. 10 units of DNaseI 
(Invitrogen) were added and the extract was incubated overnight at 4°C with the addition of 5 mM CaCl2 and 10 
mM MgCl2. Extracts were bound to streptavidin beads and analyzed by western blotting. Antibodies used were: 
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Topoisomerase I goat polyclonal (Santa Cruz, sc-5342); PARP rabbit polyclonal (Alexis Biochemicals, ALX-210-
302).
HDAC assays. Immunoprecipitations for HDAC assays were carried out using 0.3-0.5mg of nuclear extracts in 
HENG150 / 0.1% NP-40, as described above. Immunoprecipitates were washed once for 10 minutes in HENG150 / 
0.3% NP-40 and three times for 10 minutes each in HENG300 / 0.3%NP-40. Beads were resuspended in HENG50 
and HDAC assays were done using approximately 32,000cpm of 3H-labelled core histones per reaction, as previously 
described (Taunton et al., 1996).
Antibodies. The following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA): N6 GATA-1 
rat monoclonal (sc-265); M20 FOG-1 (sc-9361); SNF2h (sc-8760), Gfi-1b D19 (sc-8559) and TAL-1 (sc-12982) 
were goat polyclonal antibodies; mouse monoclonal antibodies for mSin3A (sc-5299) and HDAC2 (sc-9959); 
rabbit polyclonal antibodies for HDAC1 (sc-7872) and Sp1 (sc-59). 15G12 RbAp46/48 mouse monoclonal (ab490), 
MTA2 goat polyclonal (ab9949) and MBD2a rabbit polyclonal (ab3754) antibodies were purchased from Abcam 
(Cambridge, UK). p66 mouse monoclonal was purchased from Upstate Biotechnology (07-365; Waltham, MA). 
Rabbit polyclonal antibodies against TAL-1 were a generous gift by Richard Baer (Columbia University, NY) and by 
Catherine Porcher (WIMM, Oxford). Rabbit polyclonal antibodies against Ldb1 were kindly donated by Gordon N. 
Gill (Stanford University, CA). Rabbit polyclonal antibodies against FOG-1 were a generous gift by Stuart H. Orkin 
(Harvard Medical School, MA). Rabbit polyclonal antibodies against MTA2, Mi2 and Mbd2/3 were kindly donated 
by Paul A. Wade (NIH/NIEHS, NC). Sheep anti-serum S923 against Mbd2 and rabbit polyclonal antibody R593 
against Mbd2/Mbd3 were generously provided by Adrian Bird (University of Edinburgh, UK). Rabbit polyclonal 
antibodies against ACF1 were a generous gift of Patrick Varga-Weisz (Marie Curie Research Institute, Surrey, UK). 
Rpd3 rabbit polyclonal antibodies were donated by Alexander Brehm (Adolf Butenandt Institut, Germany). Mouse 
monoclonal antibody against B23 nucleophosmin was a kind gift by Pui K. Chan (Baylor College of Medicine, TX). 
Secondary antibodies conjugated to horseradish peroxidase were purchased from Dako (DakoCytomation, Denmark) 
and Amersham Biosciences and developed by chemiluminescence using the ECL-PLUS kit (Amersham). 
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Abstract
The TR2 and TR4 orphan nuclear receptors are the core components of the DRED complex 
previously implicated in ε and γ globin gene silencing in the adult (92, 93). Initially, DRED 
was purified as 540kDa protein complex, however only TR2 and TR4 were shown to bind to 
DR1 regulatory elements present in the ε and γ globin gene promoters (92). In order to identify 
additional DRED complex components other than TR2/TR4 we applied in vivo biotinylation 
tagging (13) of TR2 and TR4 in erythroid cells for the efficient isolation and characterization 
of protein complexes. Here we present biochemical evidence for TR2/TR4 interactions with the 
DNA methyltrasferase 1, the histone demethylase Lsd1, with histone deacetylases such as HDAC3 
and transcriptional co-repressors, such as TIF1β and RbAp46/48. The possible function of these 
factors in transcriptional repression are in agreement with previous observations of the DRED 
complex being responsible for ε and γ globin gene silencing (70, 92, 93, 95). Our collected data 
suggest that TR2/TR4 form two distinct complexes that may have distinct functions. However, 
further investigation is required to confirm this model and to further relate these interactions to the 
initially identified DRED complex and its functions. 
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Introduction
 The CAC and CCAAT box is one of the most conserved common motifs found in the globin 
promoters. The distal CCAAT box in the human γ-globin promoter contains an approximate direct 
repeat (DR1) sequence TGACCAATAGCC. Importantly the CAAT box regions of the human ε- 
and ζ –globin genes as well as of the murine εy- and βh1-globin genes also contain a DR-1 type 
sequence, as shown in Table 1 (24). 
Table1.  After (24) and (93). Alignment of the human and mouse globin genes promoter sequence. Potential DR1 sites indicated 
by bold fonts.
Distal DR1
AGGTCAnAGGTCA
Proximal DR1
TGACCTnTGACCT
Human ε AGGaCA.cAGGTCAgc TGACCaaTGACtT
Mouse εy AGGaCcacGGGTCAgg TGACCaaTGgCtT
Human γ ggttggccagccttg TGACCaaTagCCT
Mouse βh1 tcttgcccagactct TGACCaaTagCCT
Human β ggagccacaccct TGgCCaaTctaCT
Mouse βmaj agagccacaccctg gGgCCaaTctgCT
Aγ -117 HPFH TaACCAaTAGCCT
Direct repeat (DR) sites are direct binding targets for nuclear receptors (63). Interestingly, 
the hereditary persistence of fetal haemoglobin (HPFH) an inherited human condition resulting in 
continued γ-globin gene expression in adult life (73) has been associated with deletions/mutations 
in distinct sites in the γ-globin promoter, including DR1 sites such as in the -117 Greek HPFH (11). 
A growing list of factors including GATA-1, NF-E3, COUP-TF1, EKLF, Sp1, CP1/NF-Y and CDP 
have been suggested to bind to the CAC/CCAAT motifs in globin promoters (24, 95).
DNA methylation has also been implicated in γ globin silencing (17, 18, 30, 90).  A high 
local concentration of CpG residues is found in the 5’γ globin promoter (five CpGs in the first 
105bp) that is absent from the other β-like globin gene promoters (83). Previous observations 
suggested that there is a correlation between γ-globin gene expression and the lack of methylation 
of CpGs in the γ-globin promoter region (64, 83, 98). Moreover, phylogenetic footprinting studies 
demonstrated that acquisition of CpG residues in the γ globin promoter coincided with recruitment 
of the γ-globin gene to fetal expression in primates (83, 91). In addition, 5-azacytidine and its 
derivatives, which are known DNA methyltrasferase inhibitors, have been tested on baboons and 
human patients for their potential to re-activate γ-globin expression in adults, with very promising 
results (22, 33, 55, 56).  However, concern about potential carcinogenic effects have halted the 
development of 5-azacytidine derivatives as therapeutic agents for patients with β-thalassemia and 
sickle cell disease (20).
Initial studies from the Engel laboratory showed that the suppression of the ε-globin 
transcription during definitive erythropoiesis is mediated by the binding of a repressor that prevents 
EKLF from activating the ε-globin gene via the CAC element (95). That repressor activity was 
further attributed to a novel protein complex called DRED (Direct Repeat Erythroid Definitive) as 
detected by electrophoretic mobility shift assays (95). Subsequently the Engel laboratory showed 
that the DNA binding core activity of the DRED complex consists of two orphan nuclear receptors 
TR2 and TR4. The DRED complex binds to DR1 elements in ε- and γ- globin gene promoters to 
mediate stage-specific globin switching (92, 95). DNA-affinity purification of the DRED complex 
revealed five proteins: CDP, USF-1, LBP-1a, and the orphan nuclear receptors TR2 and TR4. 
However, DRED DNA binding activity was confirmed by EMSA only for TR2 and TR4 (92). TR2 
and TR4 belong to the subfamily of orphan nuclear receptors and are expressed in many tissues 
(including hematopoietic) at all developmental stages (51). Although TR2 and TR4 preferentially 
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heterodimerize, they may form homodimers (49). Significantly, initial gel filtration studies showed 
that the DRED repressor complex migrates as a much larger species than the TR2:TR4 heterodimer 
(92). In order to identify additional TR2 and TR4 interactors we applied an in vivo biotinylation 
tagging approach in order to purify TR2/TR4 complexes from mouse erythroleukemic  (MEL) 
cells (13). To this end, we generated stably transfected MEL cell lines expressing the BirA biotin 
ligase (13) and biotin-tagged versions of both TR2 and TR4 together. 
In vivo biotinylation was previously successfully applied by our laboratory to study the 
interacting partners of GATA-1 and Ldb1 in erythroid cells. Previous work ((13, 31, 74) and 
discussed in greater detail elsewhere in Chapters 2 and 3) showed that biotin tagging offered a 
powerful tool for the study of protein complexes in erythroid (and other mammalian) cells.
Here we show that we could express biotin tagged versions of TR2 and TR4 in MEL cells. 
The biotin-tagged TR2/TR4 could be efficiently bound to magnetic M280 Dynabeads. However, 
initial experiments with the TR2/TR4 complex purification indicated that significant optimization 
was needed in order to enrich for TR2 and TR4 complexes. Here we present our successful attempts 
at optimizing TR2/TR4 complex purification.In addition, we present the biochemical identification 
and analysis of the mass spectrometry results of the TR2/TR4 complexes. We identified a number 
of chromatin associated co-repressors, including DNA methyltransferase (Dnmt1), members of 
the NuRD complex and TIF1β co-purifying with TR2/TR4. Interestingly, we also identified the 
Lsd1 (AOF 2) Lysine Specific Histone Demethylase, which has recently been reported to interact 
with hematopoietic transcription factors Gfi1b and GATA-2 ((80) and H. Braun unpublished 
observations). Significantly, the most prominent interacting partner co-purifying with TR2/TR4 
is the DNA methyltransferase Dnmt1. In this chapter, we also present results suggesting that the 
mechanism of 5-azacytidine mediated γ globin re-activation involves the specific degradation of 
Dnmt1, TR2 and TR4. These findings provide new leads for investigating how these co-repressors 
may contribute to the repression the ε- and γ-globin genes. 
Material and methods:
DNA Constructs: N-terminally tagged TR2 and TR4 were constructed by cloning the 23-
amino acid biotin tag in the NcoI site overlapping the start codon of both proteins. Tagged TR2 and 
TR4 cDNAs were then cloned in the pEV-Neo β-globin based erythroidexpression vector. DNA 
constructs were made by Dr Shoko Kobayashi (the Engel lab, University of Michigan). 
Cell culture: MEL cells were cultured in DMEM medium supplemented with 10%FCS 
and Pen/Strep and were induced by adding DMSO (Sigma) to a final concentration of 2%. Stable 
transfectants (Figure 1) were obtained as previously described (3, 13). Nuclear extracts were 
prepared as described in (2, 74). 
Antibodies: TR2 and TR4 rabbit polyclonal antibodies were from Santa Cruz (Cat No 
sc-9087 and ac 9086) or generated by Engel’s laboratory. Anti-Dnmt1 antibodies were mouse 
monoclonal ab13537 (Abcam), rabbit polyclonal ab 19905 (Abcam) and mouse monoclonal IMG-
261A (Imgenex). TIF1α, -β, and -γ antibodies were generously donated by Dr. Florence Cammas 
(IGBMG, Strasbourg) (7). The actin antibody was from Abcam (ab 8226) and HDAC-1 antibodies 
were from Santa Cruz (mouse monoclonal sc- 8410) and Abcam ( rabbit polyclonal ab 7028). 
HDAC 3 antibody was from Abcam (rabbit polyclonal; ab 7030). Streptavidin HRP was from 
Perkin Elmer (NEL 750). 
Binding to strepatvidin beads: was done as described in Chapter 2 and 3 (74, 75). Benzonase 
(Novagen) treated samples were supplemented with 10mM (final concentration) of CaCl2, and 
benzonase was used in a ratio of 500 U per 1mg total protein. 
Ammonium sulphate precipitation:  was carried out as described in the initial DRED 
isolation (92).
Sucrose gradient: different concentrations of sucrose (Sigma) varying from 70% to 10% 
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were prepared in HEPES buffer (pH 7.9) buffer and stored at 4ºC (swing out rotor). The gradient 
was assembled in 5mL polyallomer tubes (Beckman), (Figure 6A) and ultracentrifuged 40000 
rpm over-night at 4ºC. Fractions (500µl each) were collected from the top of the gradient and 
injected onto the analytical superpose 6 gel filtration column. Fractionation profiles were analysed 
by Western immunoblotting. 
Size fractionation by Superose 6 column: size fractionation using the analytical Superose 
6 column and processing of fractions for analysis were carried out as described in (75) Appendix 
1. Fractionation using the preparative column was done as follows. 5 mL of nuclear extract, 
equivalent to 40 mg of total protein was injected onto a preparative grade Superose 6 XK50/600 
column connected to the AKTA FPLC system (Amersham Biosciences UK), equilibrated in running 
buffer  (20mM HEPES pH 7.9, 0.5mM EGTA, 1mM MgCl2, 200mM KCL, 10% glycerol).  The 
column was ran at 4º C. 10mL fractions (numbers 18 to 38) were pooled together and  binding 
to streptavidin beads was carried out as described in (74) Chapter 2 and 3. Eluted proteins were 
resolved by SDS-PAGE and subsequently analysed by mass spectrometry. Alternatively, proteins 
bound to the streptavidin beads were directly subjected to trypsinization, as described below and 
subsequently analysed by mass spectrometry. 
On beads trypsinization: was done as described in (78, 79). After binding and washing, 
M280 paramagnetic beads were resuspended in 50mM ammonium bicarbonate and trypsin was 
added (60ng of trypsin per mg of total protein used for binding). Digestion was carried out overnight 
at 37º C. Beads were removed using the magnetic rack and the supernatant containing trypsinized 
peptides was collected and immediately injected onto a mass spectrometer. 
Mass spectrometry analysis: was done as previously described in (65, 74, 75, 81). 
SDS-PAGE gel lanes were cut into slices using an automatic gel slicer and subjected to in-gel 
trypsinization (Promega, sequencing grade), essentially as described (86, 104). Alternatively, 
after stringent washing the streptavidin beads were incubated overnight at 37ºC with trypsin in 
ammonium bicarbonate buffer for on-beads digestion as described in (78, 79). NanoLC-MS/MS 
was performed on either a CapLC system (Waters, Manchester, UK) coupled to a Q-ToF Ultima 
mass spectrometer (Waters, Manchester, UK), operating in positive mode and equipped with a 
Z-spray source, or an 1100 series capillary LC system (Agilent Technologies) coupled to an LTQ 
mass spectrometer (Thermo) operating in positive mode and equipped with a nanospray source. 
Peptide mixtures were trapped on a Jupiter™ C18 reversed phase column (Phenomenex). Peptide 
separation was performed on Jupiter™ C18 reversed phase column (Phenomenex) using a linear 
gradient from 0 to 80% B (A = 0.1 M acetic acid; B = 80% (v/v) acetonitrile, 0.1 M acetic acid). 
The column eluent was directly sprayed into the ESI source of the mass spectrometer. Mass spectra 
were acquired in continuum mode; fragmentation of the peptides was performed in data-dependent 
mode.   
Data analysis and protein identification: peak lists were automatically created from raw 
data files using the ProteinLynx Global Server software (version 2.0; Waters, Manchester, UK) for 
Q-ToF spectra and the Mascot Distiller software (version 2.0; MatrixScience, London, UK) for 
LTQ spectra. The Mascot search algorithm (version 2.0, MatrixScience, London, UK) was used 
for searching against the NCBInr database (release data: 3rd March 2006; taxonomy: M. musculus). 
The Mascot score cut-off value for a positive protein hit was set to 50. Individual peptide MS/
MS spectra with Mowse scores below 40 were checked manually and either interpreted as valid 
identifications or discarded.
Identified proteins listed as NCBInr database entries, were screened to identify proteins 
that were also identified streptavidin pull-down experiments with extracts from “BirA-only” MEL 
cells (6). These were removed as background binding proteins. Remaining proteins were classified 
according to Gene Ontology criteria (http://www.informatics.jax.org/), and grouped according to 
Biological Process and/or Molecular Function.  
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Chromatin Immunoprecipitations: were done according to the ChIP kit Upstate/Milipore 
protocol, with minor modifications. We used 1% gelatine from cold water fish skin for blocking 
the beads, and no-SDS lysis buffer (Chapter 5). Double cross-linking using Di(N0succinimidyl) 
glutarate (Sigma), according to Porro and Perini protocol (72). Primers were designed with Primer 
express 2, in addition to primers previously published in (94). Primers used for PCR are listed in 
Table 1.
Results 
Optimization of TR2 and TR4 high molecular weight complexes from erythroid cells
We obtained stably transfected MEL cell clones expressing bio-TR2 or bio-TR4 or both 
double bio-TR2/bio-TR4 (Figure 1). Western blot analysis with TR2 and TR4 antibodies showed 
that the tagged forms were expressed at levels 2-3 fold higher than the endogenous protein levels, 
particularly in induced MEL cells where the tagged protein expresses at high levels as a result of 
the β-globin promoter of the pEV-Neo vector (Figure 2 input lane). All selected clones expressed 
tagged TR2/TR4 in both non-induced and DMSO induced MEL cells. 
The efficiency of biotinylation was tested in all three stable transfectants by direct binding 
A. single bio-TR2
B. single bio-TR4
C. Double transfectant bio-TR2/ bio-TR4
ZF TR2Bio ZF
ZF TR4Bio ZF
ZF TR2Bio ZF
ZF TR4Bio ZF
Figure 1: Scheme depicting biotinylation tagging strategy of TR2 
and TR4 in order to obtain single (panel A and B) or double (panel 
C) MEL cells transfectants expressing biotin-tagged TR2 and TR4.
cell lines, expressing (next to endogenous protein) either bio-TR2 
only (A), bioTR4 only (B), both bio-TR2 and bioTR4 (C) 
Tagged TR2
Endog. TR2
Tagged TR4
Endog. TR4
Biotin-TR2/TR4
anti-TR2
anti-TR4
Streptavidin-HRP
MEL IN. B. SUP.
TR2/TR4
transf.
Figure 2: Efficient biotinylation of tagged TR2 and TR4 in stably 
transfected MEL cell lines.  Streptavidin pull-down of nuclear extracts 
from double transfectant cell line shows that the majority (~90%) of 
bioTR2 (top panel) and bio-TR4 (middle panel) are bound to the beads, 
with little tagged protein left in the supernatant. This is also shown with 
streptavidin–HRP detection (bottom panel). Non-transfected MEL and 
input (IN.) lanes indicate the relative amounts of endogenous protein 
and biotin-tagged TR2 and TR4. Input and supernatant (SUP.) lanes 
were loaded with 10% of total material, bound (B.) lane was loaded 
with the equivalent of 1% of total protein used for binding. Detection 
using anti TR2 and anti TR4 antibodies (upper and middle panels) and 
streptavidin-HRP (bottom panel).
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protein elutes in high molecular weight (HMW) fraction, however the majority of TR2 and TR4 
proteins are present in low molecular weight (LMW) fractions. This indicates that a minority of TR2 
and TR4 form large protein complexes under the extraction conditions employed. Indeed, SDS-
PAGE analysis of bio-TR2/bio-TR4 nuclear extracts bound to streptavidin beads demonstrated 
the presence of large amounts of TR2 and TR4, with potential interacting protein present in sub-
stoichiometric amounts (Figure 4). Mass spectrometry analysis of the gel slices resulted in the 
identification of predominantly TR2/TR4 peptides with little information on the identity of other 
co-eluted proteins. To enrich for the isolation of TR2/TR4 HMW complexes, we tested ammonium 
sulphate precipitation, sucrose gradient centrifugation and superose 6 gel filtration. Of these three 
15 19 21 23 25 27 29 31 33 35 37 3917IN.
TR4
TR2
Bio-TR2/Bio- TR4
(detection: streptavidin HRP)
Non-transfected MEL
VO 670 kDa 70 kDa
Figure 3: Fractionation of nuclear extracts on an analytical superose 6 column. Fractions from non-transfected 
MEL cells were analysed with anti-TR2 (top panel) and anti-TR4 (middle panel) antibodies. Fractions from double 
transfected bio-TR2/bio-TR4 cells were analyzed with streptavidin HRP (bottom panel). The void volume (V0) and the 
elution of two molecular weight markers are indicated by arrows.
to streptavidin beads, which showed that 80-90% of the tagged protein is biotinylated in all 
transfectants. We decided to focus our attention on the analysis of the double bio-TR2/bio-TR4 
transfectant (Figure 2) since the initial analysis of the DRED complex revealed that the TR2/TR4 
heterodimer has the highest affinity toward the DR1 repeats in the human ε- and γ- globin gene 
promoters (92, 93). Furthermore, a previous study demonstrated that TR2 and TR4 preferentially 
heterodimerize (49). 
To determine whether bio-TR2/bio-TR4 form complexes in MEL cells we tested nuclear 
extracts from the double transfected cells by size fractionation using an analytical gel filtration 
superose 6 column. As a control we analyzed nuclear extracts from non-trasfected MEL cells 
under identical conditions. The elution profiles of bio-TR2 and bio-TR4 and of the endogenous 
proteins in nontransfected MEL cells were very similar (Figure 3). A proportion of TR2 and TR4 
Input BoundM
TR2/TR4
Figure 4: Coomasie blue staining of an SDS-PAGE gel after streptavidin 
pull-down of nuclear extract from bio-TR2/bio-TR4 MEL cells. The 
arrow indicates a strongly staining band where TR2 and TR4 migrate. 
TR2 and TR4 have similar molecular weight (~67kDa) and run as one 
band on the gel. 
89
Characterization of TR2/TR4 complexes in MEL cells 
Figure 5: Pie chart representing the most abundant proteins identified by mass spectrometry. Proteins have been grouped according 
to the Gene Ontology, the number of peptides and %age of total peptides is shown below to the pie chart.
methods, only size fractionation on superose 6 columns yielded reproducible enrichment of HMW 
TR2/TR4 complexes. We therefore used a preparative grade superose 6 gel filtration column with 
a matrix bed volume of 550 ml allowing us to load over 5 ml of nuclear extract totaling more 
than 40mg of protein per run. We pooled 20 fractions, spanning a size range of ~200-2000 kDa, 
for streptavidin pull-down (74). Before mass spectrometry analysis, streptavidin bound proteins 
were either first separated on SDS-PAGE followed by trypsin digestion of gel slices, or were 
digested directly on the streptavidin beads.  Both methods gave very similar results. We performed 
a total of five mass spec analyses of different nuclear extract preparations from induced MEL cells 
expressing biotin tagged TR2 and TR4, yielding similar results. Proteins potentially matching the 
peptides were identified using the NCBI database. Proteins that also appeared in streptavidin pull-
down experiments of BirA-only MEL nuclear extracts were rejected (13, 74). The list of remaining 
proteins was manually curated and grouped according to Gene Ontology criteria (Biological 
Process, Molecular Function, Cellular Component) using the Mouse Genome Informatics database 
(Table 2 and Table 3), and plotted in a pie chart to provide a general overview (Figure 5). 
Analysis of TR2/TR4 interacting proteins
The number of peptides identified per protein is an indication of its relative abundance in 
the sample. TR2 and TR4 are the most abundant proteins identified, followed by proteins involved 
in cell cycle, heat shock and the ubiquitin-proteasome pathway. In addition, we identified the 
DNA methyltransferase Dnmt1, and members of the NuRD complex, and the TIF1β and TIF1γ 
co-repressors that are known to interact with nuclear receptors (45).
In order to validate these results, we analyzed by western blotting whether these proteins 
were pulled down with TR2 and TR4 (Figure 6). This confirmed that bio-TR2/bio-TR4 specifically 
pulled down Dnmt1, TIF1β and the NuRD components RbAp46/48, Mta1 and Mi2β. We also 
confirmed interactions with HDAC3, a protein previously reported to interact directly with TR2 
(25, 57). 
100,00%461Total
0,40%2FACT
0,40%2SWI/SNF
0,65%3DNA replication
0,65%3Pc-G
0,90%4ISWI
0,90%4signal transduction
0,90%4signalosome complex
2,40%11transcription factor
3,70%17NuRD
4,55%21co-repressor
10,80%50Dnmt1
14,75%68
ubiquitin-proteasome 
pathway
16,50%76heat shock
20,80%96cell cycle
21,70%100orphan nuclear receptor
%agePeptides
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To confirm these interactions with an independent method, we performed co-
immunoprecipitations (co-IPs) using antibodies against Smc3, Hsp 90, TIF1β, TIF1γ, HDAC3, Mi2β, HDAC1, 
RbAp46/48, with mouse- and rabbit IgGs as negative controls. We used nuclear extracts from 
double (Figure 7A) and single (Figure 7B and 7C) transfectants expressing biotin-TR2 and/or 
biotin-TR4. Immunoprecipitates were assayed by Western blotting using streptavidin HRP which 
detects biotin-tagged TR2 and TR4. This confirmed that Dnmt1, TIF1β, HDAC-3, Mi2β and Hsp90 
interact with bio-TR2/bio-TR4. Smc3 antibodies did not co-IP bio-TR2/bio-TR4. In addition, 
TIF1γ, HDAC-1, Mi2β and Dnmt1 antibodies co-immunoprecipitated bio-TR2. We failed to 
confirm interaction between bio-TR2 and RbAp46/48, despite the fact that we could detect this 
protein in the double transfectant pull-downs and in co-IP. 
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TIF1
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Bio TR2/TR4
AOF2/Lsd1
SMC1
Figure 6: Confirmation of TR2/TR4 co-purified proteins by 
binding nuclear extracts from bio-TR2/bio-TR4 and BirA-
only control MEL cells to streptavidin beads followed by 
Western immunoblot analysis using antibodies specific for 
TR2/TR4 co-purified proteins. The antibodies used are listed 
on the right. The BirA-only control shows that none of the 
proteins analyzed bound as background to the streptavidin 
beads. Loading: Input (IN), bound to streptavidin beads 
(B.) and supernatant (SUP).
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Figure 7: A) Co-IP experiment using 
TR2, TR4, Dnmt1, TIF1β, Hsp90, 
Mi2β, smc3, Hdac3 and control mouse 
and rabbit IgG antibodies. Nuclear 
extract from bio-TR2/bio-TR4 double 
transfectant MEL cells was used for 
co-IP and TR2 and TR4 are detected 
with streptavidin-HRP. B) Co-IP using 
anti Mi2β, HDAC1, Dnmt1, TIF1β, 
RbAp46/48, and control rabbit and 
mouse IgG antibodies on nuclear extract 
from bio-TR2 single transfectant MEL 
cells. Bio-tagged TR2 was detected with 
streptavidin HRP. 
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TIF1b
Lsd 1
RbAp46/48
SMC1
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TR2
TR4
VO 670kDa 70 kDa
HDAC 1
Mi2β
Figure 8: Nuclear extract from 
induced, non-transfected MEL 
cells was run on the analytical 
superose 6 gel filtration 
column. Western blots detecting 
TR2, TR4 and potential 
interacting partners (Dnmt1, 
TIF1β, HDAC1, RbAp46/48, 
Mi2β, SMC1), showing 
the fractionation profiles of 
these proteins. The elution of 
molecular weight markers and 
the void volume are indicated 
by arrows on the top.
In summary, our results indicate that bio-TR2/bio-TR4 interacts with a number of 
transcriptional co-repressors. To assess whether these interactions occurred in distinct or overlapping 
complexes, we compared the superose 6 size fractionation profiles of the potential interacting 
proteins. Overlapping elution profiles would indicate that the proteins are components of the same 
complexes (Figure 8). We find that most proteins fractionate with peaks around fractions 18 to 24, 
including Dnmt1, TIF1β, HDAC1, Mi2β, RbAp46/48 and SMC1. Interpretation of these results 
with regards to possible interactions in distinct or overlapping complexes is difficult due to the 
overlapping fractionation profiles of most proteins tested. One other complicating factor is that the 
peaks of the TR2/TR4 fractionation profiles do not clearly overlap with those of the other proteins 
tested. 
Since these co-elution results were inconclusive, we performed co-IPs with antibodies against 
Dnmt1, TIF1β and HDAC1 (Figure 9). We find that the Dnmt1 antibody co-immunoprecipitates 
TIF1β (Fig. 9A). The interactions of Dnmt1 with TIF1β are also confirmed by co-IPs using TIF1β 
antibodies as the primary antibody (Fig. 9B and C). In addition, we find that Dnmt1 interacts 
with HDAC3 (Fig. 9A). Interestingly, HDAC1 antibodies could not immunoprecipitate detectable 
amounts of TIF1β (Fig. 9). These results are summarized in Figure 10.
TR2/TR4 interact with Dnmt1
As we have shown above (Figure 5 and 6 and Table 2), we could isolate Dnmt1 in our mass 
spectrometry results as a potentially TR2/TR4-interacting protein. As unrelated proteins may be 
bound to the same piece of DNA and therefore appear to be part of the same complex, we tested 
whether the interaction of TR2/TR4 with Dnmt1 is due to nucleic acid contamination. To eliminate 
nucleic acids we treated nuclear extracts with benzonase, an enzyme that hydrolyses both DNA 
and RNA.  As shown in Figure 11, Dnmt1 was co-purified with TR2/TR4 in both benzonase- and 
mock- treated samples. We conclude that the interaction of TR2/TR4 and Dnmt1 is not dependent 
on the presence of DNA. 
Affinity tags may affect the yield, solubility and even the folding of their fusion partners 
(101). This may create non-physiological interactions with other proteins. To test whether the 
TR2/TR4/Dnmt1 interaction is present in non-transfected MEL cells we performed immune 
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Figure 9: Co-IPs using antibodies against potential TR2/
TR4 interacting proteins and nuclear extracts from induced 
non-transfected MEL cells. The order of loading of input 
supernatant (unbound) and bound (immunoprecipitated) 
fractions is indicated. Input and supernatant loadingrepresents 
approx. 1% of starting material, while bound fraction 
loading represents approx 10-15 % of starting protein A) 
Co-IP experiment using Dnmt1 antibody, using mouse IgG 
as a control. C) IP using anti HDAC1 antibodies and rabbit 
IgG control. 
precipitation experiments using TR2 and TR4 antibodies. Although signals are not very strong, we 
could clearly demonstrate that Dnmt1 precipitated with TR2 and TR4 antibodies (Fig. 11B).
Developmental interaction of TR2/TR4 complexes to the globin promoters in erythroid 
cells 
Previous work showed that TR2 and TR4 are the core components of the DRED complex 
that binds to the DR1 sites in the γ- and ε- globin promoters (92). Such DR1 sites are also present 
in the mouse embryonic εy and βh1 globin promoters (24, 95). In order to test the functional 
relevance of the TR2/TR4/Dnmt1 interaction in globin gene regulation we performed Chromatin 
Immunoprecipitation (ChIP) experiments using streptavidin beads and specific antibodies. Firstly, 
we tested whether we could ChIP TR2/TR4 bound to the ε- and γ-globin promoters in non-induced 
MEL cells and 14.5 dpc fetal livers of transgenic mice carrying a human β-globin locus. Fetal 
93
Characterization of TR2/TR4 complexes in MEL cells 
livers at this stage are developmentally similar to induced MEL cells, and represent the adult stage 
of erythropoiesis (Fig 12)  However, in none of these experiments did we were able detect binding 
of TR2 or TR4 to the εy- and βh1 promoters or to the human ε- or γ-globin promoters. Instead, 
much to our surprise, initially biotin tagged TR2/TR4 double transfectant (data not shown) and 
i Bound Sup bound sup i bound sup
mock benzonase MEL
input TR2 TR4 sup IgG
Dnmt1
Dnmt1
input Dnmt1 Sup IgG
Dnmt1 Sup IgGinput
streptavidin
streptavidin
IP Ab:
IP Ab:
IP Ab:
Detecting Abs:
Detecting Abs:
Detecting Abs:
Detecting Abs:
A.
B.
C.
D.
Figure 11: Confirmation of TR2/TR4 and 
Dnmt1 interactions by immunoprecipitation 
A) Nuclear extracts of bio-TR2/bio-TR4 
were either mock or benzonase treated and 
substequently bound to the streptavidin 
beads. Nuclear extracts from BirA–only 
trasfected cells were used as a negative 
control. The western blot was detected 
with a Dnmt1 antibody. B) IP experiment 
using induced non-transfected MEL cell 
nuclear extract. Antibodies against TR2 and 
TR4 could specifically immunoprecipitate 
Dnmt1. C) Dnmt1 can specifically 
immunoprecipitate bio-TR2, as detected by 
streptavidin HRP D) reverse IP using Dnmt1 
antibody and relative IgG negative control 
and nuclear extracts from single transfectant 
bio-TR4 MEL cells. Dnmt1 can specifically 
immunoprecipitate bio-TR2, as detected by 
streptavidin HRP. 
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α-HDAC1α-Tif1βα-Lsd1α-Dnmt1Immunoprecipitated 
proteins
Immunoprecipitating antibodies
n.t.: not tested
* : previously reported in literature
Figure 10:  Potential 
cross-interactions of the 
TR2/TR4 proteins and 
interacting partners
later on single biotin-tagged TR4 and anti-TR4 antibodies showed a marked enrichment for mouse 
βmajor (βmaj) promoter (Fig.12). In addition, using a Dnmt1 antibody previously reported to work 
in ChIP assays (54), we were unable to detect any promoter-specific enrichment of Dnmt1 in 
induced MEL cells, even after using double crosslinking (first protein-protein interactions with 
DSG subsequently protein-DNA with formaldehyde) (Fig. 12F and data not shown). It is possible 
that the anti-Dnmt1 antibody did not work efficiently enough, and this problem may be overcome 
in future by using chromatin from biotin-tagged Dnmt1 MEL cells (K.Kolodziej, unpublished). 
This could be also due to the fact that the Dnmt1 antibody binds to the chromatin indiscriminately. 
We also tested chromatin prepared from 13.5 dpc fetal livers. We found enrichment of  the βmaj 
promoter only with anti-TR4 but not with anti-TR2 or anti-Dnmt1 antibody (Fig. 12E). The only 
potentially TR4-interacting factors that showed similar tendency in ChIP experiments (i.e. bound 
βmaj globin) was RbAp46/48 (Fig 12G). In summary our ChIP results suggest that only TR4 
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Figure 12:  Analysis of TR2/TR4 to human and mouse globin promoters by ChIP. A) Schematic presentation of primers used for 
mouse globin locus ChIP. B) Schematic presentation of primers used in human β- globin locus ChIP. C) ChIP using non-induced 
MEL cells chromatin from single bio-TR4 transfectant. Fold enrichment calculated over the BirA negative control experiment (by 
division) that was done in parallel. D) ChIP using chromatin from 14.5 dpc fetal liver cells. E) anti-TR4 and anti-Dnmt1 antibodies 
ChIP using chromatin from 13.5 dpc fetal livers of the transgenic mice carrying human β-globin locus YAC and. F) anti-Dnmt1 
antibody ChIP using chromatin from induce MEL cells G) anti-RbAp 46/48 antibodies ChIP using the chromatin from 14.5 dpc 
fetal livers. 
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homodimers bind to the active βmaj globin promoter in vivo. 
TR4 binds to the DR4 element in β
maj 
promoter
The βmaj ChIP primers overlap with a potential DR4 site which is 28bp downstream of the 
CAAT box that was tested in band shift experiments in (92) (Fig. 13 A). Considering that TR2 and 
TR4 bind to DR4 response elements (9, 50), we propose that the βmaj promoter contains a potential 
DR4 response element that has not been reported before. To further investigate whether this potential 
DR4 element can be bound by TR2 and TR4 we performed band shift assays with nuclear extracts 
from MEL cells (Fig. 13 B). Consistent with previous data, we find the DRED complex binding 
to DR1 in the ε-globin promoter (Fig. 5, lane 2). We used competitor oligonucleotides that were 
published previously (92): EPSI which strongly competed for DRED binding (Fig. 13B, lanes 2 and 
3) and γCAAT which was less efficient in competing the DRED complex. As a negative control we 
used βCAAT oligonucleotides, which do not compete for DRED binding (Fig. 13B, lanes 7 and 8). 
In comparison the oligonucleotide corresponding to the potential DR4 response element competed 
for DRED complex binding almost as efficiently as the γCAAT oligonucleotide. We conclude that 
TR2/TR4 may bind to the potential DR4 response element in the βmaj globin gene promoter in vivo. 
      TTCTCTGCACAGATAAGGACAAACATTATTC...AGAGGGAGTACCCAGAGCTGAGACTC 
      |   |||     ||  || |||    |||     ||||||||  |  || | |   | || 
1     TGTACTGATGGTATGGGGCCAAGAGATATATCTTAGAGGGAGGGCTGAGGGTTTGAAGTC 
 
126   CTAAGCC..AGTGAGTGGCACAGCATCCAGGGAGAAATATGCTTGTCATCACCGAAGCCT 
      | |  ||  ||  |||| || |  | ||| ||| |  || |  |||||||||  |  ||| 
61    CAACTCCTAAGCCAGTGCCAGAAGAGCCAAGGACAGGTACGGCTGTCATCACTTAGACCT 
 
184   GATTCCGTAGAGCCACACCCTGGTAAGGGCCAATCTGCTCACACAGGATAGAGAGGGCAG 
       |  | || |||||||||||| |    ||||||||| ||| ||   |  || |||||||| 
121   CACCCTGTGGAGCCACACCCTAGGGTTGGCCAATCTACTCCCAGGAGC.AGGGAGGGCAG 
 
244   GAGCCAGGGCAGAGCATATAAGGTGAGGTAGGATCAGTTGCTCCTCACATTTGCTTCTGA 
      |||||||||| | ||||| |||    || ||   ||  |  | || |||||||||||||| 
180   GAGCCAGGGCTGGGCATAAAAGTCAGGGCAGAGCCATCTATTGCTTACATTTGCTTCTGA 
 
304   CATAGTTGTGTTGACTCACAACCCCAGAAACAGACATCATGGTGCACCTGACTGATGCTG 
      || |  |||||| |||  ||||| ||  |||||||| ||||||||||||||||  ||  | 
240   CACAACTGTGTTCACTAGCAACCTCA..AACAGACACCATGGTGCACCTGACTCCTGAGG 
 
364   AGAAGGCTGCTGTCTCTTGCCTGTGGGGAAAGGTGAACTCCGATGAAGTTGGTGGTG 
      ||||| |||| ||  ||  ||||||||| |||||||||   ||||||||||||||||    
298   AGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGG 
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A. Figure 13: A) Alignment 
of sequences upstream 
of the human (lower 
sequence) and mouse 
(upper sequence) β-globin 
gene promoters. The CAAT 
box previously tested and 
used as a negative control 
for band shift assay (92) is 
marked in yellow (βCAAT 
negative control). Broken 
line arrows mark the βmaj 
primer set used in ChIP. 
Solid line arrows mark 
βmaj TATA primer set used 
in ChIP. The potential DR4 
element that was tested 
by EMSA is highlighted 
in pink. Another potential 
DR4 element that is shared 
by both species and which 
should be further tested, 
is marked by underlined 
green font. 
B). Band shift assays using 
MEL nuclear extract.  EPSI 
probe (from (92)) was 
labeled with P32 according 
to the protocol in (92). 
Cold probes (EPSI, γ 
CAAT, potential β-globin 
DR4 element, and βCAAT 
negative control) were 
used as competitors in 
two concentrations: 0.1μM 
and 1 μM.  In lane 1 only 
labelled probe was used. 
DRED complex  formation 
is indicated by an arrow.  
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The alignment of mouse and human beta globin gene promoters (Figure 13A) revealed that there 
is an additional potential DR4 response element further downstream from the CCAAT box in both 
mouse and human. Whether it can be bound by TR2 and TR4 remains to be tested. It is possible 
that the enrichments we observe by ChIP using chromatin from mouse cells are the result of TR2/
TR4 binding to both DR4 elements, and in the case of human cells the enrichment in ChIP is the 
result of binding of TR2/TR4 to only one DR4 element.
The observation that TR2/TR4 binding to the β-like globin promoters is a very intriguing 
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one and the function(s) of TR2/TR4 in regulating β-globin remains to be discovered.
5-azacytidine induces degradation of Dntm1 and TR2/TR4
5-azacytidine is a potent DNA methyltransferase inhibitor that was previously tested in tissue 
culture but also in baboons and human patients initially as an anticancer drug (90).  Recent studies 
showed that one of the possible effects of 5-azacytidine in inhibiting DNA methyltransferases is by 
specific Dnmt1 protein degradation through the proteasome pathway (28). In order to test whether 
5-azacytidine would have any effect on the TR2/TR4/Dnmt1 complex stability in erythroid cells 
we treated cultured 14.5 dpc fetal liver cells (Fig. 14A) and MEL cells (Fig. 9B) with 5-azacytidine. 
Increasing concentrations of 5-azacytidine resulted in decreasing amount of TR2/TR4 and Dnmt1 
proteins (Fig.14). This effect is specific as the levels of control proteins such as Smc-1, Septin or 
Actin did not change upon 5-azacytidine treatment (Fig 14A and B). Furthermore, the effect of 
5-azacytidine on TR2/TR4 and Dnmt1 cannot be explained solely by increased cytotoxity as the 
numbers of MEL cells do not significantly change before and after treatment (Fig. 14C).
In addition to its inhibitory and pro-apoptotic functions, 5-azacytidine has been previously 
shown to induce differentiation in many cellular systems (59, 82, 100). We therefore tested if the 
decreasing levels of Dnmt1 and orphan receptors observed after 5-AzaC treatment of MEL cells 
are a physiological consequence of cellular differentiation. To this end, we divided MEL cells into 
two groups: one was induced to differentiate with the very potent inducer DMSO, the other group 
was incubated with various concentrations of 5-azacytidine. Cells were subsequently counted and 
lysed for proteins to be analyzed by western blotting (Fig. 14D). The results show that in cells 
induced with DMSO the levels of TR2/TR4 or Dnmt1 protein did not change significantly (Fig. 
14 D, left panel). In contrast, again the levels of TR4 and Dnmt1 protein again decreased with 
increasing amounts of 5-azacytidine (Fig. 14 D, right panel). In addition, 5-azacytidine appeared 
to only slightly induce cellular differentiation (see small additional peak on the red and green 
graph cells treated with 25 and 100 μM 5-azacytidine (Figure 14 D, right panel)). 
 In order to investigate whether in the conditions we used 5-azacytidine could induce the 
embryonic and fetal globin expression, we cultured 13.5 dpc fetal liver cells in the presence of 
2.5 μM 5-azacytidine for 72 hours. A slight increase in the expression of the εy- and βh1- mouse 
embryonic globins was detected (Fig. 14). 
Discussion
The TR2/TR4 orphan nuclear receptors have been identified as components of DRED 
complex involved in developmental silencing of embryonic and fetal globin genes (70, 92, 93). In 
order to identify additional components of the DRED complex we employed biotinylation tagging 
of TR2/TR4 in MEL cells, by size fractionating nuclear extracts followed by streptavidin binding 
and mass spectrometry. Apart from TR2 and TR4 the most abundant proteins identified  in this way 
were proteins involved in the cell cycle, heat shock and the ubiquitin-proteasome pathway followed 
by chromatin associated proteins involved in transcriptional repression (Tables 2 and 3). Although 
we did confirmed the interaction of TR2/TR4 with Hsp90 (Fig. 7) we did not pursue any further 
our observations on the co-purification of cell-cycle, heat shock and ubiquitin proteasome proteins 
with TR2/TR4. Interactions of nuclear receptors with heat shock proteins acting as chaperones 
are well known and have been implicated in the refolding of nuclear receptors and their nuclear 
translocation (67). There is also increasing evidence that components of the ubiquitin-proteasome 
pathway interact with nuclear receptors in modulating their transcriptional activities  (36, 42). The 
co-purification of several cell cycle associated proteins with TR2/TR4 may be related to a wealth 
of evidence implicating nuclear receptors in cell cycle regulation in erythropoiesis (for example 
(4)). Significantly, overexpression of TR4 in myeloid cell lines led to increased cell proliferation 
(43), though we did not observe any overt effects on MEL cell differentiation upon overexpression 
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of biotin tagged TR4 and/or TR2. We do not presently know whether these TR2/TR4 protein 
interaction/complexes are distinct or overlap with other complexes that were identified in our 
studies. It is possible that they are specifically enriched in the size fractionation protocol that we 
used. In that respect, it would be interesting to determine the fractionation profiles for several 
representative members of cell cycle, heat shock and ubiquitin-proteasome proteins and compare 
them to the TR2/TR4 profiles. Interactions of nuclear receptors with heat shock proteins acting 
as chaperones are well known and have been implicated in the refolding of nuclear receptors and 
their nuclear translocation (67). There is also increasing evidence that components of the ubiquitin-
proteasome pathway interact with nuclear receptors in modulating their transcriptional activities 
(36, 42). The co-purification of several cell cycle associated proteins with TR2/TR4 may be related 
to a wealth of evidence implicating nuclear receptors in cell cycle regulation in erythropoiesis 
(for example (4)). Significantly, overexpression of TR4 in myeloid cell lines led to increased cell 
proliferation (43), though we did not observe any overt effects on MEL cell differentiation upon 
overexpression of biotin tagged TR4 and/or TR2.
Interestingly, we also identified and confirmed interactions of TR2/TR4 with the Dnmt1 
DNA methyltransferase, the Lsd1 histone demethylase, the Tif1β and γ co-repressors and members 
of the NuRD complex (mainly HDAC1, M2β, RbAp46/48). Most of these interactions have also 
been confirmed by reverse IPs (7 and 9). Due to the involvement of TR2/TR4 in the DRED complex 
and in globin gene repression, we focused on this group of chromatin associated repressive proteins. 
Most importantly, we show for the first time that Lsd1 and Dnmt1 interact together (Fig. 9). We 
do not presently know whether these interactions occur in addition or exclusively in the context 
of their interactions with TR2/TR4. We also find that TR2/TR4 interact with HDAC3, as has been 
previously reported for TR2 (25). 
Chromatin remodeling protein Mi2β interacts together with HDAC1 and RbAp46/48 in 
the NuRD complex that contains additionally Mbd3, Mta1, Mta2 and p66 proteins (105) and, as 
shown in Figure 4, they share overlapping fractionation profiles. Thus, NuRD combines in the 
same complex histone deacetylation and chromatin remodeling ATPase activities to methyl DNA 
binding. Importantly, members of the NurD complex have been reported to participate in the 
PYR complex which binds to the intergenic region between the human δ and γ globin genes (69) 
whereas the MeCP1 complex has been reported to bind to HS2 of the human β-globin LCR (62). 
Lsd1 is a lysine specific histone demethylase (87) that is associated with HDACs 1 and 2 in the 
context of the coREST co-repressor complex (44, 88) (but not with the NuRD complex). Consistent 
with this, it has been previously shown that the preferred Lsd1 substrates are hypoacetylated 
histones and treatment with the HDAC inhibitor trichostatin (TSA) causes Lsd1 target gene de-
repression (87, 88). Lsd1 has not been previously reported to interact with Dnmt1 or with Tif1β. 
Intriguingly, interactions of Lsd1 with nuclear receptors have been previously reported to result in 
gene activation (71) (also see Discussion Chapter).
TIF1 (transcriptional intermediary factor 1) β and γ are members of a family of 
transcriptional co-repressors interacting with nuclear factors (8, 48, 99). In addition, TIF1β is a 
universal co-repressor for KRAB-domain zinc-finger proteins (26, 41, 66). Importantly, TIF1β has 
been reported to co-purify with the N-CoR1 complex which contains HDAC3, but not HDAC1 
or 2 (44). It has also been reported to interact with Mi2α, HDAC1 and RbAp48 (85, 97) which 
are members of the NuRD complex. TIF1β has also been shown to interact directly with histone 
methyltrasnferase SETB1 (84) and HP1 (45, 46, 68, 77). Our results clearly show that TIF1β can 
interact with TR2/TR4, but it can also be immunoprecipitated with Dnmt1 antibodies and that 
this interaction is reciprocal (see Figure 9A and C). However, we have also clearly shown that 
there is no detectable interaction between Tif1β and HDAC1 in MEL cells (Fig.9D). This suggests 
that interactions of TR2/TR4 (and of Dnmt1) with Tif1β may be taking place in a complex that is 
distinct to TR2/TR4 complexes containing HDAC1. It is not clear from our data whether Tif1β 
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interactions with TR2/TR4 also involve HDAC3, however, Tif1β has been reported to interact 
with HDAC3 in the context of the NCoR1 complex (44) and we show here that Dnmt1 can also 
immunoprecipitate HDAC3 (Fig. 9A). It is also not clear from our data whether Lsd1 interacts 
with Tif1β, however, Lsd1 has not been previously reported to interact with any of the reported 
Tif1β interacting proteins (except HDAC1). By putting our data together and by extrapolating 
from previous results from other labs, we suggest that TR2/TR4 possibly form a distinct complex 
with Tif1β, Dnmt1 and HDAC3 (complex 1, Figure 15). In order to provide evidence for a role 
for Tif1β together with TR2/TR4 in the regulation of globin genes, we employed ChIP assays 
but failed to detect any binding of Tif1β to the mouse β-globin locus in 14.5 dpc fetal livers (data 
not shown). TIF1α and TIF1β have been previously shown to interact with the LBD of nuclear 
receptors (NR), including estrogen receptor, thyroid hormone receptor, vitamin D receptor and 
retinoic acid receptor (45, 47, 48). The TIF1 family of proteins can interact with NRs in the absence 
of activating ligands, or compete with the activating ligands for binding to the NRs. TIF1 bound to 
NRs can result in a change in the conformation of the NR protein and as result block DNA binding 
by the nuclear receptor causing transcriptional repression (e.g. by stalling the RNA polymerase or 
by outcompeting the transcriptional co-activators) (89). Thus, a possible explanation for the fact 
that we could not detect by conventional ChIP Tif1β bound to globin sequences, would be that 
when in complex it would render TR2/TR4 incapable of binding to DNA. An erythroid specific 
TIF1β knock-out (currentlu under way in the Engel lab) would help bring further insights into the 
functional relevance of Tif1β and TR2/TR4 interaction in globin gene regulation.
The Lsd1 immunoprecipitations reveals interactions with Dnmt1, HDAC1 and TR2/TR4 
(Fig. 6 and 9B). Whereas it is well documented that Lsd1 and Dnmt1 can interact with HDAC1, 
it is not clear from our data, or from previous work, whether they interact with the Mi2β and 
RbAp46/48 members of the NuRD complex. Nevertheless, for this data we would like to suggest 
that these proteins interact to form a second, possibly distinct, TR2/TR4 complex in MEL cells 
(complex 2, Figure 15).
By means of IPs we were able to demonstrate that HDAC1 can bring down TR2 (Fig. 7B 
and 9B). HDAC-1 is part of NuRD complex and therefore in this context co-exists together with 
RbAp 46/48 (14, 105), and has also been previously shown- interacts with Lsd1 (88). Histone 
deacteylation is an important repressive chromatin mark and has also been shown to be required 
for histone methylation (88). Histone acetylation occurs during chromatin remodeling which is also 
connected to the cell cycle progression (32). It has been previously suggested that specific histone 
H4 acetylation may recruit basal transcription factor TFIID to activate the β major promoter (1). 
Also acetylation of histones H3 and H4 play an important role in the stage specific regulation of 
α and γ globin gene expression (21). The histone deacetylase inhibitors sodium butyrate and TSA 
have been shown to activate globin genes (23, 35, 103) though the exact function of butyrate on 
the chromatin structure of globin genes is not yet well understood (21). In summary, there has long 
been evidence for histone acetylation playing a major role in epigenetic regulation of γ globin 
silencing. It is plausible to hypothesise that DRED, as a repressive, stage specific complex could 
contain or recruit histone deacetylase activity to ε and γ globin gene promoters. 
Previous work by the Engel laboratory showed by band shift assays TR2 and TR4 to be 
the core components of the DRED complex that binds to the DR1 sites in the γ- and ε- globin 
promoters (92). In order to test the functional relevance of TR2/TR4/Dnmt1 interaction we 
performed Chromatin Immunoprecipitation (ChIP) experiments using streptavidin pull-downs and 
specific antibodies. However, we failed to detect the binding of TR2 or TR4 to the mouse εy- and 
βh1 promoters in MEL cells or to the human ε- and γ-globin in 14.5 fetal liver cells in transgenic 
mice (Fig. 12). This is in contrast to what we would have predicted by the previous data on DRED 
binding to the embryonic and fetal globin promoters. It is possible that the epigenetic marks on the 
chromatin of the embryonic and fetal ε- and γ- globin gene promoters are already set in a manner 
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that does not require continued DRED binding anymore. We also failed to detect any enrichment 
at the globin promoters using anti Dnmt1 antibody. This may be a technical problem which can 
be overcome by using bio-Dnmt1 MEL cells chromatin for streptavidin ChiP. It is also possible 
that Dnmt1, which confers maintenance methylation function is spread across the silenced ε and γ 
globin genes making it difficult to show local enrichments at particular sites of these promoters.
Instead, to our surprise, the anti-TR2 (data not shown) and anti-TR4 ChIP showed 
consistent and specific enrichment of the adult mouse β major in MEL cells or the human β-globin 
promoters in transgenic mice. Considering that TR2 and TR4 have been reported before to bind 
to DR4 response elements (9, 50) we propose that it is plausible that β major and β-globin contain 
a functional DR4 response element that has been never reported before. Moreover the alignment 
of the mouse and human β-globin gene promoters (Fig. 13A) revealed that there is an additional 
potential DR4 response element even further downstream of the CAAT box and which is conserved 
between the two species. Whether it can be bound by TR2 and TR4 remains to be tested. 
 It should be noted though that the binding affinity of nuclear receptors for DR4 is lower than 
that for DR1 response elements: DR1>DR2: DR5, DR4, DR6> DR3 (58). In order to investigate 
whether the enrichment of the β major with anti-TR4 antibodies is genuine or an artefact caused 
by conformation or “stickiness” of chromatin of this particular promoter region (enrichment of 
IgGs negative control is usually higher with those primers as well data not shown), we performed 
band shift assays as previously documented for the binding of the DRED complex to the ε- and 
γ- globin promoters (92). On the basis of these experiments we conclude that TR2/TR4 can bind 
to the potential DR4 response element proximal to the TATA box in β major globin gene promoter. 
During chromatin preparation DNA is randomly sheared in 300-800 bp fragments, while for band 
shift assays short 20-30 bp oligos are used. This means that in ChIP experiments we can test 
binding to a much longer DNA string. Also, orphan nuclear receptors allow certain variations 
in their consensus binding sites thus escaping standardized bioinformatics tools searching for 
transcription factor binding motifs in promoters. Hence, this potential DR4 site was never spotted 
before. It has to be stressed that the function of binding of TR2/TR4 the β major globin promoter 
remains to be discovered.
Dnmt1 plays an important role during cell cycle (16, 53, 76) when it is targeted to the 
replication foci maintaining the methylation pattern following the DNA replication (6, 27, 34, 38). 
Dnmt1 has been shown to interact with the histone methylatransferases G9a and SUV39H1during 
the cell cycle to ensure the re-establishing of the epigenetic marks after cell division (19). We do 
not know whether interaction between Lsd1 and Dnmt1 and possibly TR2/TR4 are also cell-cycle 
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Figure 15:  Working model presenting two possible distinct complexes that interact with TR2/TR4. We hypothesize that 
Complex 1 consists of TR2/TR4, Dnmt1, HDAC3 and TIF1β, whereas Complex 2 consists of TR2/TR4, HDAC1, Dnmt1, Lsd1 
and possibly NuRD components RbAp46/48, Mi2β, MTA1. Further experiments should be conducted to test these models.
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related. We can not exclude the possibility that this interaction has a distinct function in cell cycle 
progression or, possibly, is regulated by the cell cycle. This hypothesis could account for the cell-
cycle related proteins which were found in our mass spec results. 
5-azacytidine (5-azaC) and its derivatives (such as 5-aza- deoxycitidine, decytabine) have 
been used for cancer therapy (5, 10, 37, 40, 52) and in treating hemoglobinopathies since they can 
induce γ-globin reactivation (82, 90, 102). Despite many efforts in the elucidation of the molecular 
mechanism that these potent DNA methyltraserase inhibitors employ, details regarding the exact 
mechanism of their action remain to be determined. 5-azaC is at first converted to a nucleoside 
triphosphate, which can be subsequently incorporated into DNA and RNA and consequently alter 
protein synthesis. Importantly, after incorporation of 5-azaC into DNA methylatransferases, Dnmts 
irreversibly bind to DNA and can no longer methylate it (12, 28, 39, 96, 106). 
However, it has also been suggested that the formation of tight covalent complexes between 
Dnmts and 5-aza-C substituted DNA alone cannot explain many aspects of the action of these 
drugs (28). Firstly, Dnmt1 activity decreases faster than incorporation of 5-azaC to DNA (12, 
28). Secondly, microarray expression profiling analysis of colon cancer (HCT116) and Dnmt1 
-/- cell lines showed that the expression changes induced by 5-azaC were not dependent on cell 
proliferation or apoptosis (29). These results did not fit with the view that 5-azaC acts solely 
by incorporation into DNA during one cell division, followed by loss of methylation during the 
subsequent round of replication (28, 29). Further, it has been suggested that 5-azaC specifically 
targets Dnmt1 for proteosomal degradation (28). We tested whether we could observe a similar 
effect of 5-azaC in MEL cells. As the amount of 5-azaC required for inducing this process depends 
on the level of Dnmt1 in the cell line (28), we tested different concentrations and we could confirm 
that 5-azaC treatment did indeed cause a decrease in Dnmt1 protein and also in TR2 and TR4 
protein in MEL cells (Fig. 14). We did not confirm however whether the degradation is specifically 
mediated by proteasome (by using Mg132) (our initial attempts were so far unsuccessful, further 
optimization is required; K.K observations) nevertheless it seems very likely that this is the case. 
It may be of interest to establish whether the specific degradation of TR2/TR4 and Dnmt1 
upon 5-azaC treatment is simultaneous, or whether the degradation of orphan receptors is a signal 
for Dnmt1 degradation (or the other way around). The understanding of these processes would 
significantly enhance the understanding of epigenetic regulation of globin promoters by DNA 
methylation particularly in the light of recent reports showing that the Dnmt1 knock-down by 
RNAi which results in a decrease of γ-globin promoter methylation (to similar levels seen upon 
5-azaC treatement) was not a primary cause of induction of γ –globin expression (60). This suggests 
that additional effects of 5-azaC, next to the inhibition of DNA methylation, are responsible for the 
activation of HbF observed in previous studies (15, 60, 61). 
Reference:
1. Amrolia PJ, Ramamurthy L, Saluja D, Tanese N, Jane SM, and Cunningham JM. The activation domain 
of the enhancer binding protein p45NF-E2 interacts with TAFII130 and mediates long-range activation of the alpha- 
and beta-globin gene loci in an erythroid cell line. Proceedings of the National Academy of Sciences of the United 
States of America 94: 10051-10056, 1997.
2. Andrews NC, and Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins 
from limiting numbers of mammalian cells. Nucleic acids research 19: 2499, 1991.
3. Antoniou M editor. Gene Transfer and Expression Protocols. 1991, p. 421-434.
4. Bauer A, Mikulits W, Lagger G, Stengl G, Brosch G, and Beug H. The thyroid hormone receptor functions 
as a ligand-operated developmental switch between proliferation and differentiation of erythroid progenitors. The 
EMBO journal 17: 4291-4303, 1998.
5. Baylin SB. Reversal of gene silencing as a therapeutic target for cancer--roles for DNA methylation and its 
interdigitation with chromatin. Novartis Foundation symposium 259: 226-233; discussion 234-227, 285-228, 2004.
6. Bestor TH. The DNA methyltransferases of mammals. Human molecular genetics 9: 2395-2402, 2000.
7. Cammas F, Herzog M, Lerouge T, Chambon P, and Losson R. Association of the transcriptional 
corepressor TIF1beta with heterochromatin protein 1 (HP1): an essential role for progression through differentiation. 
102
Chapter 4
Table 2. Mass spectrometry results
Genes & development 18: 2147-2160, 2004.
8. Cammas F, Mark M, Dolle P, Dierich A, Chambon P, and Losson R. Mice lacking the transcriptional 
corepressor TIF1beta are defective in early postimplantation development. Development (Cambridge, England) 127: 
2955-2963, 2000.
9. Chang C, and Pan HJ. Thyroid hormone direct repeat 4 response element is a positive regulatory element 
for the human TR2 orphan receptor, a member of steroid receptor superfamily. Molecular and cellular biochemistry 
189: 195-200, 1998.
10. Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic 
studies and their implications for cancer therapy. Oncogene 21: 5483-5495, 2002.
11. Collins FS, Metherall JE, Yamakawa M, Pan J, Weissman SM, and Forget BG. A point mutation in the 
A gamma-globin gene promoter in Greek hereditary persistence of fetal haemoglobin. Nature 313: 325-326, 1985.
12. Creusot F, Acs G, and Christman JK. Inhibition of DNA methyltransferase and induction of Friend 
erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2’-deoxycytidine. The Journal of biological chemistry 
257: 2041-2048, 1982.
13. de Boer E, Rodriguez P, Bonte E, Krijgsveld J, Katsantoni E, Heck A, Grosveld F, and Strouboulis J. 
Efficient biotinylation and single-step purification of tagged transcription factors in mammalian cells and transgenic 
mice. Proceedings of the National Academy of Sciences of the United States of America 100: 7480-7485, 2003.
14. Denslow SA, and Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene 26: 5433-
5438, 2007.
15. DeSimone J, Heller P, Hall L, and Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic 
baboons. Proceedings of the National Academy of Sciences of the United States of America 79: 4428-4431, 1982.
16. Easwaran HP, Schermelleh L, Leonhardt H, and Cardoso MC. Replication-independent chromatin 
loading of Dnmt1 during G2 and M phases. EMBO reports 5: 1181-1186, 2004.
17. Engel JD, and Tanimoto K. Looping, linking, and chromatin activity: new insights into beta-globin locus 
regulation. Cell 100: 499-502, 2000.
18. Enver T, Zhang JW, Papayannopoulou T, and Stamatoyannopoulos G. DNA methylation: a secondary 
event in globin gene switching? Genes & development 2: 698-706, 1988.
19. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, Carey MF, and Pradhan S. 
Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes & 
development 20: 3089-3103, 2006.
20. Fathallah H, and Atweh GF. DNA hypomethylation therapy for hemoglobin disorders: molecular 
mechanisms and clinical applications. Blood reviews 20: 227-234, 2006.
21. Fathallah H, Portnoy G, and Atweh GF. Epigenetic analysis of the human alpha- and beta-globin gene 
clusters. Blood cells, molecules & diseases 2007.
22. Fathallah H, Sutton M, and Atweh GF. Pharmacological induction of fetal hemoglobin: Why haven’t we 
been more successful in thalassemia? Annals of the New York Academy of Sciences 1054: 228-237, 2005.
23. Fathallah H, Weinberg RS, Galperin Y, Sutton M, and Atweh GF. Role of epigenetic modifications in 
normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110: 3391-3397, 2007.
24. Filipe A, Li Q, Deveaux S, Godin I, Romeo PH, Stamatoyannopoulos G, and Mignotte V. Regulation 
of embryonic/fetal globin genes by nuclear hormone receptors: a novel perspective on hemoglobin switching. The 
EMBO journal 18: 687-697, 1999.
25. Franco PJ, Farooqui M, Seto E, and Wei LN. The orphan nuclear receptor TR2 interacts directly with both 
class I and class II histone deacetylases. Molecular endocrinology (Baltimore, Md 15: 1318-1328, 2001.
26. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG, and Rauscher FJ, 
3rd. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes & development 10: 2067-
2078, 1996.
27. Fuks F, Burgers WA, Brehm A, Hughes-Davies L, and Kouzarides T. DNA methyltransferase Dnmt1 
associates with histone deacetylase activity. Nature genetics 24: 88-91, 2000.
28. Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, and Jacob ST. 5-Aza-Deoxycytidine 
Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, 
Bromo-Adjacent Homology Domain, and Nuclear Localization Signal. 2005, p. 4727-4741.
29. Gius D, Cui H, Bradbury CM, Cook J, Smart DK, Zhao S, Young L, Brandenburg SA, Hu Y, Bisht 
KS, Ho AS, Mattson D, Sun L, Munson PJ, Chuang EY, Mitchell JB, and Feinberg AP. Distinct effects on gene 
expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. 
Cancer cell 6: 361-371, 2004.
30. Goren A, Simchen G, Fibach E, Szabo PE, Tanimoto K, Chakalova L, Pfeifer GP, Fraser PJ, Engel JD, 
and Cedar H. Fine tuning of globin gene expression by DNA methylation. PLoS ONE 1: e46, 2006.
103
Characterization of TR2/TR4 complexes in MEL cells 
31. Grosveld F, Rodriguez P, Meier N, Krpic S, Pourfarzad F, Papadopoulos P, Kolodziej K, Patrinos GP, 
Hostert A, and Strouboulis J. Isolation and characterization of hematopoietic transcription factor complexes by in 
vivo biotinylation tagging and mass spectrometry. Annals of the New York Academy of Sciences 1054: 55-67, 2005.
32. Harju S, McQueen KJ, and Peterson KR. Chromatin structure and control of beta-like globin gene 
switching. Experimental biology and medicine (Maywood, NJ 227: 683-700, 2002.
33. Heller P, and DeSimone J. 5-Azacytidine and fetal hemoglobin. American journal of hematology 17: 439-
447, 1984.
34. Iida T, Suetake I, Tajima S, Morioka H, Ohta S, Obuse C, and Tsurimoto T. PCNA clamp facilitates 
action of DNA cytosine methyltransferase 1 on hemimethylated DNA. Genes Cells 7: 997-1007, 2002.
35. Ishiguro K, and Sartorelli AC. Coinduction of embryonic and adult-type globin mRNAs by sodium 
butyrate and trichostatin A in two murine interleukin-3-dependent bone marrow-derived cell lines. Blood 92: 4383-
4393, 1998.
36. Ismail A, and Nawaz Z. Nuclear hormone receptor degradation and gene transcription: an update. IUBMB 
life 57: 483-490, 2005.
37. Issa JP. Decitabine. Current opinion in oncology 15: 446-451, 2003.
38. Jones PL, and Wolffe AP. Relationships between chromatin organization and DNA methylation in 
determining gene expression. Seminars in cancer biology 9: 339-347, 1999.
39. Juttermann R, Li E, and Jaenisch R. Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated 
primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proceedings of the National 
Academy of Sciences of the United States of America 91: 11797-11801, 1994.
40. Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, 
Andreeff M, Keating M, and Talpaz M. Results of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with 
chronic myelogenous leukemia. Cancer 98: 522-528, 2003.
41. Kim SS, Chen YM, O’Leary E, Witzgall R, Vidal M, and Bonventre JV. A novel member of the 
RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. 
Proceedings of the National Academy of Sciences of the United States of America 93: 15299-15304, 1996.
42. Kinyamu HK, Chen J, and Archer TK. Linking the ubiquitin-proteasome pathway to chromatin remodeling/
modification by nuclear receptors. Journal of molecular endocrinology 34: 281-297, 2005.
43. Koritschoner NP, Madruga J, Knespel S, Blendinger G, Anzinger B, Otto A, Zenke M, and Bartunek 
P. The Nuclear Orphan Receptor TR4 Promotes Proliferation of Myeloid Progenitor Cells. 2001, p. 563-572.
44. Kuppuswamy M, Vijayalingam S, Zhao LJ, Zhou Y, Subramanian T, Ryerse J, and Chinnadurai G. 
Role of the PLDLS-binding cleft region of CtBP1 in recruitment of core and auxiliary components of the corepressor 
complex. Molecular and cellular biology 28: 269-281, 2008.
45. Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, and Chambon P. A 
possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. The 
EMBO journal 15: 6701-6715, 1996.
46. Le Douarin B, vom Baur E, Zechel C, Heery D, Heine M, Vivat V, Gronemeyer H, Losson R, and 
Chambon P. Ligand-dependent interaction of nuclear receptors with potential transcriptional intermediary factors 
(mediators). Philosophical transactions of the Royal Society of London 351: 569-578, 1996.
47. Le Douarin B, You J, Nielsen AL, Chambon P, and Losson R. TIF1alpha: a possible link between KRAB 
zinc finger proteins and nuclear receptors. The Journal of steroid biochemistry and molecular biology 65: 43-50, 
1998.
48. Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, Heery D, Gronemeyer H, Chambon P, 
and Losson R. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) 
of nuclear receptors, is fused to B-raf in the oncogenic protein T18. The EMBO journal 14: 2020-2033, 1995.
49. Lee C-H, Chinpaisal C, and Wei L-N. A Novel Nuclear Receptor Heterodimerization Pathway Mediated 
by Orphan Receptors TR2 and TR4. 1998, p. 25209-25215.
50. Lee Y-F, Pan H-J, Burbach JPH, Morkin E, and Chang C. Identification of Direct Repeat 4 as a Positive 
Regulatory Element for the Human TR4 Orphan Receptor. A MODULATOR FOR THE THYROID HORMONE 
TARGET GENES. 1997, p. 12215-12220.
51. Lee YF, Lee HJ, and Chang C. Recent advances in the TR2 and TR4 orphan receptors of the nuclear 
receptor superfamily. The Journal of steroid biochemistry and molecular biology 81: 291-308, 2002.
52. Leone G, Teofili L, Voso MT, and Lubbert M. DNA methylation and demethylating drugs in myelodysplastic 
syndromes and secondary leukemias. Haematologica 87: 1324-1341, 2002.
53. Leonhardt H, Page AW, Weier HU, and Bestor TH. A targeting sequence directs DNA methyltransferase 
to sites of DNA replication in mammalian nuclei. Cell 71: 865-873, 1992.
54. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, 
Nephew KP, and Huang TH. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets 
in breast cancer. Cancer research 64: 8184-8192, 2004.
104
Chapter 4
55. Ley TJ, Anagnou NP, Young NS, Nienhuis AW, DeSimone J, and Heller P. 5-azacytidine for beta 
thalassaemia? Lancet 1: 467, 1983.
56. Ley TJ, DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P, and Nienhuis AW. 5-Azacytidine 
increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 
62: 370-380, 1983.
57. Li G, Franco PJ, and Wei LN. Identification of histone deacetylase-3 domains that interact with the orphan 
nuclear receptor TR2. Biochem Biophys Res Commun 310: 384-390, 2003.
58. Lin TM, Young WJ, and Chang C. Multiple functions of the TR2-11 orphan receptor in modulating 
activation of two key cis-acting elements involved in the retinoic acid signal transduction system. The Journal of 
biological chemistry 270: 30121-30128, 1995.
59. Liu Y, Song J, Liu W, Wan Y, Chen X, and Hu C. Growth and differentiation of rat bone marrow stromal 
cells: does 5-azacytidine trigger their cardiomyogenic differentiation? Cardiovascular research 58: 460-468, 2003.
60. Mabaera R, Greene MR, Richardson CA, Conine SJ, Kozul CD, and Lowrey CH. Neither DNA 
hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine’s ability to induce 
human fetal hemoglobin. 2007, p. blood-2007-2006-093948.
61. Mabaera R, Richardson CA, Johnson K, Hsu M, Fiering S, and Lowrey CH. Developmental- and 
differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation. Blood 110: 1343-
1352, 2007.
62. Mahajan MC, Narlikar GJ, Boyapaty G, Kingston RE, and Weissman SM. Heterogeneous nuclear 
ribonucleoprotein C1/C2, MeCP1, and SWI/SNF form a chromatin remodeling complex at the beta-globin locus 
control region. Proceedings of the National Academy of Sciences of the United States of America 102: 15012-15017, 
2005.
63. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, 
Mark M, Chambon P, and Evans RM. The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 
1995.
64. Mavilio F, Giampaolo A, Care A, Migliaccio G, Calandrini M, Russo G, Pagliardi GL, Mastroberardino 
G, Marinucci M, and Peschle C. Molecular mechanisms of human hemoglobin switching: selective undermethylation 
and expression of globin genes in embryonic, fetal, and adult erythroblasts. Proceedings of the National Academy of 
Sciences of the United States of America 80: 6907-6911, 1983.
65. Meier N, Krpic S, Rodriguez P, Strouboulis J, Monti M, Krijgsveld J, Gering M, Patient R, Hostert 
A, and Grosveld F. Novel binding partners of Ldb1 are required for haematopoietic development. Development 
(Cambridge, England) 133: 4913-4923, 2006.
66. Moosmann P, Georgiev O, Le Douarin B, Bourquin JP, and Schaffner W. Transcriptional repression by 
RING finger protein TIF1 beta that interacts with the KRAB repressor domain of KOX1. Nucleic acids research 24: 
4859-4867, 1996.
67. Morimoto RI. Dynamic remodeling of transcription complexes by molecular chaperones. Cell 110: 281-
284, 2002.
68. Nielsen AL, Ortiz JA, You J, Oulad-Abdelghani M, Khechumian R, Gansmuller A, Chambon P, and 
Losson R. Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are 
differentially involved in transcriptional silencing by members of the TIF1 family. The EMBO journal 18: 6385-6395, 
1999.
69. O’Neill DW, Schoetz SS, Lopez RA, Castle M, Rabinowitz L, Shor E, Krawchuk D, Goll MG, Renz M, 
Seelig HP, Han S, Seong RH, Park SD, Agalioti T, Munshi N, Thanos D, Erdjument-Bromage H, Tempst P, and 
Bank A. An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. Molecular and cellular 
biology 20: 7572-7582, 2000.
70. Omori A, Tanabe O, Engel JD, Fukamizu A, and Tanimoto K. Adult stage gamma-globin silencing is 
mediated by a promoter direct repeat element. Molecular and cellular biology 25: 3443-3451, 2005.
71. Perillo B, Ombra MN, Bertoni A, Cuozzo C, Sacchetti S, Sasso A, Chiariotti L, Malorni A, Abbondanza 
C, and Avvedimento EV. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene 
expression. Science (New York, NY 319: 202-206, 2008.
72. Perini G, Diolaiti D, Porro A, and Della Valle G. In vivo transcriptional regulation of N-Myc target genes 
is controlled by E-box methylation. Proceedings of the National Academy of Sciences of the United States of America 
102: 12117-12122, 2005.
73. Poncz M, Henthorn P, Stoeckert C, and Surrey S. Globin gene expression in hereditary persistence of fetal 
haemoglobin and (delta beta) (0)-thalassaemia. Oxford surveys on eukaryotic genes 5: 163-203, 1988.
74. Rodriguez P, Bonte E, Krijgsveld J, Kolodziej KE, Guyot B, Heck AJ, Vyas P, de Boer E, Grosveld F, 
and Strouboulis J. GATA-1 forms distinct activating and repressive complexes in erythroid cells. The EMBO journal 
24: 2354-2366, 2005.
75. Rodriguez P, Braun H, Kolodziej KE, de Boer E, Campbell J, Bonte E, Grosveld F, Philipsen S, and 
105
Characterization of TR2/TR4 complexes in MEL cells 
Strouboulis J. Isolation of transcription factor complexes by in vivo biotinylation tagging and direct binding to 
streptavidin beads. Methods in molecular biology (Clifton, NJ 338: 305-323, 2006.
76. Rountree MR, Bachman KE, and Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to 
form a complex at replication foci. Nature genetics 25: 269-277, 2000.
77. Ryan RF, Schultz DC, Ayyanathan K, Singh PB, Friedman JR, Fredericks WJ, and Rauscher FJ, 
3rd. KAP-1 corepressor protein interacts and colocalizes with heterochromatic and euchromatic HP1 proteins: a 
potential role for Kruppel-associated box-zinc finger proteins in heterochromatin-mediated gene silencing. Molecular 
and cellular biology 19: 4366-4378, 1999.
78. Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, and Elia G. In vivo protein biotinylation for 
identification of organ-specific antigens accessible from the vasculature. Nature methods 2: 291-298, 2005.
79. Rybak JN, Scheurer SB, Neri D, and Elia G. Purification of biotinylated proteins on streptavidin resin: a 
protocol for quantitative elution. Proteomics 4: 2296-2299, 2004.
80. Saleque S, Kim J, Rooke HM, and Orkin SH. Epigenetic Regulation of Hematopoietic Differentiation by 
Gfi-1 and Gfi-1b Is Mediated by the Cofactors CoREST and LSD1. Molecular Cell 27: 562-572, 2007.
81. Sanchez C, Sanchez I, Demmers JA, Rodriguez P, Strouboulis J, and Vidal M. Proteomics analysis 
of Ring1B/Rnf2 interactors identifies a novel complex with the Fbxl10/Jhdm1B histone demethylase and the Bcl6 
interacting corepressor. Mol Cell Proteomics 6: 820-834, 2007.
82. Sasaki R, and Miura Y. Effect of 5-azacytidine on the differentiation of human leukemia K-562 cells. 
International journal of cell cloning 4: 192-202, 1986.
83. Saunthararajah Y, Lavelle D, and DeSimone J. DNA hypo-methylating agents and sickle cell disease. 
British journal of haematology 126: 629-636, 2004.
84. Schultz DC, Ayyanathan K, Negorev D, Maul GG, and Rauscher FJ, 3rd. SETDB1: a novel KAP-1-
associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic 
genes by KRAB zinc-finger proteins. Genes & development 16: 919-932, 2002.
85. Schultz DC, Friedman JR, and Rauscher FJ, III. Targeting histone deacetylase complexes via KRAB-
zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of 
the Mi-2{alpha} subunit of NuRD. 2001, p. 428-443.
86. Shevchenko A, Wilm M, Vorm O, and Mann M. Mass spectrometric sequencing of proteins silver-stained 
polyacrylamide gels. Analytical chemistry 68: 850-858, 1996.
87. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, and Shi Y. Histone demethylation 
mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953, 2004.
88. Shi YJ, Matson C, Lan F, Iwase S, Baba T, and Shi Y. Regulation of LSD1 histone demethylase activity 
by its associated factors. Mol Cell 19: 857-864, 2005.
89. Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ, and O’Malley BW. Role of co-activators 
and co-repressors in the mechanism of steroid/thyroid receptor action. Recent progress in hormone research 52: 141-
164; discussion 164-145, 1997.
90. Stamatoyannopoulos G. Prospects for developing a molecular cure for thalassemia. Hematology (Amsterdam, 
Netherlands) 10 Suppl 1: 255-257, 2005.
91. Tagle DA, Koop BF, Goodman M, Slightom JL, Hess DL, and Jones RT. Embryonic epsilon and gamma 
globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental 
regulation and phylogenetic footprints. Journal of molecular biology 203: 439-455, 1988.
92. Tanabe O, Katsuoka F, Campbell AD, Song W, Yamamoto M, Tanimoto K, and Engel JD. An embryonic/
fetal beta-type globin gene repressor contains a nuclear receptor TR2/TR4 heterodimer. The EMBO journal 21: 3434-
3442, 2002.
93. Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT, Chang C, 
Yamamoto M, Tanimoto K, and Engel JD. Embryonic and fetal beta-globin gene repression by the orphan nuclear 
receptors, TR2 and TR4. The EMBO journal 26: 2295-2306, 2007.
94. Tanabe O, Shen Y, Liu Q, Campbell AD, Kuroha T, Yamamoto M, and Engel JD. The TR2 and TR4 
orphan nuclear receptors repress Gata1 transcription. Genes & development 21: 2832-2844, 2007.
95. Tanimoto K, Liu Q, Grosveld F, Bungert J, and Engel JD. Context-dependent EKLF responsiveness 
defines the developmental specificity of the human epsilon-globin gene in erythroid cells of YAC transgenic mice. 
Genes & development 14: 2778-2794, 2000.
96. Taylor SM, and Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 
5-azacytidine. Cell 17: 771-779, 1979.
97. Underhill C, Qutob MS, Yee S-P, and Torchia J. A Novel Nuclear Receptor Corepressor Complex, N-CoR, 
Contains Components of the Mammalian SWI/SNF Complex and the Corepressor KAP-1. 2000, p. 40463-40470.
98. van der Ploeg LH, and Flavell RA. DNA methylation in the human gamma delta beta-globin locus in 
erythroid and nonerythroid tissues. Cell 19: 947-958, 1980.
99. Venturini L, You J, Stadler M, Galien R, Lallemand V, Koken MH, Mattei MG, Ganser A, Chambon P, 
106
Chapter 4
Losson R, and de The H. TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene 
18: 1209-1217, 1999.
100. Wang XM, Wang X, Li J, and Evers BM. Effects of 5-azacytidine and butyrate on differentiation and 
apoptosis of hepatic cancer cell lines. Annals of surgery 227: 922-931, 1998.
101. Waugh DS. Making the most of affinity tags. Trends in biotechnology 23: 316-320, 2005.
102. Weatherall DJ. ABC of clinical haematology. The hereditary anaemias. BMJ (Clinical research ed 314: 492-
496, 1997.
103. Weinberg RS, Ji X, Sutton M, Perrine S, Galperin Y, Li Q, Liebhaber SA, Stamatoyannopoulos G, and 
Atweh GF. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 105: 1807-1809, 2005.
104. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, Fotsis T, and Mann M. Femtomole 
sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 379: 466-469, 
1996.
105. Xue Y, Wong J, Moreno GT, Young MK, Cote J, and Wang W. NURD, a novel complex with both ATP-
dependent chromatin-remodeling and histone deacetylase activities. Mol Cell 2: 851-861, 1998.
106. Yoder JA, Soman NS, Verdine GL, and Bestor TH. DNA (cytosine-5)-methyltransferases in mouse cells 
and tissues. Studies with a mechanism-based probe. Journal of molecular biology 270: 385-395, 1997.
107
Characterization of TR2/TR4 complexes in MEL cells 
Table 2.
NCBI ID Description GO Classification* Peptides
gi|20072056 Brg1 SWI/SNF, chromatin remodeling 2
gi|40254165 SMC hinge domain containing 1 cell cycle? 18
gi|6678832 mcm6 cell cycle 11
gi|6678830 mcm5, cdc46 cell cycle 7
gi|6754816 septin 2 cell cycle 7
gi|51980515 cdk9 cell cycle 6
gi|53551 mcm3 cell cycle 6
gi|10242373 mcm7 cell cycle 6
gi|36031035 SMC3 cell cycle 5
gi|50510569
SCC-112 novel cell cycle-
regulated molecule cell cycle? 4
gi|9957546 Septin 8 cell cycle 4
gi|28204888 septin 9 cell cycle 4
gi|2183319 mcm2 cell cycle 3
gi|9790237 SMC1 cell cycle? 3
gi|1293686 HCF1 cell cycle, transcription factor 3
gi|26354124 cdc1, septin 7 cell cycle 2
gi|12963599 cyclin H cell cycle 2
gi|19527092 RCC1 cell cycle 2
gi|50360 Cdc2a, cdc2, cdk1 cell cycle 1
gi|22779899 cdc5l cell cycle 1
gi|4099131 Mad2l1 cell cycle 1
Total 96
gi|37360250 TIF1gamma co-repressor 3
gi|6755787 TIF 1 beta co-repressor 17
gi|3452507 CtBP1 protein co-repressor 1
Total 21
gi|1363105 replication licensing factor MCM4 DNA replication 3
gi|31419356 Dnmt1 Dnmt1 50
gi|33695134
structure specific recognition 
protein 1‡ FACT 2
gi|14028669
DNA-dependent ATPase SNF2H 
‡ ISWI 4
gi|39204553 Mi2 beta NuRD 4
gi|16905113 MTA1 NuRD 11
gi|2347180 HDAC1 NuRD 2
Total 17
gi|1144348 TR4 orphan nuclear receptor 58
gi|1173533 TR2 orphan nuclear receptor 42
Total 100
gi|2239142 
polycomb-M33 interacting protein 
Ring1B Pc-G complex, ubiquitin ligase 3
gi|1262300 casein kinase II alpha subunit signal transduction 3
gi|46237616 casein kinase 2, beta subunit signal transduction 1
Total 4
gi|2895588 TFII-I protein long form; p128 transcription factor 2
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gi|19527168 Psip1 transcription factor 5
gi|110759 nuclear factor I (clone B5) transcription factor 1
gi|26344676 Pur alpha transcription factor 1
gi|35505176 CAND1 transcription factor, ubiquitin cycle 2
Total 11
gi|91870 polyubiquitin (clone arf3) ubiquitin-proteasome pathway 2
gi|12848428 Psmd14 ubiquitin-proteasome pathway 2
gi|30519947 Psmd11 ubiquitin-proteasome pathway 4
gi|12845617 Psmd6 ubiquitin-proteasome pathway 5
gi|12852148 Psmc6 ubiquitin-proteasome pathway 8
gi|7110703 Psmc5 ubiquitin-proteasome pathway 1
gi|6679503 Psmc3 ubiquitin-proteasome pathway 3
gi|13542777 Psmd2 ubiquitin-proteasome pathway 3
gi|6755210 Psmd13 ubiquitin-proteasome pathway 6
gi|6679503 Psmc3 ubiquitin-proteasome pathway 1
gi|20988514 Psmd11 ubiquitin-proteasome pathway 1
gi|26347233 Psmd5 ubiquitin-proteasome pathway 3
gi|2137840 Psmd3 ubiquitin-proteasome pathway 7
gi|1698570 Psme1 ubiquitin-proteasome pathway 2
gi|6754724 Psmd7 ubiquitin-proteasome pathway 5
gi|55217 murine valosin-containing protein ubiquitin-proteasome pathway 15
Total 68
gi|6753486 Cops2
signalosome complex, cell 
proliferation 1
gi|33563284 Cops6 signalosome complex 2
gi|6753490 Cops4 signalosome complex 1
Total 4
gi|194027 heat-shock protein hsp84 heat shock 65
gi|1661134 heat shock 70 protein heat shock 11
Total 76
Grand Total 461
* : most proteins that were identified have multiple GO entries. For practical reasons, we  h a v e 
chosen to present on GO term that we consider to be the most descriptive. 
‡ : proteins routinely identified in mass spec experiments be streptavidin pulldown of  b i o t i n 
tagged unrelated chromatin associated factors. In the absence of any other  FACT or ISWI complex 
partners, we tend to consider these proteins as chromatin  associated background
Table 2:  Classification by Gene Ontology (GO) criteria of proteins identified by mass spectrometry as co-puri-
fying with TR2/TR4
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Table 3 MS1 MS2 MS3 MS4 MS5
Cell Cycle Cdc2a, cdc2, cdk1 yes
cdc5l yes yes yes yes
cdk9 yes
cyclin H yes
HCF1 yes yes
Mad2l1 yes
mcm2 yes yes
mcm3 yes
mcm4 yes yes
mcm5, cdc46 yes yes
mcm6 yes yes
mcm7 yes yes yes
RCC1 yes
SCC-112 novel cell cycle-regulated 
molecule yes yes
septin 2 yes yes yes yes
Septin 8 yes
cdc10, septin 7 yes yes yes yes
septin 11 yes yes
septin 9 yes
SMC hinge domain containing 1 yes
SMC1 yes yes
SMC3 yes yes yes
SMC4 yes yes yes
Smc2l1 yes
Smc1l1 yes
Co-repressors TIF1 gamma yes yes
TIF1 beta yes yes yes yes
HP1 gamma yes
CtBP1 protein [Mus musculus]* yes
IRA1 yes
Sin3A yes
FACT Ssrp1 yes yes
suppressor of Ty 5 homolog yes
suppressor of Ty 16 homolog yes yes
NuRD Mi2 beta yes yes yes yes
MTA1 yes yes yes
HDAC 1 yes yes yes yes
mRbAp48 yes yes yes yes
Mi2 alpha yes
Chd5 yes
HDAC 2 yes
retinoblastoma binding protein 5 yes
signal transduction casein kinase II alpha subunit yes yes yes
casein kinase II, beta subunit yes yes
ubiquitin cycle  polyubiquitin (clone arf3) yes
proteasome Psmd14 yes
Psmd11 yes yes
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Psmd6 yes
Psmc6 yes yes yes
Psmc5 yes yes
Psmc3 yes
Psmd2 yes
Psmd13 yes
Psmc3 yes
Psmd5 yes
Psmd3 yes yes
Psme1 yes
Psmd7 yes
valosin-containing protein yes yes yes yes yes
Cops2, COP9 yes
Cops6, COP9 yes
Cops4, COP9 yes
CAND1 yes yes yes yes
Psmc1 yes
Psmd12 yes
Psmc2 yes
Prp19 yes
FANCL yes
DNA 
methyltransferase Dnmt1 yes yes yes yes
Table 3:  Presence of potential interacting proteins in different mass spectrometry analyses. For MS4 and MS5, 
benzonase was used in strptavidin binding experiments
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Abstract:
In vivo biotinylation tagging has been used by virtue of its very tight binding to (immobilised) 
streptavidin as a high affinity approach for purifying nuclear protein complexes from mammalian 
cells (25) and has also been also shown to work well in combination with other tags (37). Here 
we describe the optimization of biotin mediated ChIP assays using the biotin-tagged GATA-1 
hematopoietic transcription factor in erythroid cells. We show that the choice of beads is crucial 
for the efficient enrichment of target genes in chromatin binding. In addition, we show that using 
fish skin gelatin in blocking the beads and omitting SDS when sonicating chromatin, significantly 
improve enrichments in streptavidin-ChIP. Together these steps provide an optimized approach for 
the high affinity, low background application of biotinylation tagging in ChIP assays. Finally we 
show that under these optimized conditions the V5 peptide tag performs equally well in antibody 
mediated ChIPs.
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Introduction
 Affinity tagging is used as a powerful and elegant tool for the recovery and purification 
of recombinant proteins. Among a number of affinity-based purification technologies, the use of 
the biotin/(strept)avidin system occupies a prominent place due to its unique characteristics (14), 
which include: (a) the very tight and specific binding of biotin by avidin (or streptavidin) which, 
with a Kd of 10
15 L*mol -1, is one of the highest non covalent interactions known in nature, close 
to almost 103 – 106 times greater than the interaction of epitopes with their specific antibodies. 
Once formed, the biotin-streptavidin complex is not disturbed by changes in pH, introduction of 
detergents or high salt concentration, thus remaining stable even under very stringent washing 
conditions; (b) biotin is a very small molecule and is not known to affect the biological activity of 
tagged proteins (11, 21); (c) there are few (mostly cytoplasmic) naturally biotinylated proteins in 
mammalian cells. As a result  the non-specific background binding of nuclear extract is low (10). 
Early experiments applying biotinylation tagging of specific proteins in E.coli and yeast 
(9) combined the use of the bacterial BirA biotin ligase together with a 75 amino-acid long tag 
derived from naturally biotinylated proteins such as carboxylases. More recently, it was shown 
that short artificial tags obtained by screening a combinatorial synthetic peptide library can also 
be very efficiently biotinylated by BirA and have been subsequently used as the tags of choice (4, 
10, 28).  
Previous work in our lab has used one such short (23aa) tag for the purification of GATA-1 
complexes from nuclear extracts of erythroid cells (10, 25) GATA-1 is a DNA sequence-specific 
zinc finger transcription factor that is essential for the differentiation of erythroid, megakaryocytic, 
eosinophil and mast cell lineages (6, 13). N-terminally tagged GATA-1 was co-expressed with 
the E.coli BirA biotin ligase in mouse erythroleukemic (MEL) cells and subsequently purified 
from nuclear extracts together with interacting proteins by binding to streptavidin beads (10). In 
this way, a number of known and novel GATA-1 protein partners were identified (25). We also 
provided preliminary evidence that biotinylation tagging could be applied in place of antibodies in 
ChIPs of GATA-1 target genes (10, 18). 
Several groups, including ours are testing different tags to search for the most optimal for 
the isolation of transcription factor complexes and their target genes by ChiP-on-chip or ChIP-
sequencing (ChIP-seq). In this selection three criteria are important: (a) tags must have high binding 
affinity; (b) tag binding must be insensitive to formaldehyde fixation; (c) tags should be preferably 
small and not strongly charged so as to minimize possible interference with transcription factor 
function. These different (and equally efficient) tags could be used in tandem, separated by a 
protease cleavage site to allow an extra affinity purification step for lowering the background of 
non-specific proteins. At the same time this approach can greatly enhance the ability to purify the 
complexes to homogeneity (by using several factors of the same complex differentially tagged and 
co-expressed) for other applications, e.g. for crystallisation and structure determination. 
Here we present the optimization and comparison of various ChIP protocols using tagged 
GATA-1 in combination with known target genes (25) as an example. We first show that different 
streptavidin beads are not equally efficient in ChIP assays. We also show that effective blocking 
with fish skin gelatin and omission of SDS during chromatin sonication are important factors in 
reducing background signals, which is a major concern in ChIP using complex chromatin from 
mammalian cells. Further, we present that these optimal conditions can be efficiently applied for 
the V5 tag and antibodies mediated ChIP. Finally, it is also important to note that the most frequent 
formaldehyde cross-link is formed at the end of the side-chain of lysine (K) and histidine (H) 
and hence a number of tags containing a lysine/histidine in the recognised part of the tag may 
have very poor yields. To underline this importance we also present evidence that formaldehyde 
crosslinking can affect the efficiency of the biotin-tag, more than V5–tag binding.
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Materials and methods
 Cells and constructs. MEL cells were cultured as previously described (2). Constructs 
and stably transfected cell lines were described previously  (10).  
Chromatin crosslinking. Approximately 2x107 induced MEL cells were crosslinked with 
1% formaldehyde for 10 minutes at room temperature and processed for sonication essentially 
as described in the Upstate protocol. Chromatin was sonicated on ice with a Sanyo Soniprep 150 
sonicator at amplitude 6 using 10 cycles of 15 sec “on” and 45 sec “off” to a DNA fragment size 
in the range of 300 to 800 nucleotides. The alternative “no SDS” sonication buffer is: 10mM Tris, 
1mM EDTA and 0.5mM EGTA. All buffers were supplemented with Complete Protease Inhibitor 
Cocktail (Roche). Aliquots of sonicated chromatin of 10x106 cells were stored at –80°C.
Streptavidin ChIP. Chromatin pull-downs with streptavidin beads were carried 
out overnight using 20 µl of streptavidin Dynabeads M280 (Invitrogen) or 20µl of UltraLink 
Immobilized NeutrAvidin Protein (Pierce) per chromatin aliquot. For streptavidin agarose (Sigma) 
or Streptavidin mutein (Roche) chromatin pull-downs, 60µl of agarose slurry or beads were used 
per aliquot. All the beads/slurry were blocked with 400µg sonicated salmon sperm DNA for 1h at 
4°C. Pre-clearing of chromatin prior to binding to M280 streptavidin beads was done using 20µl 
of Protein G Dynabeads (Invitrogen) preblocked with salmon sperm DNA). Chromatin incubation 
with beads was carried out in a total reaction volume of 1mL supplemented with Complete Protease 
Inhibitor, at 4ºC overnight on a rotating wheel. After binding, beads were washed with 1mL of low 
salt, high salt, LiCl and TE (10mM Tris-HCl pH 8.0, 1mM ETDA) wash buffers, 3-5 minutes each, 
as described in Upstate protocol.  An additional urea wash (5M urea/2M thiourea/1% TritonX100) 
was carried out after LiCl buffer wash and before the TE washes (see Results). After the washes, 
bound chromatin was eluted by resuspending Neutravidin, Mutein, streptavidin agarose and M280 
beads in 500 μl 0.1M sodium carbonate, 1%SDS, 0.2M NaCl elution buffer transferring to a fresh 
tube and decrosslinking with shaking at 65°C for at least 5h. Thermal elution of chromatin from 
M280 Dynabeads was carried out by resuspending beads in 500 μl 95% formamide, 0.1M sodium 
bicarbonate and boiling at 95ºC for 10 min. M280 Dynabeads were subsequently separated from the 
buffer using a magnetic rack. Eluted chromatin was transferred to a fresh tube and decrosslinking 
was carried out as described above. Decrosslinked samples were deproteinized as described by 
the Upstate protocol. DNA was recovered by phenol/chloroform/isoamyl alcohol extraction and 
isopropanol precipitation using 20µg glycogen as carrier. 
Antibody ChIP. GATA-1 ChIP has been previously described (25). Anti-GATA-1 
antibodies used were N6 and M20 (Santa Cruz). Anti GATA-1 antibody immunoprecipitates were 
eluted from the beads by incubation in elution buffer (0.1M sodium carbonate, 1%SDS) twice for 
15 minutes each at room temperature.
Blocking with Cold Sea Fish Skin Gelatin. A 45% Fish Skin gelatine (FGEL) stock 
solution (Sigma) was used to block beads at 0.5%, 1% or 2% final concentrations together with 
sonicated salmon sperm DNA by incubation for 1h at room temperature. Where indicated, FGEL 
was also added to chromatin and beads to a 1% final concentration during overnight binding. 
Real time PCR. This was done in an Opticon I (MJ Research) thermal cycler using SYBR 
Green and Platinum Taq polymerase (Invitrogen) as described previously (25). Primers (listed in 
Table1) were designed using Primer Express 2.0 (PE Applied Biosystems). For each experiment 
at least two runs were done with each sample loaded in duplicate.  PCR conditions: 95°C for 10 
min, 40 cycles of 30 sec at 95 °C, 60 sec at 60°C, 15 sec at 75°C. Enrichment for a specific DNA 
sequence was calculated using the comparative CT method, as previously described (22). The 
enrichment of bound DNA over input is calculated using the formula 2Ct(IP)–Ct(Ref). Enrichment over 
the negative primer set or negative control chromatin from MEL cells expressing BirA only was 
subsequently calculated by dividing.
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Nuclear extracts, and immunoblotting. These were done as previously described (10). 
Results and Discussion
GATA-1 is a key transcriptional regulator of erythroid genes. In addition, a number of 
genes involved in cell cycle regulation or cell survival and proliferation, such as Bcl-2, c-myc 
and c-myb, have also been identified as GATA-1 targets in erythroid cells (5, 15, 26, 30). We have 
previously shown that GATA-1 binds together with Gfi1b to the repressed c-myb promoter in 
induced MEL cells, thus suggesting a role for this complex in proliferation arrest during terminal 
GATA
promoter
+1
enhancer-ve
- 0.7kb- 1.35kb
GATA
EKLF promoter
- 0.8kb
promoter
Myb promoter
+1
-ve
GATA
Figure1. Location of the ChIP primers in the EKLF and c-myb promoters. “GATA” boxes indicate GATA-1 
binding sites.
erythroid differentiation (16, 17, 25). GATA-1 also regulates expression of key hematopoietic 
transcription factor genes in erythroid differentiation, such as GATA-2 and EKLF. For example, 
binding of GATA-1 to the EKLF promoter and enhancer is essential for its  transcriptional activation 
(1, 25), with forced GATA-1 expression activating the proximal EKLF promoter in non-erythroid 
cells (7). 
 We previously showed using biotin-tagged GATA-1 that a streptavidin binding of 
crosslinked chromatin could substitute for antibodies in enriching for GATA-1 target genes in 
ChIP assays (10). Due to the potential advantages offered by the very high affinity of streptavidin 
for binding to biotin and the importance of having multiple tags that can be used in the same cell, 
we wanted to extended these observations in developing an optimized protocol for the streptavidin 
binding of chromatin from cells expressing biotin-tagged GATA-1. In doing so, we used the EKLF 
and c-myb promoters as examples of GATA-1 gene targets that are upregulated or repressed, 
respectively, in erythroid cells. Figure 1 shows the location of primers used for the EKLF and myb 
promoters and negative control sequences. Primer sequences are listed in Table 1.
Name of the primer Sequence
Myb prom FOR ACTGCAGGGGCGCCAGATTT
Myb prom REV GGAGAAAGGGGAGGAGAAGGAGGTA
Neg myb FOR GAAGTAGAGGCAGGATAATCAGGAA
Neg myb REV AGGATGAACCAGGGCTAATGC
EKLF Upstream FOR CTGGCCCCCCTACCTGAT
EKLF Upstream REV GGCTCCCTTTCAGGCATTATC
EKLF Promoter FOR TATCGCACACACCCCTCCTT
EKLF Promoter REV CCCACATCTGATTGGCTGTCT
Neg EKLF FOR TGCTCCCCACTATGATAATGGA
Neg EKLF REV GCCACAACCAAAGAAGACATTTT
Comparison of different types of streptavidin beads
Biotinylation of biological substrates is frequently used in a variety of different applications 
and hence many manufacturers offer a wide range of immobilized streptavidin matrices. We have 
previously used paramagnetic M280 streptavidin Dynabeads for the isolation of protein complexes 
(10, 12, 24, 25, 27). We also tested the performance of M280 beads in chromatin immunoprecipitations 
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Figure 2. Comparison of different 
derivatives of immobilized streptavidin: NeutrAvidin, 
streptavidin agarose, streptavidin mutein and M280 
Dynabeads. Relative enrichment for EKLF (panel 
A) and c-myb (panel B) promoters was calculated 
over negative control chromatin isolated from cells 
expressing BirA biotin ligase, but not tagged GATA-1. 
The difference in the scales between the two genes 
indicates a lower enrichment for the c-myb promoter 
presumably due to the “closed” nature of the chromatin 
of this repressed gene.
and compared them to three other available products: streptavidin agarose, streptavidin mutein and 
NeutrAvidin. Streptavidin agarose was used to test whether an immobilization matrix different to 
that of paramagnetic particles would give better yields. Neutravidin is a streptavidin derivative 
without carbohydrate side chains which is predicted to reduce background binding. Streptavidin 
mutein is a mutated recombinant streptavidin which binds biotin with a lower affinity thus allowing 
elution of bound material under gentler conditions by using biotin. Chromatin from biotin-tagged 
GATA-1 cells and non-transfected cells (expressing BirA ligase only) was bound to different types 
of beads, under identical conditions (overnight binding and subsequent washes). Biotin-tagged 
GATA-1 was eluted from the beads by decrosslinkig, except for the mutein beads where we used 
biotin for elution. The results shown in Figure 2A and B clearly show that the M280 streptavidin 
Dynabeads are the most efficient in capturing biotin-tagged GATA-1 bound to the EKLF and myb 
promoters. As a result, the M280 Dynabeads were used in all subsequent experiments. 
Pre-clearing chromatin
Pre-clearing of chromatin is one of the methods used to decrease background binding in 
ChIP assays using antibodies. We tested this by preclearing chromatin with Protein G paramagnetic 
beads (Dynal) for 1 hour at 4°C. As shown in Figure 3, this resulted in lower background and 
improved enrichment (Fig. 3) of EKLF sequences bound by biotin tagged GATA-1. Similar results 
were also obtained with the c-myb promoter (not shown).
Blocking with fish skin gelatin 
Among various blocking compounds (e.g. BSA, Chicken Egg Albumin etc.) fish skin gelatin 
(FGEL) has been shown to be very effective for blocking in Western and ELISA experiments (20, 
35). We therefore investigated whether the use of FGEL for blocking would help improve the 
performance of M280 beads in streptavidin ChIP. Figure 4 shows that addition of as little as 0.5% 
120
Chapter 5
0
2
4
6
8
10
12
14
16
18
20
minusFGEL FGEL0.5% FGEL1% FGEL2%
fo
ld
 e
nr
ic
hm
en
t o
ve
r n
on
-tr
an
sf
ec
te
d 
co
nt
ro
l negative
enhancer
promoter
EKLF
Figure 4.  The effect of using different 
concentrations of FGEL in blocking the beads. 
Relative enrichment was calculated for EKLF 
sequences over chromatin from control cells.
(final concentration) of FGEL (together with salmon sperm DNA) can significantly improve the 
yield of EKLF target sequences bound by GATA-1. Similar results were also observed with the 
c-myb promoter (data not shown). Thus blocking the beads for 1 hour with FGEL and salmon sperm 
DNA reduces the background compared to blocking with salmon sperm DNA only. In addition to 
blocking the beads, we also used 1%FGEL by adding it to chromatin during binding to the beads 
with similar results to those obtained when only blocking the beads with FGEL (not shown). As a 
result, we have included 1%FGEL in blocking the beads in all subsequent experiments. 
It has been shown previously that biotin tagging allows more stringent washes (containing 
up to 3% SDS) compared to other affinity tags (like TAP tag) (34). For example, urea and thiourea 
are reagents widely used in proteomics to resuspend hydrophobic proteins. We therefore tested 
whether the background binding of hydrophobic proteins can be reduced by washing in urea/
thiourea/SDS. We found that the additional wash did not significantly lower the background or 
increase the specific binding signals of the EKLF or c-myb promoters (data not shown) and this 
parameter was not investigated further. 
The non-covalent binding between of biotin to streptavidin is one of the strongest known in 
nature (3, 38). However this presents a drawback when eluting bound chromatin from the beads as 
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Figure3. Preclearing chromatin with Protein G 
Dynabeads. A) Relative enrichment of EKLF sequences 
calculated over chromatin from control cells. The 
enrichment of the specific EKLF promoter elements 
appears lower after preclearing presumably due to some 
loss of chromatin in the additional preclearing step. B) 
Relative enrichment of biotin-tagged GATA-1 binding at 
EKLF promoter and enhancer calculated over the negative 
control sequence for biotin-tagged GATA-1 chromatin and 
chromatin from BirA expressing cells as negative control.
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Figure  5. Comparison of sonication 
buffers with or without the addition of SDS. 
A) Relative enrichment of EKLF sequences 
calculated over chromatin from control cells. 
B) Relative enrichment of c-myb promoter 
sequences calculated over chromatin from 
control cells.
is usually done in ChIP using antibodies. We tried to overcome this problem by “thermal elution” 
i.e. by boiling the beads after the binding (see Materials and Methods). We found this method to 
be very inefficient and did not pursue it any further. 
To possibly overcome this problem, elution from the beads by biotin (similar to mutein) 
could be applied, although in our hands this did not prove to be very efficient. A better alternative 
would be inclusion of protease (TEV or Precission) cleavage sites (8, 19, 23, 36)
Sonication without SDS
Most ChIP protocols, including those used in our laboratory, are based on the Upstate ChIP 
protocol which includes sonicating chromatin in a buffer containing 1% SDS. Addition of SDS 
introduces stringent conditions and helps prevent the aggregation of insoluble protein complexes. 
However, high SDS concentration may affect optimal binding of chromatin by the antibody or 
beads and in some approaches inclusion of SDS  is not compatible with further experimental 
procedures, for example in chromatin fractionation by CsCl gradient centrifugation (29, 31). 
We therefore tested whether sonicating chromatin without SDS would improve the 
efficiency of a streptavidin ChIP. Omission of SDS did not affect the efficiency of DNA shearing. 
As shown in Figure 5, sonicating chromatin without SDS resulted in higher enrichment of both 
EKLF and c-myb promoter sequences, albeit with a small increase in the background binding 
of the EKLF negative control sequence. Enrichment of the negative control primer in the c-myb 
promoter is similar in both conditions. Similar results were also obtained with other biotin-tagged 
proteins (KK and FP unpublished observations). Thus, omitting SDS from the sonication buffer 
improves the yield of a streptavidin pull-down significantly.  
Comparison of biotin and V5 epitope tags to anti GATA-1 N6 and M20 antibodies
All the experiments described above were carried out with an N-terminally biotin-tagged 
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Figure 6. 
A) Schematic representation of the biotin-V5-
tagged GATA-1
B) Western blot showing the relative amounts of 
biotin-V5 –GATA 1 and endogenous GATA-1 in 
the extract used for ChIP. The biotin-V5-GATA-1 
was detected with N6 anti-GATA-1 antibody. 
C) Comparison of V5, M280 and two different 
anti-GATA-1 antibodies, N6 and M20, tested for 
the binding of GATA-1 to the EKLF promoter. The 
enrichment is calculated over a non-transfected 
BirA cells control or over IgG negative control, 
respectively. V5 ChIP gives the highest yield 
in the EKLF enhancer and promoter elements, 
streptavidin ChIP with M280 Dynabeads gives 
comparable yield in the upstream enhancer element 
as M20 anti-GATA-1 antibody. The M20 antibody 
can enrich for more GATA-1 bound to the EKLF 
promoter than the M280 Dynabeads. The N6 
antibody precipitates the least amount of GATA-1 
bound to EKLF promoter elements. 
D) Comparison of V5, M280 and two different 
anti-GATA-1 antibodies N6 and M20, tested for 
the binding of GATA-1 to the EKLF promoter. 
Enrichment of the specific binding to EKLF 
promoter and enhancer was calculated over the 
negative primer set (-1.35kb element in EKLF 
promoter). V5agarose and M280 Dynabeads bring 
down comparable amounts of GATA-1 bound to 
EKLF enhancer and promoter sequences. The M20 
antibody enriches the most for GATA-1 bound 
to the EKLF upstream enhancer. Rat and goat 
IgGs as well as BirA control show similarly low 
enrichments of specific primer sets.
E)  Comparison of V5, M280 and two different 
anti-GATA-1 antibodies N6 and M20, tested as 
binding of GATA-1 to myb promoter. 
GATA-1 (10). We also generated a second construct containing a tandem affinity tag created by 
fusing the short (14 aa) biotin tag (4) with the 14aa V5 tag to the C-terminus of GATA-1(Figure 
6A). V5 is a short peptide sequence derived from the C-terminus of the P and V proteins of 
Simian virus 5 (33, 39). This construct can be used in the two-step affinity purification of tagged 
protein complexes, thus reducing background binding. This is an important consideration in 
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Figure 7. A) The structure of biotin lysine and histidine B) Western blot analysis of two binding experiments where non-
crosslinked nuclear extract (lane 1,2,3) and formaldehyde crosslinked chromatin (lane 4,5,6) were tested. Input and supernatant 
fractions (lanes 1 and 2, 4 and 5 respectively) represent 1% of total material, while bound lane (3 and 6) represent 25% of 
total material. The biotin-V5-tagged GATA-1 was detected with anti-GATA-1 antibody. C) After stripping the same membrane 
was incubated with streptavidin-HRP. D) Western blot showing comparison of binding of two different extracts: non-crosslinked 
nuclear extract (lane 5-9) and crosslinked chromatin (lane 1-5) precipitation by V5 agarose. The biotin-V5- tagged GATA-1was 
detected with N6 antibody. Lanes 1= input crosslinked loaded 1% of total protein, 2= bound (after washing, before elution), 3= 
gata-1 eluted from the beads loaded 10% of total material, 4= leftover on the beads after elution loaded 10% of total material, 5= 
input non- crosslinked loaded 1% of total material, 6= unbound supernatant after binding loaded 1% of total protein, 7= bound 
(after washing, before elution), 8=GATA-1 eluted from the beads loaded 10% of total protein, 9= leftover on the beads after elution 
loaded 10% of total protein,
ChIP experiments particularly in applications involving ChIP-on-chip or ChIP sequencing. This 
construct also allows comparison with the streptavidin-ChIP results obtained with the biotin tag 
fused to the N-terminus of GATA-1. 
We obtained a MEL stable transfectant expressing GATA-1-V5-bio at approximately equal 
levels to the endogenous GATA-1 protein (Figure 6B). We compared the efficiency of ChIP by 
streptavidin binding or V5 antibody immunoprecipitation to two anti-GATA-1 antibodies: the N6 
rat monoclonal antibody against the N-terminus of GATA-1 and the M20 goat polyclonal antibody 
against the C-terminus of GATA-1. We find that both the streptavidin pull-down with M280 
Dynabeads and the ChIP with V5 antibodies are at least as good as or more efficient in enriching 
for EKLF sequences compared to the anti-GATA-1 N6 and M20 antibodies, when compared to IgG 
controls or chromatin from cells expressing BirA only (Figure 6C). This difference in efficiencies 
becomes even greater considering that the anti-GATA-1 antibodies can precipitate both tagged 
and endogenous GATA-1, whereas streptavidin and V5 antibodies bind only tagged GATA-1. 
As mentioned above, relative levels of bio-V5- tagged GATA-1 and endogenous GATA-1 in the 
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extract used in this experiment are similar (Fig6B). This means that the enrichments obtained with 
antibodies should be hypothetically approximately twice as high as with affinity tags pull-downs. 
Thus, the results obtained with the M20 antibody are an over estimate when compared to the tag 
based ChIPs (in particular see figure 6D).
The V5 tag appears to work at least as well as streptavidin binding in ChIP (Fig 6C). When 
normalising to control cells expressing only BirA, the V5 ChIP gives actually a slightly better 
enrichment compared to the streptavidin ChIP (Fig. 6C), albeit with a slightly higher background 
binding to the negative control sequence (Fig. 6C and D). One explanation for the difference 
observed between the V5 ChIP and the streptavidin ChIP may be that the elution from the anti-V5 
agarose beads is more efficient than that from the M280 streptavidin beads. 
Remarkably, when we tested the c-myb promoter sequences under the same conditions, we 
found that the M20 antibody (a polyclonal antibody) gave much higher enrichment (Figure 6D). 
This suggests that the epitope(s) of GATA-1 recognized by M-20 antibody is more accessible for 
binding by antibodies in the crosslinked “closed” chromatin environment of the repressed c-myb 
gene, when compared with N-terminus and the very C-terminus of the protein. 
Formaldehyde crosslinking affects the biotin-tag more than the V5 tag
Formaldehyde cross-linking as first introduced by Salomon et al in Drosophila (32),  has 
been widely used to study the binding of proteins to DNA elements in intact cells. We tested whether 
the structure of the biotin and V5 tags or of the GATA-1 protein is affected by formaldehyde cross 
linking. The V5 aa sequence (GKPIPNPLLGLDST) contains one lysine (K) residue, whilst the 
biotin (with chemical formula C10H16N2O3S, see the structure in Figure 7A) is potentially more 
sensitive to formaldehyde cross linking. To this end, the extracts containing equal amounts of 
GATA-1-V5-bio (see input lanes 1 and 4 in figure 7A) were bound under identical conditions. 
Input, bound and unbound fractions we loaded on an SDS-PAGE gel and the western blots were 
detected with an anti GATA-1 (N6) antibody and with streptavidin-HRP. The results showed that 
the binding of crosslinked material to the M280 Dynabeads was less efficient, as there was much 
more GATA-V5-bio found in unbound fraction in comparison to the binding of non-crosslinked 
material where there was hardly any GATA-V5-bio left in the unbound fraction (compare the 
amounts of GATA-1 in lane 2 and lane 5 of unbound fractions 7A and B). In addition, anti-GATA-1 
antibody as well as streptavidin–HRP detection (Fig 7A and B) showed that there was significantly 
less GATA-1-V5-bio bound to the M280 Dynabeads in cross-linked extract pull-down than in 
non-crosslinked material (compare lane 3 with 6 in figures 7A and 7B). We subsequently tested 
whether crosslinking affects binding to the anti-V5 agarose. The western blot data presented 
in Figure 7C suggests that crossilinked and non-crosslinked material can be equally efficiently 
bound by anti-V5 beads (Figure 8, compare line 2 with 7 and 3 with 8). This observation likely 
explains the slightly higher V5 enrichments in the graphs in Figure 6. Although more sensitive to 
formaldehyde, it should be emphasized that despite its sensitivity to formaldehyde the biotin-tag 
performed very well in all our ChIP experiments. 
In summary, we show that pre-clearing chromatin and blocking streptavidin beads with 
fish skin gelatin reduces the background binding. In addition avoiding SDS in the sonication buffer 
appears to increase enrichment for bio-GATA-1 binding to specific DNA sequences. Lastly, we 
provide evidence that a tandem affinity tag composed of the biotin tag and the V5 epitope tag works 
very efficiently in ChIP, either when used independently or in combination. Our preliminary ChIP-
sequencing data (E. de Boer and E. Soler, unpublished) show that biotin and V5 tagging can be 
very efficiently used for transcription factor target sequence mapping and that the background seen 
in these experiments contains mostly non-specific DNA fragments that can be easily distinguished 
from specific target sites. 
 Thus, affinity tagging of transcription factors offers an easy, rapid and effective way for 
comparative and functional studies of different transcription complexes.
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During hematopoiesis, the controlled expression of lineage-specific genes is crucial for 
proliferation and differentiation cues. Many transcription factors are essential for the development 
of a given hematopoietic lineage, for example GATA-1 which is required for generation of the 
erythroid and megakaryocytic lineages (Cantor and Orkin 2002; Ferreira, Ohneda et al. 2005; 
Rodriguez, Bonte et al. 2005). The ability of such factors to influence cell fate is related to their 
ability to recognize specific DNA sequences via their DNA-binding domains, and recruit to the 
regulatory elements of genes (via protein interaction domains) co-activators or co-repressors (Rice, 
Hormaeche et al. 2007). The aim of this thesis was to gain insight into transcription factor function 
in regulating erythroid gene expression in general and developmental switches in globin gene 
expression, specifically. We undertook a biochemical approach using in vivo biotinylation tagging 
to isolate and characterize transcription factor complexes of GATA-1 and of the TR2/TR4 orphan 
nuclear receptors from erythroid cells
Biotinylation tagging•	
In this thesis we show that in vivo-biotin tagging is a very efficient approach to isolate and 
characterize protein complexes (Chapter 2 and 3). We applied this method to show that GATA-1 
can form distinct protein complexes, with either repressive or activating functions ((Rodriguez, 
Bonte et al. 2005) and Chapter 3). By using biotin-tagged deletion mutants of GATA-1, we could 
also show that distinct domains of the GATA-1 protein confer specific protein-protein interactions 
((Rodriguez, Bonte et al. 2005) and Chapter 3).
Moreover in vivo biotinylation tagging can be very efficiently used in ChIP experiments 
instead of antibodies (Chapter 5). Using GATA-1 as an example, investigated the optimal conditions 
for streptavidin ChIP assays were investigated. The results in Chapter 5 show that the type of 
streptavidin beads used for chromatin binding is critical, as in our experience the M280 Dynabeads 
performed best. Blocking the streptavidin beads with gelatin from cold water fish skin (FGEL) 
and using a sonication buffer without SDS in the chromatin preparation step significantly reduces 
background binding. 
In addition, the work described here shows that under these optimized conditions antibody 
based tags can also be efficiently used in ChIP experiments as we were also able to show that 
the V5 tag performs as efficiently as the biotin-tag in ChIP experiments. This provides a uniform 
integrated platform for identifying protein interactions and building interactome networks between 
the hematopoietic transcription factors, as well as for identifying transcription factor binding sites 
in a genome wide manner for example, in ChIP-on-chip experiments or for ChIP sequencing using 
massive parallel sequencing platforms (E. de Boer and E. Soler, unpublished). 
I will limit the further discussion to TR2/TR4 because the results obtained for GATA-1 
were extensively discussed in the thesis of Patrick Rodriguez (Rodriguez 2006)
Identification of TR2/TR4 interacting proteins •	
Chapter 4 of this thesis describes the efficient expression of biotin-tagged TR2 and TR4 in 
doubly transfected MEL cells. Both tagged and endogenous TR2 and TR4 have similar fractionation 
profiles on an analytical gel filtration column. However, only a small portion of TR2/TR4 proteins 
was present in high molecular weight fractions, with the majority of TR2/TR4 protein present in low 
molecular weight fractions (i.e. migrating essentially with the mobility of TR2/TR4 heterodimers 
and TR2 and TR4 monomers alone). As a consequence we had to develop optimization steps in 
order to enrich for the TR2/TR4 high molecular weight complexes in our streptavidin binding 
experiments. After testing a number of approaches, a preparative grade superose 6 gel filtration 
column followed by streptavidin binding and in-gel or on-beads trypsinization was determined to 
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be the most efficient approach (see Chapter 4). This procedure, followed by mass spectrometry 
analysis enabled us to identify a long list of potential interacting proteins, some of which we were 
able to confirm by western blot and co-immunoprecipitation (co-IP). We show that biotinylated-
TR2/TR4 reproducibly and specifically binds Dnmt1, HDAC3, TIF1β, Lsd1 and components of the 
NuRD complex (including HDAC1, Mta-1, RbAp46/RbAp48 and Mi2β) by streptavidin binding 
and IPs.  We also showed that those interactions are reciprocal, i.e. antibodies that recognize (some 
of) these factors can, in turn, bring down TR2/TR4 in MEL nuclear extracts (Chapter 4).
 In our mass spectrometric analysis we did not recover any of the initial proteins that 
were reported to co-purify with the DRED complex: CDP-1, USF1, and Lbp1a. We also failed to 
confirm these interactions by IPs (data not shown) in agreement with the data of Tanabe and Engel 
(unpublished). We conclude that these factors represent contaminants that were bound to the DNA 
on the DNA affinity column that was used in the original purification of the DRED complex from 
MEL cells (Tanabe, Katsuoka et al. 2002). Moreover, of the previously published TR2 and TR4 
interacting factors, we could only confirm in our studies the co-purification of HDACs (Franco, 
Farooqui et al. 2001; Zhang and Dufau 2003). We failed to detect previously reported TR2 and 
TR4 co-factors such as RIP140, TIP27 or TRA16 (Lee, Chinpaisal et al. 1998; Yang, Wang et al. 
2002; Nakajima, Fujino et al. 2004). This may result from differences in the assays and cell lines 
used: TIP27, TRA16 and RIP140 are co-factors that were identified in yeast and mammalian two-
hybrid studies (which often result in false positives) (Lee, Chinpaisal et al. 1998; Franco, Farooqui 
et al. 2001; Yang, Wang et al. 2002; Nakajima, Fujino et al. 2004). Furthermore, to confirm these 
interactions most of the authors used COS-1 cells, transiently or stably transfected with either His- 
(Yang, Wang et al. 2002), GST- (Lee, Chinpaisal et al. 1998; Franco, Farooqui et al. 2001) or Flag- 
tagged (Nakajima, Fujino et al. 2004) forcibly expressed TR2 or TR4 together with those co-factors, 
followed by immunoprecipitation of nuclear extracts. Examining abundantly expressed proteins 
in heterologous cell types, forcibly expressed to high concentrations will allow the detection of 
low affinity interactions that may not be visible or take place at normal concentrations. Such 
expression studies are no longer generally believed to provide sufficient evidence for relevant in 
vivo interactions; most current studies demand evidence that such interactions exist through the 
analysis of cells that express the proteins at their native abundance. Additionally, in most of the 
cited experiments the stringencies of IPs were much milder than those used by us, again favoring 
the detection of low affinity interactions. In contrast, we were able to confirm the interactions we 
identified by mass spectrometry using not only stably transfected cell lines (where we showed 
that biotin-tagging allows more stringent conditions to be used), but also non-transfected MEL 
nuclear extracts. In some experiments we also used benzonase digestion to demonstrate that the 
interactions observed and reported here are not DNA mediated. 
A possible explanation for the lack of finding in our mass spectrometry results of previously 
reported TR2/TR4 interacting proteins might be that the exclusion of the DNA affinity column 
from our purification steps resulted in the loss of some genuine DRED components during the 
experimental procedure. Perhaps our method picked up more abundant proteins forming a complex 
with TR2/TR4 which are not tightly involved in globin gene regulation and failed to detect less 
abundant proteins that are involved. This may be the reason why we could not see any clear 
binding by any of these factors to the ε- or γ-globin gene promoters (though we tested primers 
which mapped only in the vicinity of DR1 elements). It is possible that the pool of free TR2/TR4, 
observed in the low molecular weight fractions, is actively exchanged between several complexes 
and that more purification steps are needed in order to identify which of the complexes is the 
“globin switching” entity. In order to extend our isolation technique to enrich for DR1 binding 
complexes, we could possibly apply additional steps prior to the streptavidin pull-down step. 
On the basis of the mass spectrometry analysis and immunoprecipitation data and assuming 
we did not miss the relevant complex(es), we hypothesized that TR2/TR4 can form two distinct 
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transcription factor complexes. Complex 1 consists of TR2/TR4 together with Dnmt1, HDAC3, 
and TIF1β, whereas complex 2 consists of TR2/TR4 with (at least a subset of) NuRD components 
(Mi2β, RbAp46/48, Mta1, HDAC1), and possibly also Lsd1 and Dnmt1. Finding which of the 
complexes confers the DRED repression function would be an immediate goal, followed by the 
question whether the DRED complex confers only a repressive function (as proposed by (Tanabe, 
Katsuoka et al. 2002; Tanabe, McPhee et al. 2007))? 
The question about function of the DRED complex has been addressed in transgenic and 
knockout experiments in mice. The results from experiments with TR2/TR4 null mice and TgdnTR4 
mutant mice (dominant negative TR4 mutant that does not bind to DNA) suggest that TR2/TR4 may 
act in a stage–selective manner: as an ε–globin repressor in primitive and definitive erythropoiesis 
and as a γ-globin repressor only in definitive erythropoiesis (Tanabe, McPhee et al. 2007). 
Interestingly, forced expression of TR4 (TgTR4) in mice resulted in εy–globin reduction 
in yolk sac, with no difference in βh1 expression, and also in induction of adult β-globin gene 
expression. Forced expression of TR2 did not cause any changes in the β-type globin genes in the 
yolk sac (Tanabe, McPhee et al. 2007). These observations are particularly interesting in light of 
the ChIP results showing binding of TR4 to the β-globin promoters (tested on both the mouse and 
human genes). We were able to confirm this binding in vitro by band shift assays. It is possible 
that TR4 (in co-operation with TR2 or other nuclear receptors or as a homodimer) may confer 
an activating function in globin gene regulation as has been previously shown for other genes 
regulated by TR4 (Hwang, Burbach et al. 1998; Yan, Karam et al. 1998; Koritschoner, Madruga 
et al. 2001; Lee, Lee et al. 2002; Shyr, Hu et al. 2002; Yang, Wang et al. 2002; Wang, Lee et al. 
2006). It is interesting that recent publications reported a link between the androgen and estrogen 
receptors and the Lsd1 histone demethylase  in gene activation (Metzger, Wissmann et al. 2005; 
Wissmann, Yin et al. 2007; Perillo, Ombra et al. 2008). This could potentially offer an explanation 
for our observations of TR4 binding in vivo to the active β-globin promoter. However we have 
as yet failed to detect Lsd1 binding to the β globin promoter by ChIP (in MEL cells), probably 
because the anti-Lsd1 antibodies did not perform well in our ChIP experiments. Lsd1 has also been 
reported to interact with BHC80 which resembles TIF1β (Moosmann, Georgiev et al. 1996) in that 
it is a PHD domain-containing protein (Shi, Matson et al. 2005). BHC80 inhibits co-REST/Lsd1-
mediated demethylation in in vitro experiments (Shi, Matson et al. 2005). In light of this report it 
would be interesting to test whether there is a functional interaction between TIF1β and Lsd1 in 
regulating globin gene expression i.e. to test whether TIF1β would negate Lsd1 induced repressive 
chromatin formation during ε and γ globin silencing. 
Additional gain-of-function experiments were designed in order to address the TR2/
TR4 function in erythropoiesis (Tanabe, McPhee et al. 2007). These experiments showed that 
forced expression of TR2 and TR4 resulted in severe repression of εy globin gene in fetal livers 
and induction of βh1 expression (up to 8-fold over the levels in the wild type littermate livers), 
which may be the result of lack of εy competition for the LCR. Adult β-globin accumulation 
was unaffected (Tanabe, McPhee et al. 2007). Furthermore, when the adult spleens from TR2/
TR4 overexpressing mice were tested, βh1 levels were higher compared to wild type litter mates 
while εy or β- globin expression levels were unaffected (Tanabe, McPhee et al. 2007). It has been 
suggested that in primitive erythroid cells of the yolk sac TR2/TR4 bind only to DR1 sites in 
the ε-globin gene promoter resulting in silencing. At this stage, TR2/TR4 would have no effect 
on γ-globin expression. The ε gene–selective binding was proposed to be a result of the greater 
number of DR1 elements in the ε–globin gene promoter and a greater affinity of TR2/TR binding 
(Tanabe, McPhee et al. 2007). To explain the induction of γ (and βh1) globin gene expression in 
transgenic mice with forced expression of TR2/TR4, Tanabe et al (Tanabe, McPhee et al. 2007) 
suggest two models (Figure 1). 
The first model (Figure 1A) suggest that over-expression of TR2/TR4 causes sequestration 
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and dilution of potential co-repressors (which are present in limited abundance) thus preventing 
them from binding to globin promoters. That would suggest that the levels of Dnmt1, and possibly 
of Lsd1 or NuRD complex components in erythroid cells are limiting factors for the silencing of 
the γ (or βh1) globin genes, which seems unlikely. It is of course possible that there is another, yet 
undiscovered TR2/TR4 co-repressor that was not detected in our analysis due to its low levels, 
transient interactions or technical aspects of our purification procedure.
 The second model (Figure 1B) suggests that the action of TR2/TR4 would be dependent 
on co-activators, co-repressors, ligands or post-translational modifications (Tanabe, McPhee et al. 
2007). Hence, similarly to the GATA-1 situation (see (Rodriguez, Bonte et al. 2005) and Chapter 
2), TR2 and TR4 can form distinct activating and repressive complexes (Figure 1D) depending 
on the context (and possibly on the post translational modifications or ligand binding). Whether 
the presumptive complex with Lsd1 plays an activating function while the interaction with NuRD 
and Dnmt1 would confer a repressive function (Figure 1D) remains to be tested. Such an analysis 
would require sequential IPs or pull-downs with two different tags to dissect the distinct protein 
complexes, followed by extensive ChIP experiments showing the binding of all the different 
complexes to different promoters during different stages of erythropoiesis. In addition different 
modifications of the factors may be present requiring additional sophisticated mass spectrometry 
experiments to determine which of the factors carry modifications and whether these modifications 
are dynamic during development and/or differentiation.  
In addition, we suggest that TR2/TR4 may have a secondary effect on globin gene regulation 
by affecting the expression of other transcription factors such as GATA-1 (Figure 1C). It was 
recently demonstrated that forced expression of TR2/TR4 in mice repressed GATA-1 in primitive 
and definitive erythroid cells by binding to the (-3.7kb) GATA-1 hematopoietic enhancer (G1HE)
(Tanabe, Shen et al. 2007). We were also able to show the binding of TR2/TR4 to the (-3.7kb) 
G1HE element in ChIP experiments (after (Tanabe, Shen et al. 2007)). We could hypothesize that 
TR2/TR4 could bind promoters of other transcription factors genes. GATA-1 binds to several 
gene promoters including the β- and γ-globin gene promoters (reviewed in (Stamatoyannopoulos 
1991)), hence it is possible that some of the effects on globin gene expression in the transgenic 
TR2/TR4 mice are due to loss of GATA-1 binding (or possibly due to loss of binding of other TR2/
TR4-regulated transcription factors) (Figure 1D). 
 The models described above are rather complex, and do not consider competition between 
the genes of the β-globin locus for the activating function of the LCR, a mechanism that has been 
discussed extensively in the literature (Choi and Engel 1988; Enver, Raich et al. 1990; Hanscombe, 
Whyatt et al. 1991; Dillon, Trimborn et al. 1997; Grosveld, de Boer et al. 1998). It is possible that 
silencing of the ε-globin gene by forced expression of TR2/TR4 alone is sufficient for activation 
of the γ-globin to the levels observed by Tanabe et al (Tanabe, McPhee et al. 2007) (Fig. 1E). That 
would also suggest that the major role of TR2/TR4 is stage specific ε-globin silencing and that 
those factors play a minor role in γ globin regulation or even that they do not have any function in 
γ globin gene regulation. 
The enrichments we observe in ChIP experiments for the ε and γ globin promoters are 
unexpectedly low in light of the band shift assays results previously reported for DRED (Tanabe, 
Katsuoka et al. 2002; Tanabe, McPhee et al. 2007). However, we can not exclude the possibility 
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Figure 1. A model of the role of TR2/TR4 complexes in stage specific human globin genes regulation (after (Tanabe, McPhee et al. 
2007)). A) In primitive erythroid cells TR2/TR4 and co-repressors (DRED) repress ε globin transcription, but have no effect on the 
γ globin expression. In definitive erythroid cells the activity (abundance?) of DRED increases and allows a gradual repression of 
the γ-globin gene expression (TR2/TR4 have lower affinity for DR1 in the γ-globin promoter than for DR1 in ε-globin promoter). 
B) Model 2 suggests that TR2/TR4 by interacting with co-factors other than DRED confer an activator function on γ-globin in 
definitive erythroid cells. C) Model 3 suggests that in definitive erythroid cells an activating complex formed by TR2/TR4 acts on 
the γ and later on the β-globin gene promoters. D) It is suggested that TR2/TR4 together with Dnmt1, TIF1β, HDAC3 and possibly 
other un-known co-factors plays a repressive role in ε globin gene regulation. A complex of TR2/TR4, Lsd1, Dnmt1 and NuRD 
could possibly function in γ-globin silencing in definitive erythroid cells. In addition, we suggest that TR2/TR4 together with Lsd1 
in a distinct complex may bind and possibly activate the adult β-globin. Moreover, GATA-1, the expression of which expression is 
regulated by TR2/TR4 may bind and regulate γ-globin gene expression. E) It is also possible that upon forced TR2/TR4 expression 
the ε-globin gene is silenced and no longer competes for the LCR. As a result, γ-globin expression is increased.  
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that despite their high affinity for DR1 elements as measured by in vitro band shift assays, the 
action of TR2/TR4 on globin gene expression (that was shown by loss of function and gain of 
function studies on transgenic mice) is indirect and it is an effect of other TR2/TR4 sensitive 
transcription factors binding to the ε and γ (or εy and βh1) globin gene promoters. It may also be 
possible that the binding of TR2/TR4 requires unidentified but rate limiting co-factors or ligands. 
We suggest that for further evidence of TR2/TR4 action on globin gene promoters as well as on the 
essential hematopoietic factors, ChIP-on-chip or ChIP sequencing strategies could be applied.
 TR2/TR4 interacts with Dnmt1•	
Importantly, the results presented in this thesis demonstrate that TR2/TR4 interact with 
Dnmt1 (Chapter 4). This is a potentially important finding, since DNA methylation has long 
been associated with transcriptionally silent chromatin. Whether DNA methylation induces 
transcriptional silencing per se, or functions as a stabilizer of silencing remains enigmatic (Rice, 
Hormaeche et al. 2007). In addition, Dnmt1 was recently reported by an in vitro study to bind to an 
HPFH mutation at a position -3.7 kb from of the γ-globin promoter (Olave, Doneanu et al. 2007). 
It was recently demonstrated that the initial activation of embryonic/fetal genes is a result of 
promoter demethylation as opposed to de novo methylation in adults. The differentiation of HSCs 
(hematopoietic stem cells) derived from either baboon fetal liver or adult bone marrow into mature 
erythroblasts was accompanied by a progressive decrease in γ-globin promoter methylation and 
concomitant activation in both fetal liver and adult bone marrow. The difference in γ globin gene 
demethylation was correlated with the difference of γ globin expression at different developmental 
stages (Singh, Lavelle et al. 2007). These results suggest the existence of a DNA demethylase 
activity to counterbalance the repression mediated by Dnmts (Rice, Hormaeche et al. 2007; Singh, 
Lavelle et al. 2007).  
It is therefore essential to assess the functional relevance of the Dnmt1 and TR2/TR4 
interaction in erythropoiesis. A Dnmt1 conditional knock-out in the erythroid lineage, which is 
currently under analysis in the Engel lab, will be a key experiment in this line of investigation. 
Recent studies show that 5-azacytidine treatment can induce fetal hemoglobin (HbF) not 
only by affecting general mechanisms such as DNA methylation but also by a more focused effect 
(Gore, Baylin et al. 2006; Mabaera, Greene et al. 2007). In studies which demonstrated an enhanced 
clinical response rate of AML patients that was associated with demethylation of a region in the 
p15 promoter and acetylation of histones H3 and H4 (Gore, Baylin et al. 2006), the induction of 
histone acetylation in response to 5-azacytidine was observed before the HDAC inhibitor was 
administered (Gore, Baylin et al. 2006). In light of these results it would be interesting to test 
HDAC levels as well as histone acetylation in our 5-azaC experiments in MEL and fetal liver cells. 
One could hypothesize that the decreasing levels of the factor responsible for recruiting HDAC 
to the specific site of the promoter may result in decreased HDAC activity on this promoter and 
possibly further histone acetylation and gene activation. 
In addition, G9A mediated methylation in euchromatin is a mark for HP1 and Dnmt1 
recruitment, as it was shown that 5-aza-2’-deoxycytidine treatment decreased DNA and/or 
histone H3K9 methylation levels on the DSC3 and MASPIN tumor suppressor gene promoters, 
by decreasing levels of Dnmt1 and G9A HMTase levels (Wozniak, Klimecki et al. 2007).  This 
is analogous to the effects observed by us (Chapter 4) and others (Ghoshal, Datta et al. 2005). 
Therefore we postulate that the effects of 5-azacytidine on TR2/TR4 and Dnmt1 could be extended 
to include testing the levels of Lsd1 and HDAC proteins, in combination with changes in histone 
modifications of globin genes. 
Future directions•	
In this thesis we show that using affinity tagging provides a powerful tool for isolating 
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transcription factor complexes for studying protein interactions and also binding to target genes. 
Further testing and development of new tags, that can be efficiently used in protein as well as 
chromatin immunoprecipitations is essential for further investigation of transcription factor 
interactomes in erythroid (and other) cell types. 
We show that erythroid transcription factors can play different functions depending on 
the interacting partners. A well documented example is GATA-1 (Rodriguez, Bonte et al. 2005), 
however we cannot exclude the possibility that TR2/TR4 can also function as both repressors and 
activators depending on the context. 
As mentioned above, further continuation of the investigations into TR2/TR4 interacting 
partners will require further IPs and sequential IPs in order to verify our two complexes hypothesis 
(Chapter 4). Biotin-tagged Lsd1 (H. Braun, unpublished) and biotin-tagged Dnmt1 (K. Kolodziej, 
unpublished) MEL cell lines could provide additional useful tools in this analysis. Additional ChIP 
verification of the binding of the components of particular complexes to globin genes and the 
G1HE element should be carried out in parallel. We should stress the immediate requirement for 
in vivo verification of the in vitro band shift data for TR2/TR4 binding to DR1 elements in the ε 
and γ globin gene promoters.  In addition, the Dnmt1 erythroid-specific conditional knock-out and 
TIF1β conditional knock-out (both are currently under way in the Engel lab) are going to provide 
important evidence for the function of these proteins (also in the context of their interaction with 
TR2/TR4) in globin gene regulation. 
Our mass spectrometry results also suggest a possible link between TR2/TR4 and cell 
cycle proteins. The analysis of TR2/TR4 behavior during different cell stages (by means of GFP 
tagging or immunofluorescence) in MEL or cultured fetal liver cells, could initiate this (possibly 
interesting and informative) line of investigation. 
Furthermore, for both the TR2/TR4 and GATA-1 projects we envisage developing ChIP-
sequencing approaches across the different stages of erythropoiesis. These experiments could be 
important for designing new therapeutic agents for the treatment of hemoglobinopathies.
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Summary
Most proteins mediate their function within macromolecular networks. Studies in model 
organisms suggest that such complex protein networks have topological and dynamic properties 
that reflect biological phenomena. Thus, an understanding of biological mechanisms and disease 
processes demands a ‘systems’ approach that goes beyond one-at-a time studies of single 
components to more global analyses of the structure, function and dynamics of the networks in 
which proteins function (Cusick, Klitgord et al. 2005).
In Chapter 2 of this thesis we present optimal conditions for the efficient application of 
in vivo biotinylation tagging for studying protein-protein interactions of transcription factors in 
erythroid cells (de Boer, Rodriguez et al. 2003). This chapter concentrates mostly on the technical 
aspects of the biotin-tagged transcription factor complex purification and analysis by direct binding 
to streptavidin beads using GATA-1 complexes from mouse erythroleukemic (MEL) cells as an 
example.
Chapter 3 presents a more detailed description of the approach we undertook in order to map 
the network of interactions mediated by GATA-1, an  essential transcription factor for erythroid 
development (Rodriguez, Bonte et al. 2005).  Our data indicate that GATA-1 can function as a 
repressor and activator of its target genes depending on target gene context and the partners that is 
interacting with. Thus, GATA-1 interacts with the large repressive MeCP1 chromatin remodeling/
histone deacetylase complex, with the Snf2h/ACF1 chromatin remodeling complex and with 
hematopoietic transcription factors Gfi1b, FOG-1 and the Ldb1/TAL1 complex. Significantly, 
these GATA-1 protein interactions are distinct. In addition, FOG-1 mediates GATA-1 complexes 
with the MeCP1 complex. Our data suggest that the GATA-1 complexes with FOG-1/MeCP1 
and with Gfi1b confer repressive function potentially on distinct subsets of genes. Other GATA-1 
interactions; with FOG-1 (alone) and the Ldb1/TAL1 complex are involved in the transcriptional 
activation of erythroid genes. The interaction of GATA-1 with Snf2h/ACF1 complex can have 
either repressive or activating function, however we do not have enough evidence at this stage to 
clarify this. 
In Chapter 4 we show the application of in vivo biotinylation tagging to resolve protein 
complexes involved in globin gene developmental regulation. TR2 and TR4 nuclear orphan 
receptors have been previously reported to be part of the DRED complex (Tanabe, Katsuoka et 
al. 2002), which is implicated in ε and γ globin gene silencing (Tanabe, McPhee et al. 2007). Our 
data demonstrate that TR2 and TR4 interact with Dnmt1, NuRD components, HDAC3, TIF1β and 
Lsd1 in MEL cells.  We hypothesize that TR2/TR4 may form at least two distinct complexes, one 
involving Dnmt1, TIF1β and HDAC3 and the other involving Dnmt1, Lsd1 and subset of NuRD 
components. Identifying an interaction between TR2/TR4 and Dnmt1 is particularly interesting, 
since methylation has been long been implicated in globin gene regulation. In addition, we could 
show a specific decrease of Dnmt1 and TR2/TR4 protein levels upon treatment of erythroid cells 
with the potent DNA methyltransferases inhibitor 5-azacytidine, as has been previously described 
for Dnmt1(Ghoshal, Datta et al. 2005). Finally, we suggest that TR2/TR4 by binding to a novel 
DR4 element in the β-globin promoter may be involved in β-globin gene activation in the adult 
stage.
Chapter 5 shows the application of affinity tagging, with a focus on biotin-tagging, in 
chromatin immunoprecipitation (ChIP) experiments. We tested several conditions in order to 
optimize ChIP assays so as to improve specific enrichments and decrease non-specific background. 
In addition we highlight the requirement of testing additional tags as we show that, next to biotin-
tagging, V5 tagging can also be efficiently applied in ChIP assays. These observations have 
important implications since the study of transcription factor networks and their target genes will 
require using several, possibly equally efficient, affinity tags. 
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In summary, this thesis demonstrated the utility of affinity tags, and specifically of vivo 
biotinylation tagging for the isolation transcription factors complexes in erythroid cells and in 
identifying in vivo bound transcription factor gene targets. We believe that this approach offers a 
uniform and powerful platform for the further in-depth studies of protein and gene target networks 
in erythropoiesis, and effectively, any other cellular system. 
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Samenvatting
De meeste eiwitten verrichten hun functie binnen een complex netwerk van verschillende 
macromoleculen. Onderzoek in modelorganismen suggereert dat complexe eiwitnetwerken 
topologische en dynamische eigenschappen hebben die biologische fenomenen weergeven. Om 
biologische processen en ziektebeelden die daarmee samenhangen te kunnen begrijpen  is een 
“systems” aanpak noodzakelijk  dat verder gaat dan de studie van enkele onderdelen  maar  een 
meer globale analyse is van de structuur, functie en dynamiek van het netwerk waarin eiwitten 
functioneren .( Cusick, Klitgord et al. 2005)
   In Hoofdstuk 2 van dit proefschrift tonen we de optimale condities voor het gebruik van “ in vivo 
biotinylation tagging”  wat een  zeer efficiënte methode is om eiwit-eiwit  interacties in erythroide 
cellen te bestuderen.( de Boer, Rodriguez et al. 2003)
Dit hoofdstuk gaat hoofdzakelijk over technische aanpak van de analyse en zuivering van de 
complexen van transcriptiefactoren met een biotinetag door directe binding aan streptavidin 
bollen. Hierbij zijn de GATA-1 complexen van muis erythroleukemie (MEL) cellen als voorbeeld 
gebruikt
      Hoofdstuk 3 bevat een gedetailleerde beschrijving van manier waarop we het netwerk van 
interacties met GATA-1, een transcriptiefactor die essentieel is voor erythroide ontwikkeling,  in 
kaart gebracht hebben ( Rodriguez, Bonte et al 2005)  Onze data laten zien dat  GATA-1  een 
functie als activator of repressor van zijn targetgenen kan hebben, dit hangt af van de context van 
het targetgen en de partners waarmee GATA-1 samenwerkt. Zo heeft GATA-1 een interactie met 
het grote repressieve MeCP1 chromatine hermodulering/histon deacetylase complex , met het 
Snf2h/ACF1 chromatine hermodulering complex , met de hematopoëtische transcriptiefactoren 
Gfi1b, FOG-1 en het Ldb1/TAL-1 complex. Dit zijn duidelijk afzonderlijke eiwitinteracties.
Bovendien helpt FOG-1 de samenwerking van GATA-1 complexen met het MeCP1 complex. 
Onze data laten zien dat GATA-1 complexen met FOG-1/MeCP1 en met Gfi1b 
hun onderdrukkende rol op een bepaalde groep genen uitoefenen. Andere GATA-1 interacties; met 
FOG-1 alleen en met het Ldb1/TAL1 complex zijn betrokken bij de activering van de transcriptie 
van erythroide genen . De interactie van GATA-1 met het Snf2h/ACF1 complex kan een activerende 
of repressieve functie hebben hoewel we op dit moment nog niet genoeg data hebben om dit te 
verklaren.
     In Hoofstuk 4 laten we de toepassing zien van in vivo biotinylering “tagging”om eiwitcomplexen 
te ontrafelen die betrokken zijn bij de regulatie van de ontwikkeling van globine genen. TR2 en 
TR4 zijn nucleaire “orphan receptors”en al eerder is getoond dat zij deel uitmaken van het DRED 
complex ( Tanabe, Katsuoka et al 2007) wat betrokken is bij het “silencen”van het epsilon en 
gamma globine gen ( Tanabe, McPhee et al 2007)
Onze resultaten laten zien  dat TR2 en TR4 een interactie hebben met Dnmt1, onderdelen van 
NuRD, HDAC3, TIF1 beta en Lsd1 in MEL cellen. We veronderstellen dat TR2/TR4 tenminste 
twee afzonderlijke complexen kan vormen, de een met Dnmt!, TIF1 beta en HDAC3, de ander 
met Dnmt1, Lsd1 en een aantal onderdelen van NuRD. Het vaststellen van een interactie van 
TR2/TR4 met Dnmt1 in het bijzonder is interessant  omdat methylatie al lang een rol schijnt te 
spelen bij de regulatie van globine genen. Bovendien tonen we een specifieke afname van de 
hoeveelheid Dnmt1 en TR2/TR4 na behandeling van erythroide cellen met de krachtige DNA 
methyltransferase remmer 5-azacytide, zoals al eerder beschreven is voor Dnmt1(Ghoshal, Datta 
et al 2005) Tenslotte suggereren we dat TR2/TR4 door binding aan een nieuw DR4 element in de 
beta globine promoter betrokken kan zijn bij activering van het beta globin gen in het volwassen 
stadium.
    Hoofstuk 5 bevat de toepassing van affiniteit”tagging”in het bijzonder biotine”tagging”, bij 
chromatine immunoprecipitatie (ChIP) proeven.
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We hebben verschillende condities getest om de ChIP proeven te optimaliseren om de specifieke 
verrijking te verbeteren en de niet-specifieke achtergrond te verlagen. Daarbij  leggen we de 
nadruk op de noodzaak van het testen van verschillende “tags”want zoals we laten zien kan, 
behalve biotine”tagging” , ook V5 “tagging” efficiënt in ChIP proeven gebruikt worden. Dit is een 
belangrijke waarneming omdat voor de studie van transcriptiefactor netwerken en hun targetgenen 
het nodig zal zijn om verschillende, even doelmatige affiniteit”tags”te gebruiken.
        Samengevat demonstreert dit proefschrift het nut van affiniteit”tags”, in het bijzonder dat van 
in vivo biotinylatie “tagging”voor de isolatie van transcriptiefactor complexen in erythroide cellen 
en de identificatie van in vivo gebonden gen-targets.
We geloven dat deze aanpak een breed en krachtig platvorm is voor de verdere  bestudering van 
eiwitten en gen target netwerken in erythropoese en effectief in elk ander celsysteem.
Vertaling: Ernie de Boer
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